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Abstract  VIII 
Abstract 
The establishment of a permissive tumor microenvironment is a key step for tumor 
progression and metastasis formation. Tumor cells are known for their ability to create such a 
favorable tumor niche by influencing the surrounding benign stroma cells through the 
secretion of cytokines or growth factors. Recently, there is increasing evidence that also 
extracellular vesicles (EV) released by the tumor cells are important means of intercellular 
communication. Therefore, we aimed to investigate their role in tumor-tumor and tumor-
stroma crosstalk in human breast cancer.  
 
Human breast cancer cells were found to release tumor microvesicles (T-MV) as well as 
tumor exosomes (T-Exo). Both significantly enhanced invasiveness of the tumor cells in an 
auto- and heterologous feedback loop, whereas benign MV or the particle-free supernatant 
had no such effect. In case of T-MV, their pro-invasive function was dependent on a 
dynamin-dependent uptake into their recipient cells. Moreover, all pro-invasive T-MV carried 
a highly-glycosylated isoform of the Extracellular Matrix Metalloproteinase Inducer 
(EMMPRIN) with N-glycosylation at N160 and N268. Anti-EMMPRIN strategies such as 
knockdown or deglycosylation antagonized the pro-invasive function of T-MV on tumor 
invasion. Interestingly, EMMPRIN-carrying T-MV increased tumor invasiveness in a matrix 
metalloproteinase-independent mechanism by activating p38/MAPK signaling. EMMPRIN is 
not only involved in MV-mediated pro-invasive tumor-tumor crosstalk in vitro, but can also 
be used as a novel marker to detect T-MV which are circulating at high numbers in peripheral 
blood of breast cancer patients in vivo.  
 
Apart from their autologous influence on tumor invasion, we identified tumor-EV (T-EV) as 
mediators of a reciprocal tumor-Mϕ communication loop. They were able to reprogram Mϕ 
by inducing Wnt5a expression which was not observed for benign MV. Wnt5a induction was 
mediated by p38/MAPK signaling which could be antagonized by the Wnt-inhibitor DKK-1. 
Mϕ-Wnt5a was then exported on Mϕ-derived EV and transported back to the tumor cells 
where it increased their invasive potential. Wnt5a expression on EV was shown to depend on 
the seven-pass transmembrane protein Evenness interrupted (Evi) which had been 
demonstrated so far only for exosomes and not for non-canonical Wnt ligands like Wnt5a.  
 
In conclusion, breast cancer cells were demonstrated to release T-EV into the local 
environment as well as the bloodstream, where they interact with surrounding tumor as well 
as stroma cells and support the establishment of a favorable tumor niche.  
List of Figures  IX 
List of Figures 
Fig. 1: Metastasis – a complex process of linked sequential steps .......................................................... 3 
Fig. 2: Schematic representation of the EMMPRIN structure ................................................................ 6 
Fig. 3: Evi is essential for secretion of Wnt proteins .............................................................................. 9 
Fig. 4: Horizontal transfer of proteins and nucleic acids by EV ........................................................... 15 
Fig. 5: Schematic representation of the modified Boyden chamber assay. ........................................... 29 
Fig. 6: Schematic representation of the EV isolation protocol .............................................................. 30 
Fig. 7: MV and Exo are different populations of extracellular vesicles ................................................ 49 
Fig. 8: T-MV enhance tumor invasion in an autologous and heterologous way. .................................. 51 
Fig. 9: MV uptake does not differ between MV populations, but is important for their pro-invasive 
function and relies on a dynamin-dependent mechanism. .................................................................... 53 
Fig. 10: EMMPRIN expression discriminates MV and Exo ................................................................. 55 
Fig. 11: Knockdown of EMMPRIN in SK-BR-3 cells reduces the pro-invasive effect of T-MV. ....... 56 
Fig. 12: The pro-invasive effect of T-MV is mediated by HG-, and not IG-EMMPRIN ..................... 57 
Fig. 13: 2D-DIGE of deglycosylated T-MV ......................................................................................... 58 
Fig. 14: EMMPRIN-2 is the predominant isoform on T-MVM ............................................................. 60 
Fig. 15: Mass spectrometry reveals differential glycosylation of HG- and IG-EMMPRIN ................. 61 
Fig. 16: T-MV have no effect on known EMMPRIN target genes in tumor cells ................................ 62 
Fig. 17: p38 signaling partially mediates the pro-invasive function of T-MV ...................................... 63 
Fig. 18: JNK-signaling is not involved in the pro-invasive function of T-MV ..................................... 64 
Fig. 19: Immunophenotype of isolated human Mϕ. .............................................................................. 65 
Fig. 20: Analysis of the Mϕ phenotype after MV stimulation. ............................................................. 66 
Fig. 21: T-EV induce Wnt5a in human Mϕ .......................................................................................... 66 
Fig. 22: Wnt5a is newly transcribed in Mϕ after T-MV stimulation .................................................... 67 
Fig. 23: Human Mϕ incorporate T-MV, but their uptake is not essential for Wnt5a induction ............ 68 
Fig. 24: Human Mϕ export the Wnt5a protein on their own EV........................................................... 70 
Fig. 25: Wnt5a is expressed on MV and Exo ........................................................................................ 71 
Fig. 26: MV-mediated Wnt5a induction in Mϕ is mediated by p38/MAPK signaling which can be 
antagonized by DKK1 ........................................................................................................................... 72 
Fig. 27: Wnt5a-positive stroma-derived MV are ingested by breast cancer cells ................................. 73 
Fig. 28: Wnt5a is associated with EV in a nonspecific as well as specific, Evi-dependent way .......... 75 
Fig. 29: Implications of Evi knockdown for cellular Wnt5a expression ............................................... 76 
Fig. 30: Knockdown of Evi impairs MV-mediated tumor invasion as well as the pro-invasive 
phenotype of the tumor cells per se. ..................................................................................................... 77 
Fig. 31: ZA influences MV-mediated tumor-Mϕ crosstalk ................................................................... 78 
Fig. 32: Tumor marker on T-MV .......................................................................................................... 80 
Fig. 33: Tumor marker on T-Exo .......................................................................................................... 80 
List of Figures  X 
Fig. 34: MACS of T-MVS spiked into human AB serum samples ....................................................... 82 
Fig. 35: LD, rather than LS, columns lead to higher MV yields in MACS of T-MV ........................... 83 
Fig. 36: MACS of T-ExoS spiked into human AB serum samples........................................................ 84 
Fig. 37: MACS for MV in serum samples from cancer patients ........................................................... 85 
Fig. 38: Characterization of P-MV ........................................................................................................ 86 
Fig. 39: Characterization of Mϕ-MV .................................................................................................... 87 
Fig. 40: Blood cell markers on T-MV ................................................................................................... 88 
Fig. 41: Comparison of EDTA and heparin as anticoagulants for patient samples............................... 89 
Fig. 42: Isolation and characterization of EV from peripheral blood of cancer patients ...................... 90 
Fig. 43: Tumor markers on MV derived from metastatic cancer patients ............................................. 91 
Fig. 44: Detection of T-MV in peripheral blood of metastatic breast cancer patients .......................... 92 
Fig. 45: Schematic presentation of EV-mediated tumor-tumor crosstalk in human breast cancer ..... 107 
Fig. 46: Schematic presentation of EV-mediated tumor-Mϕ crosstalk in human breast cancer ......... 108 
Fig. 47: MS/MS spectra ...................................................................................................................... 128 
 
List of Tables  XI 
List of Tables 
Tab. 1: Cell lines ................................................................................................................................... 18 
Tab. 2: Cell culture media and additives ............................................................................................... 19 
Tab. 3: Chemicals, enzymes and recombinant proteins ........................................................................ 20 
Tab. 4: Antibodies ................................................................................................................................. 20 
Tab. 5: Oligonucleotides ....................................................................................................................... 22 
Tab. 6: Plasmids .................................................................................................................................... 23 
Tab. 7: Commercial kits and standards ................................................................................................. 23 
Tab. 8: Equipment ................................................................................................................................. 24 
Tab. 9: Sucrose step gradient ................................................................................................................ 31 
Tab. 10: Proteins exclusively present on untreated T-MVM ............................................................... 127 
Tab. 11: Proteins exclusively present on deglycosylated T-MVM ...................................................... 127 
 
 
Abbreviations  XII 
Abbreviations 
2D-DIGE two-dimensional difference gel electrophoresis 
CD  cluster of differentiation 
cDNA  complementary DNA 
DKK-1 Dickkopf-1 
DMSO dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
ECM  extracellular matrix 
EDTA  ethylenediaminetetraacetic acid 
eGFP  enhanced green fluorescent protein 
EGFR  epidermal growth factor receptor 
EMMPRIN extracellular matrix metalloproteinase inducer 
EpCAM epithelial cell adhesion molecule 
ER  estrogen receptor 
ESCRT Endosomal Sorting Complexes Required for Transport 
EV  extracellular vesicles 
Evi  eveness Interrupted 
Exo  exosome(s) 
FC  flow cytometry 
FCS  fetal calf serum 
FEP  fluorinated ethylene propylene 
Fig.  figure 
FITC  fluorescein isothiocyanate 
Her2  human epidermal growth factor receptor 2 
HG  highly glycosylated 
HRP  horseradish peroxidase 
hTERT-MV microvesicles derived from hTERT-HME1 cells 
IG  intermediately glycosylated 
IL  interleukin 
ILV  intraluminal vesicles 
IQR  interquartile range 
LC-MS/MS liquid chromatography-mass spectrometry/mass spectrometry 
LG  low glycosylated 
L-MV  microvesicles derived from murine L cells 
Abbreviations  XIII 
L-MVWnt5a microvesicles derived from murine Wnt5a-overexpressing L cells 
L-ExoWnt5a exosomes derived from murine Wnt5a-overexpressing L cells 
LPS  lipopolysaccharide 
Mϕ  human macrophage(s) 
Mϕ-MV microvesicles derived from human macrophages 
Mϕ-Exo exosomes derived from human macrophages 
MACS  magnetic-activated cell sorting 
MEGM mammary epithelial cell growth medium 
MMP  matrix metalloproteinases 
mRNA messenger RNA 
MTT  3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MUC1  mucin 1 
MV  microvesicle(s) 
MVB  multivesicular bodies 
PAGE  polyacrylamide gel electrophoresis 
PBS  phosphate-buffered saline 
PCP  planar cell polarity 
PE  phycoerythrin 
P-MV  platelet-derived microvesicles 
PNGaseF Peptide-N-Glyosidase F 
PR  progesterone receptor 
qRT-PCR quantitative real-time polymerase chain reation 
rh  recombinant human 
RNA  ribonucleic acid 
RUNX1 runt-related transcription factor 1 
SD  standard deviation 
SDS  sodium dodecyl sulfate 
SEM  standard error of the mean 
shRNA small hairpin RNA 
sn  supernatant 
Tab.  table 
TBST  Tris-buffered saline with Tween 20 
TEM  transmission electron microscopy 
T-EV  tumor-derived extracellular vesicles 
Abbreviations  XIV 
T-Exo  tumor-derived exosomes 
T-ExoM exosomes derived from MCF-7 breast cancer cells 
T-ExoS exosomes derived from SK-BR-3 breast cancer cells 
TLR  Toll-like receptor 
T-MV  tumor-derived microvesicles 
T-MVM microvesicles derived from MCF-7 breast cancer cells 
T-MVS microvesicles derived from SK-BR-3 breast cancer cells 
Tsg101 tumor susceptibility gene 101 
WB  Western Blot 
wt  wild type 
ZA  zoledronic acid 
 
Measurement units: 
% (v/v) % volume per volume 
% (w/v) % weight per volume 
bp base pairs 
°C degree Celsius 























Introduction  1 
1 Introduction 
1.1 Breast cancer 
Breast cancer is the most common malignancy of women in the Western world and the second 
most common cancer worldwide after lung cancer (Hutchinson, 2010). More than 95% of 
breast cancers are carcinomas meaning that they arise from transformed epithelial cells 
(Tomaskovic-Crook et al, 2009). While 5-6% of breast cancers are considered hereditary 
mostly caused by mutations in the BRCA1 and BRCA2 gene (Malone et al, 1998), also 
environmental factors and especially estrogens are considered to support the onset of the 
disease (Hilakivi-Clarke, 2000). Based on microarray profiling, three major subtypes can be 
defined (Perou et al, 2000) which also differ in clinical outcome of the patients (Sorlie et al, 
2001): Hormone receptor-positive, Her2/neu-positive and triple-negative breast cancers.  
The majority of breast cancers (around 70%) express the estrogen receptor (ER) accompanied 
by a varying expression of the progesterone receptor (PR) and are therefore considered as 
hormone-receptor positive (Dunnwald et al, 2007). They are mainly found in older women 
and are associated with better prognosis compared to the other two subtypes (Dunnwald et al, 
2007). While primary systemic chemotherapy in these patients depends on individual risk 
assessment, all patients with detectable ER expression are treated adjuvantly with endocrine 
therapy (e.g. tamoxifen) (Senkus et al, 2013) which counteracts the stimulating effects of 
estrogen on cancer cell growth and has a response rate of around 80% in metastatic patients 
positive for both ER and PR (Higgins & Stearns, 2009).  
Between 15 to 30% of breast cancers are characterized by overexpression of Her2, usually 
due to amplification of the ERBB2 gene (Slamon et al, 1987). Although they generally have a 
poor outcome, recent developments of new anti-Her2 treatment strategies such as the 
monoclonal antibody trastuzumab have improved prognosis (Dawood et al, 2010; Saini et al, 
2011). The third breast cancer subgroup comprises tumors that are ER-, PR- and Her2-
negative and are therefore referred to as triple-negative or basal-like. This type of tumor is 
found more often in younger women and although tumors initially respond to chemotherapy, 
they often relapse and thus are associated with a poor prognosis (Dunnwald et al, 2007).  
Up to 15% of all breast cancer patients present with aggressive disease and develop 
metastases within 3 years after diagnosis (Weigelt et al, 2005). These metastases are 
preferentially formed in the liver, lung, brain or bone (Lee, 1983). Unfortunately, even after 
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reaching a complete remission during primary treatment, there is a prolonged risk for 
recurrence of the disease, mainly in the form of metastases, for up to 20 years (McKay & 
Langlands, 1992). In order to monitor therapeutic response and detect disease progression, 
several serum markers have been proposed. Among them is the epithelial transmembrane 
glycoprotein MUC1, also known as CA 15-3, which is the most widely used serum marker in 
breast cancer and was also shown to have prognostic value (Duffy et al, 2000). Moreover, it 
has already been used as a marker to detect tumor cells in peripheral blood of metastatic 
breast cancer patients (Alix-Panabieres et al, 2005). Other markers tested for the detection of 
circulating breast cancer cells are CK19, CK20, CAE, EGFR or Her2 (Gilbey et al, 2004). 
However, up to date no reliable, routinely applicable test to monitor disseminated tumor cells 
in peripheral blood is available and only sparse data regarding the prognostic value of 
individual markers exist.  
1.2 Metastasis – one of the hallmarks in cancer progression 
Metastasis describes the spreading of tumor cells to distant organs or parts of the body leading 
to the formation of secondary tumors. It was defined as one of the six hallmarks of cancer by 
Hanahan and Weinberg (Hanahan & Weinberg, 2000). The occurrence of metastases often 
confers a devastating clinical fate because more than 90% of cancer-related deaths are due to 
metastases which are often resistant to therapy (Weigelt et al, 2005). Metastasis consists of 
several sequential steps which are displayed in Fig. 1 and can be stopped at multiple stages 
when one of these steps is not completed successfully (Poste & Fidler, 1980).  
Acquisition of an invasive phenotype is the first step for metastatic tumor progression which 
leads to local degradation of the surrounding tissue at the primary tumor site completed by 
breakdown of the basal membrane (Weber, 2008). This enables the tumor cells to spread 
throughout the body on three major paths including lymphatic vessels, blood vessels or along 
surfaces across body cavities (Stacker et al, 2002). Through stimulation of neovascularization, 
even small tumors (< 2 mm diameter) have access to the vasculature (Dvorak, 1986). After 
successful intravasation, circulating tumor cells must attach to the parenchyma of distant 
tissues to invade into and colonize these sites. These last steps are considered as highly 
inefficient and rate-limiting since from an estimated amount of up to 1 ∙ 10
6
 tumor cells which 
can be shed daily per gram of tumor mass (Butler & Gullino, 1975), only less than 0,01% of 
these circulating tumor cells succeed in the establishment of a metastatic lesion (Fidler, 1970).  
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Interestingly, different types of cancers seem to favor particular organs as metastatic sites as 
mentioned in chapter 1.1 for breast cancer. This is in line with the “Seed and Soil” hypothesis 
which was already formulated in 1889 by the English surgeon Stephen Paget. It comprises the 
idea that different cancer cells (= the “seed”) have an affinity for certain organs (= the “soil”) 
because they offer a compatible microenvironment which allows tumor growth (Paget, 1889).  
 
Fig. 1: Metastasis – a complex process of linked sequential steps 
Metastasis is a complex multi-step process which begins in a vascularized primary tumor with the local invasion 
of tumor cells. After breakdown of the basement membrane, tumor cells detach from the tumor and spread 
throughout the body in blood and lymphatic vessels. Adhesion to blood vessel walls followed by extravasation of 
cancer cells into the parenchyma of distant organs paves the way for subsequent colonization of the tissue and 
formation of secondary tumors. Taken from (Wirtz et al, 2011) with permission from the Nature Publishing 
Group.  
This idea still holds truth today. While a lot of research is focused on the intrinsic 
characteristics of tumor cells which drive oncogenic transformation and allow subsequent 
metastasis of these cells, the role of the tumor microenvironment for cancer progression is 
increasingly recognized (Joyce & Pollard, 2009).  
1.3 Tumor microenvironment 
Malignant tumors consist not only of the transformed cancer cells, but grow in a particular 
microenvironment which comprises benign surrounding stroma cells including e.g. 
fibroblasts, muscle cells, endothelial and immune cells (Bissell & Radisky, 2001). Moreover, 
also non-cellular components like cytokines, growth factors and especially the extracellular 
matrix (ECM) are major components of the local microenvironment. The ECM has a unique 
composition in each tissue which is highly influenced by reciprocal interactions between the 
different stroma cells (Frantz et al, 2010).  
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Although normal stroma can counteract or even block tumor progression, exactly the opposite 
effect can be observed when the stroma is altered at the site of tumor growth (Bissell & 
Radisky, 2001). During the last years it became increasingly apparent that tumor cells are able 
to influence the surrounding stroma cells to create a favorable tumor niche which is required 
for successful establishment of metastatic sites (Joyce & Pollard, 2009; Qian & Pollard, 
2010). One of the pro-invasive factors produced by the tumor cells is the pro-inflammatory 
mediator TNFα, shown to induce expression of adhesion molecules on endothelial cells 
(Mannel et al, 1994; Stoelcker et al, 1995) thereby supporting adhesion and migration of 
tumor cells. Moreover, TNFα was demonstrated to impair NK cell activity which might 
represent a possible mechanism against anti-tumor immunity (Hafner et al, 1996). Apart from 
TNFα, also expression of VEGF by the tumor cells themselves (Aonuma et al, 1999) or 
associated stroma cells e.g. fibroblasts or macrophages (Decaussin et al, 1999; Lin et al, 2006) 
favors tumor progression by inducing angiogenesis.  
1.3.1 Tumor-associated macrophages 
Macrophages (Mϕ) are often found at high numbers in tumor infiltrates (Pollard, 2004). In 
some breast cancer they even constitute more than 50% of the tumor mass (Lewis & Pollard, 
2006). Although immune cell infiltrates were first considered a failed attempt of the body to 
combat the tumor cells, it is now known that tumor cells can specifically attract and 
manipulate these cells to assist in tumor progression (Joyce & Pollard, 2009). In line with this, 
infiltrating Mϕ were detected especially at the invasive front of mammary tumors in human 
samples as well as in mouse models (Pukrop et al, 2006; Wyckoff et al, 2007). The number of 
tumor-associated Mϕ was found to correlate with poor prognosis (Shih et al, 2006). In 
contrast, Mϕ depletion by knockdown of macrophage colony-stimulating factor (M-
CSF/CSF1) or treatment with clodronate inhibited tumor growth and metastasis in mouse 
models (Hiraoka et al, 2008; Lin et al, 2001) which supports the hypothesis that Mϕ exert 
protumoral functions in cancer progression.  
Mϕ differentiate from blood monocytes which are recruited to inflammatory or neoplastic 
sites (Mantovani et al, 1992). They are known as extremely heterogeneous cell population 
which interacts with the surrounding microenvironment and reacts to certain stimuli with 
phenotypic changes as well as specialized and polarized effector functions (Gordon, 2003; 
Mosser, 2003). In an attempt to group Mϕ phenotypes, Mantovani defined two major Mϕ 
subtypes in 2004: On the one hand, classically-activated, pro-inflammatory M1 Mϕ which 
develop upon exposure to Interferon-γ or microbial stimuli like lipopolysaccharide (LPS) and, 
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on the other hand, anti-inflammatory M2 Mϕ which differentiate in the presence of 
Interleukin (IL) -4 and IL-13, IL-10 or exposure to immune complexes (Mantovani et al, 
2004). M1 Mϕ characteristically express high levels of IL-12 and IL-23 and are known to 
induce a Th1-directed adaptive immune response with anti-microbial and anti-tumor activity. 
In contrast, M2 Mϕ display high levels of IL-10, IL-1ra and IL-1 decoy receptor as well as 
low IL-12 expression and mediate immunosuppressive functions and tissue repair (Solinas et 
al, 2009). Tumor-associated Mϕ have been described to acquire a tumor-supporting M2-
polarized phenotype when infiltrating the tumor stroma (Mantovani et al, 2002).  
In a mouse model of mammary tumorigenesis Mϕ have been identified as source of growth 
factors, cytokines and matrix-degrading enzymes including matrix metalloproteinases (MMP) 
which mediated tumor progression (Lin et al, 2006). Up to now many studies have revealed 
pro-invasive tumor-Mϕ interactions. For instance, reciprocal signaling was demonstrated for 
breast cancer cells which stimulate infiltrated Mϕ by secretion of CSF1 and these respond 
with production of EGF that stimulates cancer cell growth and intravasation (Goswami et al, 
2005; Qian & Pollard, 2010; Wyckoff et al, 2007). Moreover, co-culture of benign breast 
cancer cells with human Mϕ significantly increases invasiveness of the tumor cells which is 
mediated by MMP and is dependent on the expression of the Extracellular MMP Inducer 
(EMMPRIN) in the tumor cells (Hagemann et al, 2004; Hagemann et al, 2005). In addition, 
co-culture induces the expression of the pro-invasive factor Wnt5a in Mϕ which is critical for 
the pro-invasive crosstalk that can be antagonized by the Wnt-inhibitor DKK-1 (Pukrop et al, 
2006).  
1.3.2 Matrix-Metalloproteinases 
The MMP family comprises more than 21 endopeptidases that are capable of degrading 
virtually all proteins of the ECM (Egeblad & Werb, 2002). They are secreted as inactive 
zymogens and need to be activated by proteolytic cleavage in order to be fully functional 
(Sternlicht & Werb, 2001). The coordinated balance between secretion of MMP by stromal 
fibroblasts and expression of tissue inhibitors of MMP (TIMP) and other enzymes is crucial 
for normal tissue homeostasis (Cruz-Munoz & Khokha, 2008).  
The significance of MMP for tumor progression is due to the fact that they help tumor cells to 
remodel and degrade the ECM which facilitates cancer cell migration and invasion (Egeblad 
& Werb, 2002). ECM degradation further leads to release of ECM-embedded tumor-
supporting growth factors like e.g. VEGF or TGF-β (Kessenbrock et al, 2010). Tumor cells 
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were found to regulate stromal MMP expression via the Extracellular Matrix 
Metalloproteinase Inducer (EMMPRIN) (Jiang et al, 2001). However, MMP cannot only be 
secreted by stroma cells, but also have been reported to be released by the tumor cells 
themselves (Matrisian et al, 1986; Turpeenniemi-Hujanen et al, 1985).  
1.3.3 Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) 
EMMPRIN, also known as CD147 or Basigin, is a cell surface transmembrane glycoprotein 
that belongs to the immunoglobulin superfamily (Biswas et al, 1995). It is encoded by the 
BSG gene and consists of a 29 kDa backbone protein which is known to be highly 
glycosylated. Three putative N-glycosylation sites have been described so far. Depending on 
the glycosylation status EMMPRIN appears in a size which can range from 32 kDa up to 
65 kDa (Weidle et al, 2010). Four different splice variants of the protein have been identified 
with EMMPRIN-2 being the most abundant one (Liao et al, 2011). All four isoforms share a 
common C-terminal structure consisting of a 21 amino acid cytoplasmic tail, a 21 amino acid 
transmembrane domain and an extracellular Ig-like domain (Liao et al, 2011). In contrast to 
EMMPRIN-3 and -4, the main isoform EMMPRIN-2 additionally possesses a second and the 
retina-specific isoform EMMPRIN-1 a third Ig-like domain as shown in Fig. 2.  
 
Fig. 2: Schematic representation of the EMMPRIN structure 
The topology of the main isoform EMMPRIN-2 is displayed on the left. Next to the cytoplasmic tail and the 
transmembrane domain, it contains two extracellular Ig-like domains as well as a signal peptide sequence (21 
amino acids) at the N-terminus. In comparison, the retina-specific isoform EMMPRIN-1 which is shown on the 
right harbors a third extracellular Ig-like domain due to transcription of an additional exon. The three potential 
N-glycosylation sites are indicated in purple, the phosphoserine residues as putative phosphorylation sites in red. 
Taken from (Weidle et al, 2010) with permission of the International Institute of Anticancer Research.  
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The name EMMPRIN comes from the observation that EMMPRIN-expressing tumor cells as 
well as their supernatants have been shown to induce various MMP in stroma cells e.g. 
fibroblasts, endothelial cells or Mϕ (Biswas et al, 1995; Guo et al, 1997; Kataoka et al, 1993; 
Muralidharan-Chari et al, 2010). Furthermore, it was shown to be capable of inducing 
expression of the pro-invasive factors CSF1, TNFα or VEGF (Schmidt et al, 2008b; Seizer et 
al, 2010; Tang et al, 2005). Homophilic interactions of EMMPRIN molecules on opposing 
cells were described to stimulate EMMPRIN expression itself in a positive feedback loop 
(Sun & Hemler, 2001; Tang et al, 2004b). In Lu-16 fibroblasts stimulation with purified 
EMMPRIN activates p38 signaling which can be blocked by the p38-inhibitor SB-203580 and 
resulted in decreased MMP induction (Lim et al, 1998).  
A tumor-promoting role of EMMPRIN has been suggested due to observations that increased 
expression of EMMPRIN stimulates tumor growth and metastasis in vitro (Zucker et al, 2001) 
and was found to be the most frequently upregulated protein in transcriptome analysis of 
single micrometastatic cells in cancer patients in vivo (Klein et al, 2002). Moreover, 
EMMPRIN was found overexpressed in many different types of cancer and high expression 
correlated with poor prognosis (Nabeshima et al, 2006).  
1.4 Wnt signaling 
The Wnt signaling pathway plays a crucial role not only in cell-cell communication during 
development and normal tissue homeostasis, but its deregulation is also often associated with 
tumorigenesis and cancer progression. The more than 19 identified Wnt ligands belong to a 
family of highly conserved secreted glycoproteins and are capable of activating Wnt signaling 
(Gordon & Nusse, 2006). During ß-catenin-dependent, canonical Wnt signaling binding of 
Wnt proteins to a receptor complex consisting of a Frizzled receptor and the co-receptor 
LRP5/6 (Tamai et al, 2000; Wehrli et al, 2000) induces stabilization and translocation of 
cytoplasmic ß-catenin to the nucleus where it binds to LEF/TCF transcription factors and 
activates target gene expression (van de Wetering et al, 1997). Apart from the Wnt inhibitory 
factor-1 (WIF-1) and secreted Frizzled-Related Proteins (sFRP), the family of Dickkopf 
(DKK) proteins is known to inhibit Wnt signaling by binding to the co-receptor LRP6 
(Semenov et al, 2008).  
In addition to the canonical pathway, two ß-catenin-independent non-canonical pathways 
have been described: The planar cell polarity (PCP) pathway and the Wnt/Ca
2+
 pathway. 
Activation of the latter has been associated with an increase in intracellular calcium levels 
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which leads to activation of PKC and CamK II (Kuhl et al, 2000) which, in turn, activate 
several nuclear transcription factors including e.g. NFκB or CREB (De, 2011). The Wnt/Ca
2+
 
pathway was shown to play a pivotal role in cardiac development (Rao & Kuhl, 2010) and 
was suggested to exert tumor-suppressing effects in human basal cell carcinoma (Nitzki et al, 
2010).  
In contrast, PCP signaling was described to enhance tumor cell migration and invasion in 
several human cancer models due to its regulatory influence on cytoskeletal organization and 
cell motility (Ripka et al, 2007; Weeraratna et al, 2002). Activation of the PCP pathway 
induces a signaling cascade that results in activation of JNK-signaling and ROCK-mediated 
actin reorganization (Wallingford & Habas, 2005). Both non-canonical pathways, Wnt/Ca
2+
 
and PCP, can be activated by the Wnt ligand Wnt5a (De, 2011; Yamanaka et al, 2002).  
1.4.1 Wnt5a – a controversially discussed Wnt ligand 
Wnt5a was originally described as a non-canonical ligand although recent data show that it is 
also capable of activating ß-catenin-dependent canonical Wnt signaling (Mikels & Nusse, 
2006). In this context, its influence on canonical signaling seems to depend on the receptor 
context (Mikels & Nusse, 2006).  
The Wnt5a protein was found to be glycosylated and palmitoylated, the latter being essential 
for its function (Kurayoshi et al, 2007). Due to its high hydrophobicity, it can bind to the 
ECM which was suggested to be involved in formation of local gradients (Ai et al, 2003). The 
role of Wnt5a in cancer is controversially discussed (McDonald & Silver, 2009; Pukrop & 
Binder, 2008). On the one hand, it was shown to have no transforming activity (Olson & 
Papkoff, 1994; Wong et al, 1994), was found to be downregulated on the mRNA level in 
neuroblastoma, leukemia or endometrial carcinoma compared to corresponding benign tissues 
(Blanc et al, 2005; Bui et al, 1997; Liang et al, 2003) and even inhibited cell migration and 
invasion in several cancer models (Dejmek et al, 2005; Jiang et al, 2013; Kremenevskaja et al, 
2005). On the other hand, Wnt5a is overexpressed in many human cancers (Pukrop & Binder, 
2008) and was shown to induce expression of several pro-invasive factors including MMP 
(Prieve & Moon, 2003), CD44 and vimentin (Dissanayake et al, 2007) or laminin γ2 (Hanaki 
et al, 2012). Wnt5a was not only expressed in the tumor cells themselves, but especially in 
tumor-associated Mϕ (Pukrop et al, 2006; Smith et al, 1999), which were predominantly 
localized at the invasive front of the tumor (Pukrop et al, 2006).  
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1.4.2 Secretion of Wnt proteins 
Although the first Wnt gene was already isolated in 1982 (Nusse & Varmus, 1982), the 
mechanism of Wnt protein synthesis and secretion is still not completely understood. Wnt 
proteins are generally modified by a series of posttranslational modifications which are 
important for their secretion and function. Especially palmitoylation was found to be crucial 
for the activity of Wnt proteins (Willert et al, 2003). After translation most Wnt proteins are 
lipid-modified by the acyltransferase Porcupine which is located in the membrane of the 
endoplasmic reticulum (Kadowaki et al, 1996; Willert et al, 2003). It was shown that 
Porcupine-mediated acetylation requires correct previous glycosylation of Wnt3a (Komekado 
et al, 2007) or Wnt5a (Kurayoshi et al, 2007) and missing glycosylation significantly 
impaired secretion of both Wnt proteins.  
 
 
Fig. 3: Evi is essential for secretion of Wnt proteins 
After lipid modification by the acyltransferase Porcupine in the endoplasmic reticulum, Wnt proteins are 
transported to the Golgi complex where they bind to Evi and are escorted to the cell surface in secretory vesicles 
for secretion (left). In contrast, loss of Evi results in an accumulation of synthesized Wnt proteins inside the cell 
(right). Taken from (Ching & Nusse, 2006) with permission from Elsevier.  
Lipid-modified Wnt proteins then bind to p24 proteins and are transported to the Golgi 
complex (Buechling et al, 2011; Port et al, 2011) where they associate with Evi, also known 
as WLS or Gpr177. Evi is a seven-pass transmembrane protein that is specifically required for 
escorting Wnt proteins from the Golgi complex to the plasma membrane (Banziger et al, 
2006; Bartscherer et al, 2006). Loss of Evi causes an accumulation of Wnt proteins in the 
Wnt-producing cell (Bartscherer et al, 2006) as depicted in Fig. 3. Furthermore, Evi has often 
been proposed to exert a chaperone function for the correct folding of synthesized Wnt 
proteins, although this has not been confirmed yet. After secretion of Wnt proteins Evi is 
either targeted to lysosomal degradation or can be recycled via endosomes and the retromer 
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complex to the Golgi where it can associate with new Wnt proteins and participate in a second 
round of Wnt secretion (Bartscherer & Boutros, 2008; Port et al, 2008). Following secretion, 
Wnt proteins are found in the supernatant of the Wnt-producing cell, but were also predicted 
to be tethered to the cellular plasma membrane due to their hydrophobic lipid moieties (Janda 
et al, 2012).  
1.5 Extracellular vesicles (EV) 
Intercellular communication was always believed to be mediated by direct cell-cell 
interactions or via soluble mediators e.g. growth factors, hormones or cytokines. However, in 
the last years it became increasingly accepted that extracellular vesicles (EV) represent 
additional novel means of intercellular communication (Raposo & Stoorvogel, 2013). Three 
different EV populations, including microvesicles, exosomes and apoptotic bodies, have been 
identified so far and shall be introduced in this chapter focusing on the differences in their 
biogenesis and composition.  
1.5.1 Exosomes (Exo) 
Exosomes (Exo) have been first described in 1987 in studies on reticulocyte maturation 
(Harding et al, 1983; Pan & Johnstone, 1983) and are precipitated from cell culture 
supernatants or body fluids by ultracentrifugation at 100.000 g (Thery et al, 2006). They can 
be distinguished from microvesicles by electron microscopy due to their smaller size which 
ranges from 30-100 nm as well as their typically cup-shaped appearance (Thery et al, 2002). 
In order to further identify the nature of isolated vesicles from cell culture supernatants, they 
are typically loaded onto sucrose gradients where Exo float at densities ranging from 1.13-
1,19 g/ml (Hugel et al, 2005) which may vary from cell to cell depending on the Exo protein 
content (Stoorvogel et al, 2002; Thery et al, 2002).  
In contrast to microvesicles which bud off from the cellular plasma membrane, Exo are 
derived from intraluminal vesicles (ILV) which are stored in multivesicular bodies (MVB). 
MVB are part of the endosomal compartment and originally contain internalized proteins 
from the cellular plasma membrane as well as proteins from the trans Golgi network which 
are destined for degradation (Gruenberg & Stenmark, 2004). In general, MVB can be 
processed via two different routes: Either they fuse with lysosomes leading to degradation of 
their content or they fuse with the cellular plasma membrane and release their cargo of ILV 
into the extracellular space (exemplified in Fig. 4). These ILV are since that moment referred 
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to as Exo (Gruenberg & Stenmark, 2004). Transport to and docking of MVB at the plasma 
membrane with subsequent fusion is dependent on several Rab proteins including Rab-11 
(Savina et al, 2005), Rab 27 (Ostrowski et al, 2010) and Rab 35 (Hsu et al, 2010) as well as 
intracellular calcium levels (Savina et al, 2005). It is a constant process (Thery et al, 2002), 
but can be regulated in some cell types by an increase of intracellular calcium (Raposo et al, 
1997). ILV are formed by inward budding and subsequent fission from the limiting membrane 
of MVB (van Niel et al, 2006). For this reason, they contain endosomal MVB membrane 
proteins as well as cytoplasmic proteins which are engulfed by chance or because of transient 
interaction with an endosomal transmembrane protein. Protein sorting into ILV was described 
to be associated with the Endosomal Sorting Complexes Required for Transport (ESCRT), 
although also ESCRT-independent mechanisms seem to play a role (van Niel et al, 2006).  
In line with this, Exo typically carry the two proteins Alix and Tsg101 (Thery et al, 2001) 
which belong to the ESCRT system (Katzmann et al, 2001; von Schwedler et al, 2003). 
Moreover, Exo express tetraspanin proteins including e.g. CD9, CD81 (Yoshioka et al, 2013) 
or CD63 (Fevrier & Raposo, 2004). Since tetraspanins are known to be enriched in 
specialized membrane microdomains (Hemler, 2003), this may hint to the a specific protein 
sorting process from endosomal membranes into ILV (de Gassart et al, 2003). Typical marker 
proteins which are further associated with Exo are chaperones (e.g. HSP90, HSC70), flotillin-
1 (de Gassart et al, 2003) and flotillin-2 (Canfran-Duque et al, 2013; Strauss et al, 2010) or 
Rab proteins (e.g. Rab2, Rab7) (Fevrier & Raposo, 2004). Exo were also found to express 
some proteins from the cell membrane. However, this seems to be a very selective process 
since some very abundant membrane proteins were not detected on exosomes (Blanchard et 
al, 2002; Thery et al, 2001) 
1.5.2 Microvesicles (MV) 
Microvesicles (MV) are a heterogeneous population of membrane vesicles with a diameter 
ranging from 100-1000 nm (Cocucci et al, 2009) and can be pelleted by a centrifugal force of 
10.000 up to 20.000 g (van der Pol et al, 2012). Studies of pure MV populations are limited 
because they were originally pelleted together with Exo at 100.000 g which resulted in mixed 
populations of MV and Exo. Only recently, MV were accepted as distinct EV population and 
have been isolated apart from Exo. However, the purity of EV populations isolated by 
differential ultracentrifugation is questionable and so far there are no specific MV-associated 
markers known to reliably separate them from the other EV populations. In general, the 
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expression pattern of cytosolic as well as membrane proteins transported on MV depends on 
their cell of origin as well as the process which triggers their release (VanWijk et al, 2003).  
MV seem to be ubiquitously shed by all types of cells by outward budding of the cellular 
plasma membrane and subsequent fission of the formed vesicle as shown in Fig. 4. Their 
release was observed to be significantly increased through shear stress (Holme et al, 1997) 
and the activation of distinct receptors or signaling pathways (Bianco et al, 2005; MacKenzie 
et al, 2001; Obregon et al, 2006; Pizzirani et al, 2007; Sims et al, 1989). These observations 
are in line with the fact that calcium is known to induce strong shedding responses 
(Moskovich & Fishelson, 2007; Pilzer et al, 2005). An increase in intracellular calcium levels 
was shown to activate calpain, a calcium-dependent cytosolic protease which mediates Talin 
degradation (Miyoshi et al, 1996). Loss of the cytoskeletal protein Talin is responsible for 
destabilization of the membrane cytoskeleton which enables membrane blebbing and MV 
release (VanWijk et al, 2003). Also inhibition of microtubule assembly by e.g. colchicine, 
vinblastine or cold temperatures destabilizes the membrane skeleton and favors membrane 
blebbing (Liepins, 1983). Some insight into the molecular mechanism of MV shedding was 
contributed recently by Muralidharan-Chari et al who demonstrated a crucial role of the small 
GTP-binding protein ARF6 in the regulation of MV release by activation of the motor protein 
Myosin which is important for fission of formed MV (Muralidharan-Chari et al, 2009; 
Muralidharan-Chari et al, 2010).  
MV are characterized by an externalization of phosphatidylserine, a phenomenon also seen on 
apoptotic bodies. This is due to the fact that both apoptosis and cellular activation are 
characterized by a disruption of normal membrane asymmetry. In unstimulated, healthy cells 
membrane asymmetry is mainly achieved by lipid transporter enzymes of the flippase family 
which flip phosphatidylserine to the cytoplasmic face (VanWijk et al, 2003). In case of 
cellular activation associated with an increase in intercellular calcium, flippase transporters 
are inactivated, while outward-directed (e.g. floppase) or bi-directional (e.g. scramblase) lipid 
transporters are activated (Bevers et al, 1999; Hugel et al, 2005). This finally results in 
bidirectional phospholipid redistribution and phosphatidylserine externalization. Expression 
of phosphatidylserine at the external leaflet of the plasma membrane represents a typical 
recognition signal for phagocytes inducing clearance of the respective cells or vesicles (Fadok 
et al, 1992). Furthermore, phosphatidylserine and tissue factor which are both present on MV 
are known to act synergistically in triggering blood coagulation and are therefore viewed as 
the two main factors being responsible for the procoagulant activity of MV that seems to be 
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involved in the pathogenesis of many cardiovascular diseases (Lechner & Weltermann, 2008; 
Morel et al, 2006; VanWijk et al, 2003).  
There is some evidence that MV function depends on the uptake into their target cell 
(Kawamoto et al, 2012). In 2009, Cocucci et al suggested that MV uptake could either occur 
by direct membrane fusion or by endocytosis (Cocucci et al, 2009). Recent studies which 
demonstrated reduced MV uptake during low temperatures or inhibition of the GTPase 
dynamin rather point to an endocytosis-mediated uptake (Kawamoto et al, 2012).  
1.5.3 Apoptotic bodies 
From the three EV populations, apoptotic bodies are the least characterized. They are released 
from apoptotic cells which undergo several steps in their dying process including cell 
shrinkage, chromatin condensation, nuclear fragmentation, membrane blebbing and finally the 
breakdown of the cell into apoptotic bodies (Reed, 2000). This is mainly mediated by activity 
of caspase-3 which belongs to the caspase family of intracellular cysteine proteases and 
induces reorganization of the cytoskeleton (Shigemura et al, 2001). Apoptotic bodies are 
mainly cleared by phagocytic cells, especially Mϕ, without eliciting an inflammatory response 
(Henson et al, 2001; Reed, 2000) which is essential for normal tissue homeostasis.  
Apoptotic bodies have been described to have a size of 1-4 µm (Hristov et al, 2004). They 
typically stain positive for Annexin V (Hristov et al, 2004) and show an externalization of 
phosphatidylserine (Martin et al, 1995) which makes it difficult to discriminate them from 
MV. However, in contrast to MV, apoptotic bodies specifically stain positive for PI and DAPI 
(Hristov et al, 2004) resulting from the presence of DNA inside the bodies. Proteomic studies 
by Turiak et al demonstrated a surprisingly similar protein expression pattern in apoptotic 
bodies and MV from thymus cells of BALB/c mice (Turiak et al, 2011).  
Next to cytoplasm, apoptotic bodies further contain tightly packed cell organelles, in some 
cases together with nuclear fragments, which could be visualized by electron microscopy 
(Elmore, 2007). Moreover, RNA was observed to be packed separately from DNA into 
apoptotic bodies resulting in two different subpopulations of apoptotic bodies: One that is 
packed with DNA, one that is enriched in RNA (Halicka et al, 2000). Apoptotic bodies also 
seem to be involved in horizontal transfer of biomolecules since apoptotic bodies of 
oncogene-transfected cells transferred DNA to p53
-/-
 mouse embryonic fibroblasts which 
induced a tumorigenic phenotype of these cells in in vivo experiments (Bergsmedh et al, 
2001). Furthermore, apoptotic bodies released from tumor cell lines were able to suppress 
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CD8
+
 T cell responses in vivo (Xie et al, 2009) and induced expression of the growth factor 
VEGF and the survival factor Bcl-2 in Mϕ involved in the clearance of the bodies (Golpon et 
al, 2004). Taken together, these observations suggest a role of tumor-derived apoptotic bodies 
in cancer progression.  
1.6 The significance of extracellular vesicles in cancer 
1.6.1 EV as biomarkers in cancer 
MV and Exo are not only present in in vitro cell culture models, but have been detected in 
vivo in almost all body fluids including blood, cerebrospinal fluid, breast milk, ascites fluid, 
semen, urine or saliva (Muralidharan-Chari et al, 2010; Raposo & Stoorvogel, 2013) 
suggesting their potential as biomarkers for cancer. A study from Baran et al could already 
demonstrate elevated levels of EV in peripheral blood of gastric cancer patients, their amount 
correlating with disease progression and tumor stage (Baran et al, 2010). This was also 
confirmed for EV present in ascites fluid of ovarian cancer patients (Graves et al, 2004). 
Further studies revealed that especially the number of procoagulant platelet-derived MV (P-
MV) carrying tissue factor was elevated in metastatic cancer patients and was associated with 
venous thromboembolic events and shorter overall survival (Helley et al, 2009; Toth et al, 
2008a; Zwicker et al, 2009). In patients with disseminated breast or pancreatic cancer elevated 
expression of tissue factor and the tumor antigen MUC-1 on circulating MV also correlated 
with lower survival rates (Tesselaar et al, 2007). Analysis of EV in plasma samples of cancer 
patients revealed an increased expression of the tumor marker Her-2 (Baran et al, 2010). 
Profiling of Exo secreted into the urine of patients with bladder cancer compared to healthy 
controls elucidated an upregulation of 8 proteins in patient samples with five of them being 
part of oncogenic EGFR signaling (Smalley et al, 2008). Taken together, these studies 
strongly suggest that EV might be useful as easy accessible targets for early disease detection, 
monitoring or prognosis establishment in cancer.  
1.6.2 EV as mediators of intercellular communication in cancer 
Several studies have suggested that EV not only serve as potential biomarkers in cancer, but 
are also actively involved in disease progression. This effect is mainly attributed to their role 
as mediators of intercellular communication which are able to transport proteins, lipids or 
nucleic acids from their cell of origin to the recipient cell (Fig. 4) (Cocucci et al, 2009). They 
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cannot only influence neighboring cells, but are also transported to distant sites when they are 
secreted into lymphatic or blood vessels (Peinado et al, 2012). Since EV represent platforms 
which transport combinations of multiple ligands and receptors, they are considered as more 
powerful means of intercellular communication compared to single secreted proteins (Cocucci 
et al, 2009). A major breakthrough was the finding that EV are often enriched in specific 
RNA molecules and can transport mRNA as well as miRNA to their recipient cells, where 
they are transcribed and modulate target gene expression (Mittelbrunn et al, 2011; Ratajczak 
et al, 2006; Valadi et al, 2007).  
 
Fig. 4: Horizontal transfer of proteins and nucleic acids by EV 
While MV are directly shed from the cellular plasma membrane, Exo are formed by inward budding into the 
lumen of multivesicular bodies or endosomes (MVB or MVE, respectively). There, they are stored until fusion 
of MVB with the plasma membrane. During their formation MV and Exo can incorporate cytosolic RNA as well 
as membrane-associated (triangles and squares) or transmembrane (rectangles) proteins and transport them to 
their recipient cells. EV can either interact with receptors at the plasma membrane of their target cell (1) or they 
are taken up by fusion with the plasma membrane (2) or by endocytosis (3). Ingested EV may then release their 
cargo by fusion with the deliminating membrane of the endocytic compartment (4). Taken from (Raposo & 
Stoorvogel, 2013) under a Creative Commons Attribution 3.0 License.  
One mechanism how EV contribute to tumor progression is by modulating and preventing 
anti-tumor immune reactions. Tumor-derived Exo (T-Exo) were shown to suppress NK cell 
(Liu et al, 2006) and T cell activity (Taylor & Gercel-Taylor, 2005). Moreover, tumor-derived 
MV (T-MV) shed by human melanoma or colorectal cancer cells were reported to fuse with 
monocytes and inhibit their differentiation to antigen-presenting cells, while in parallel 
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inducing expression of immunosuppressive cytokines that block activation and function of 
cytolytic T cells (Valenti et al, 2006). However, there are also studies which show that 
dendritic cells pulsed with tumor antigens can release Exo which carry functional MHC class 
I and II molecules and are able to prime tumor-specific cytotoxic T cells (Wolfers et al, 2001; 
Zitvogel et al, 1998). Apart from their influence on cells of the immune system, T-Exo have 
been identified as transporters which mediate export of cytostatic drugs out of the tumor cells 
during chemotherapy (Shedden et al, 2003). Lymphoma cells were shown to release Exo 
which shield the cells from attacking antibodies in immunochemotherapy approaches (Aung 
et al, 2011) confirming the role of Exo in the acquisition of chemotherapy resistance.  
EV were also shown to be directly involved in tumor progression: On the one hand, MV are 
known as carriers of MMP and their regulators e.g. EMMPRIN or urokinase-type 
plasminogen activator (µPA) which help in the degradation of the surrounding ECM and 
thereby promote tumor invasion (Dolo et al, 1999; Dolo et al, 1998; Muralidharan-Chari et al, 
2010). On the other hand, T-Exo from breast cancer cells were observed to directly stimulate 
tumor cell proliferation in vitro (Koga et al, 2005). Furthermore, EV were found to transfer 
malignant characteristics from highly malignant to less malignant cells of the same tumor type 
which led to transformation of the latter and increased the metastatic potential of the cells (Al-
Nedawi et al, 2008; Angelucci et al, 2000; Poste & Nicolson, 1980). However, studies of 
direct tumor-tumor interactions via EV are limited. Much more attention has been paid to EV 
as mediators of tumor-stroma crosstalk. In this context, T-EV have been shown to activate 
tumor-associated fibroblasts or endothelial cells which, in turn, release pro-invasive factors 
like VEGF or MMP (Baj-Krzyworzeka et al, 2006; Castellana et al, 2009; Taraboletti et al, 
2006) that support tumor invasion and neoangiogenesis. In mouse models of pancreatic cancer 
and melanoma metastasis, injected T-Exo accumulated in nearby lymph nodes and bone 
marrow and helped in the creation of a premetastatic niche by transforming benign stroma 
cells via horizontal transfer of distinct mRNAs and miRNAs (Hood et al, 2011; Peinado et al, 
2012; Rana et al, 2013).  
1.7 Aims of the study 
As explained in 1.3.1, Mϕ which get in contact with tumor cells do not acquire a pro-
inflammatory M1 phenotype associated with anti-tumor immunity, but in contrast are 
reprogrammed by the tumor cells to assist in tumor progression. In line with this, previous 
results from our group demonstrated that co-culture of human Mϕ with breast cancer cells 
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increases tumor invasiveness through induction of Wnt5a in the Mϕ (Hagemann et al, 2004; 
Pukrop et al, 2006). Since in the co-culture system both cell populations are separated by a 
membrane with a pore diameter of 10 µm, this suggests that not direct cell-cell interactions, 
but factors in the supernatant, either soluble or corpuscular, are responsible for intercellular 
communication. For this reason, it was the aim of this study to further define the role of EV 
for intercellular communication in human breast cancer progression by answering the 
following questions: 
 
1) Which EV populations are released by breast cancer cells? 
    How do they influence the invasiveness of the tumor cells? 
 
Our first goal was to establish a protocol for the reproducible isolation of the two main EV 
populations, MV and Exo, and identify specific markers for both. Since little is known about 
the effect of tumor-derived EV (T-EV) on the tumor cells themselves, we then investigated 
the role of T-EV in tumor-tumor crosstalk and aimed to specify their mode of action.  
 
2) What is the role of T-EV in tumor-Mϕ interactions, especially regarding the induction and 
     transport of Wnt5a? 
 
To investigate whether T-EV are responsible for the pro-invasive tumor-Mϕ crosstalk, we 
analyzed if they mediate Wnt5a induction in Mϕ. Although Wnt proteins are known to be 
very hydrophobic and thus limited in their mobility, they participate in short- as well as long-
range signaling events (Hardin & King, 2008). We therefore hypothesized that Wnt proteins 
are exported on EV and that this process requires the protein Evi which is known to be crucial 
for Wnt secretion.  
 
3) Are circulating T-EV also present in peripheral blood of metastatic cancer patients?      
    Which markers can be used to detect and discriminate them from non-tumor cell-derived  
    EV? 
 
Several studies on EV-mediated tumor progression in mouse models have shown the 
importance of T-EV in premetastatic niche formation in vivo (Hood et al, 2011; Peinado et al, 
2012). In order to analyze whether they can also be detected in peripheral blood of cancer 
patients, we first aimed to characterize T-EV in vitro and then use the defined markers to 
establish a protocol for the isolation of T-EV in vivo.  
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2 Materials and Methods 
2.1 Materials 
2.1.1 Biological material 
2.1.1.1 Cell lines 
The cell lines used in this study are listed in Tab. 1.  
Tab. 1: Cell lines 
cell line cell type characteristics obtained from reference 
     
hTERT-HME1 human mammary 
epithelial cell line 
immortalized with hTERT Clontech, Saint-
Germain-en-Laye, 
France 
(Van der Haegen & 
Shay, 1993) 
L cells murine fibroblast 
cell line 
derived from C3H/An Dr. J. C. Gross, 
Heidelberg 
(Eagle, 1955) 
Wnt5a-L cells murine fibroblast 
cell line 
derived from C3H/An, stably 
transfected to overexpress 
hWnt5a 
Dr. J. C. Gross, 
Heidelberg 
(Menck et al, 2013) 
MCF-7 human breast 
cancer cell line 
ER+, PR+, Her2- DSMZ, Braunschweig (Soule et al, 1973) 
MDA-MB231 human breast 
cancer cell line 
ER-, PR-, Her2- ATCC, Wesel (Cailleau et al, 1974) 
SK-BR-3 human breast 
cancer cell line 
ER-, PR-, Her2+ ATCC, Wesel (Trempe, 1976) 
     
2.1.1.2 Primary cells 
Human platelets were derived from outdated platelet concentrates (expired <1 day) which 
were kindly provided by the Department for Transfusion Medicine, University Medical 
Center Göttingen.  
Buffy coats were obtained as well from the Department of Transfusion Medicine, University 
Medical Center Göttingen, preferably from donors with blood group 0+ or B+, alternatively.  
2.1.1.3 Patient samples 
Tissues from cerebral metastases were obtained from patients previously diagnosed with 
primary breast cancer who underwent neurosurgical resection. Peripheral blood for the 
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collection of EV was collected from advanced cancer patients diagnosed with multiple 
metastases. Samples were processed < 30 min after blood withdrawal to prevent degradation 
of EV by serum proteases. All of the materials were obtained after informed consent and 
approved by the University Human Studies Committee of the University of Göttingen 
(reference numbers: 24/10/05 and 21/3/11).  
Human AB serum samples were provided by the Department for Transfusion Medicine, 
University Medical Center Göttingen. For inactivation of the complement system, samples 
were heated for 30 min at 56°C followed by centrifugation at 3000 g for 15 min. Supernatants 
were pooled and stored at -20°C.  
2.1.2 Cell culture media and additives 
All media and additives used for the culture of cell lines and primary cells are listed in Tab. 2.  
Tab. 2: Cell culture media and additives 
product company 
  
DMEM medium Biochrom (Berlin) 
Doxycycline Clontech (Saint-Germain-en-Laye, France) 
Fetal calf serum (FCS) Sigma (München) 
MEGM medium PromoCell (Heidelberg) 
penicillin/streptomycin (P/S) Biochrom (Berlin) 
puromycin Sigma (München) 
RPMI-1640 medium with Phenol Red Gibco (Darmstadt) 
RPMI-1640 medium without Phenol Red PAA (Cölbe) 
Trypsin Biochrom (Berlin) 
  
2.1.3 Chemicals, enzymes and recombinant proteins 
All used chemicals, enzymes as well as recombinant proteins were purchased from Sigma 
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Tab. 3: Chemicals, enzymes and recombinant proteins 
product company 
  
Actinomycin D (Act D) Lundbeck Pharmaceuticals Ireland (Dublin, Ireland) 
Biocoll Separating Solution, density 1,077 g/ml Biochrom (Berlin) 
phenol/chloroform/isoamyl alcohol (25:24:1) Roth (Karlsruhe) 
ECLPrime Western Blot Detection Reagent GE Healthcare (Freiburg) 
ECM gel R&D systems (Wiesbaden) 
EpCAM MicroBeads Miltenyi Biotec (BergischGladbach) 
IDCTM latex particles aldehyde/sulfate, 4% (w/v) Invitrogen (Darmstadt) 
Laemmli loading buffer, non-reducing, 4x bioPLUS (Mol, Belgium) 
Laemmli loading buffer Roti®-Load 1, reducing, 4x Roth (Karlsruhe) 
LPS from Escherichia coli Enzo Life Sciences (Lörrach) 
PercollTM Solution (density 1,130 g/ml) GE Healthcare 
Phosphatase inhibitor PhosSTOP, 10x Roche (Granzach-Wyhlen) 
PNGaseF New England Biolabs (Frankfurt a. M.) 
Ponceau S Merck (Darmstadt) 
rhDKK1 R&D systems (Wiesbaden) 
rhM-CSF ImmunoTools (Friesoythe) 
rhWnt5a R&D systems (Wiesbaden) 
SB-203580 Calbiochem (Darmstadt) 
SYBR green Roche (Mannheim) 
  
2.1.4 Antibodies 
The antibodies used in this study are listed in Tab. 4.  
Tab. 4: Antibodies 
target host species label application company 
     
CD11c mouse PE FC (5 µl) #IM1760, Beckman Coulter (Krefeld) 
CD14 mouse FITC FC (5 µl) #325603, BioLegend (Fell) 
CD45 mouse FITC FC (5 µl) #7782, Beckman Coulter (Krefeld) 
CD62P mouse FITC FC (5 µl) #555523, BD (Heidelberg) 
CD62E mouse PE FC (4 µl) #336008, BioLegend (Fell) 
CD63 mouse  - FC (1 µl) #556019, BD (Heidelberg) 
CD235a mouse PE FC (5 µl) #A07792, Beckman Coulter (Krefeld) 
c-jun rabbit  - WB (1:1000) #9165, cell signaling (Frankfurt a. M.) 
EGFR mouse PE FC (1 µl) #352903, BioLegend (Fell) 
EMMPRIN rabbit  - WB (1:1000) 
FC (5 µl) 
 
#sc-13976, santa cruz (Heidelberg) 
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target host species label application company 
     
EMMPRIN mouse Alexa 
Fluor 488 
FC (0,5 µl) #306207, BioLegend (Fell) 
EpCAM mouse APC FC (5 µl) #324207, BioLegend (Fell) 
Evi/WLS rabbit  - WB (1:500) #MABS87, Millipore (Darmstadt) 
Flotillin-2 mouse  - WB (1:1000) #610383, BD (Heidelberg) 
Her2/neu (erb-B2) rabbit  - WB (1:1000) 
FC (1 µl) 
#2165, cell signaling (Frankfurt a. M.) 
IgG1 mouse Alexa 
Fluor 488 
FC (1 µl) #400132, BioLegend (Fell) 
 mouse FITC FC (5 µl) #345815, BD (Heidelberg) 
 mouse PE FC (5 µl) #A07796, Beckman Coulter (Krefeld) 
 mouse PE FC (1/0,5 µl) #400114, BioLegend (Fell) 
IgG2b mouse APC FC (0,156 µl) #400322, BioLegend (Fell) 
mouse Goat HRP 
FITC 
WB (1:6000) 
FC (0,5 µl) 
#sc-2005, santa cruz (Heidelberg) 
#sc-2010, santa cruz (Heidelberg) 
MUC1 mouse PE FC (1 µl) #355603, BioLegend (Fell) 
p38 total rabbit  - WB (1:1000) #9212, cell signaling (Frankfurt a. M.) 
P-c-jun rabbit  - WB (1:1000) #9261, cell signaling (Frankfurt a. M.) 






FC (0,5 µl) 
#sc-2004, santa cruz (Heidelberg) 
#406403, BioLegend (Fell) 
rat goat HRP WB (1:6000) #sc-2006, santa cruz (Heidelberg) 
RUNX1 rabbit  - WB (1:500) #2593 cell signaling (Frankfurt a. M.) 
Tubulin mouse  - WB (1:5000) #05-829, Millipore (Darmstadt) 
Tsg101 mouse  - WB (1:1000) #7964, santacruz (Heidelberg) 
Wnt5a rat  - WB (1:2000) #MAB645, R&D systems(Wiesbaden) 
     
2.1.5 Oligonucleotides, plasmids and shRNA constructs 
Tab. 5 depicts all oligonucleotides, Tab. 6 all plasmids used for this study. The shRNA 
constructs for the stable knockdown of Evi/WLS were obtained from Sigma and were kindly 
provided by Dr. J. C. Gross (German Cancer Center, Heidelberg). The ns ctl sequence is 5′-
CCCGTGTAAATATGTACATTT-3′, the EVI targeting sequence is 5′-
GATCTACAAGTTGACCCGCAA-3′. 
The shRNA constructs for the stable knockdown of EMMPRIN were purchased from Thermo 
Scientific. While the ns ctl sequence is proprietary, the EMMPRIN targeting sequence is 
TCCAAGTTCTCACCTCTTA (Oligo ID: V3THS_412786).  
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Tab. 5: Oligonucleotides 
































hsWnt5a Ex4 fw AGGGCTCCTACGAGAGTGCT 
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Tab. 6: Plasmids 
plasmid characterstics/genotype reference 
   
pCMVΔR8.91 packaging plasmid Addgene (Cambridge, USA) 
pCS2+-xWnt5a-eGFP encodes a Xenopus xWnt5a-eGFP fusion protein PD Dr. Dietmar Gradl, Karlsruhe Institute 
of Technology, unpublished 
pVSG-G packaging plasmid Addgene (Cambridge, USA) 
   
2.1.6 Commercial kits and standards 
All commercial kits and standards for agarose or protein gels are listed in Tab. 7.  
Tab. 7: Commercial kits and standards 
product company 
  
Dc protein assay Bio-Rad (München) 
DNA ladder 100kb Fermentas (St. Leon-Rot) 
High Pure RNA Isolation kit Roche (Grenzach-Wyhlen) 
iScript cDNA synthesis kit Bio-Rad (München) 
LD columns for MACS Miltenyi Biotec (Bergisch-Gladbach) 
Legend MaxTM ELISA kits for IL-1ß, IL-10, IL-12 BioLegend (Fell) 
LS columns for MACS Miltenyi Biotec (Bergisch-Gladbach) 
Nanofectin Kit PAA (Cölbe) 
PKH26 Red Fluorescent Cell Linker Kit Sigma (München) 
Precision Plus Dual-Color protein standard Bio-Rad (München) 
Refraction-2DTM Labeling Kit DyeAGNOSTICS (Halle) 
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2.1.7 Equipment 
All lab equipment used for the experiments is listed in Tab. 8.  
Tab. 8: Equipment 
product company 
  
autoclave Varioklav Thermo Scientific (Bonn) 
Axiovert 200 M fluorescence microscope Zeiss (Jena) 
CCD camera for transilluminator Intas (Göttingen) 
centrifuge Multifuge 3 L-R Heraeus Thermo Scientific (Bonn) 
CO2 incubator CB150 Binder (Tuttlingen) 
FACS Canto II flow cytometer  BD (Heidelberg) 
FEP Teflon-coated cell culture bags, small/large CellGenix (Freiburg) 
MACS separator MACSVario Miltenyi Biotec (Bergisch-Gladbach) 
Magnetic stirrer REO basic C IKA Lab equipment (Staufen) 
MilliQ water purification system Millipore (Schwalbach) 
NanoDrop ND-1000 spectrophotometer Peqlab (Erlangen) 
Neubauer Improved cell counting chamber LO Laboroptik (Friedrichsdorf) 
pH meter 761 Calimatic Knick Elektronische Messgeräte (Berlin) 
Pipetboy Integra biosciences (Femwald) 
Photometer infinite F50 Tecan (Crailsheim) 
refrigerated microfuge SIGMA 1-15K Sigma Laborzentrifugen (Osterode am Harz) 
rotor Sw32 Ti for ultracentrifugation (6x38,5ml) Beckman Coulter (Krefeld) 
rotor Sw32.1 Ti for ultracentrifugation (6x17ml) Beckman Coulter (Krefeld) 
rotor TLA-120.2 for ultracentrifugation (10x1,5ml) Beckman Coulter (Krefeld) 
Thermal cycler T3000 Biometra (Göttingen) 
thermomixer 5437 Eppendorf (Hamburg) 
ultracentrifuge Optima XPN-80 Beckman Coulter (Krefeld) 
ultracentrifuge TL-100 Beckman Coulter (Krefeld) 
UV transilluminator TI3 Biometra (Göttingen) 
vortex shaker Genius 3 IKA Lab equipment (Staufen) 
Water bath Köttermann (Uetze,Hänigsen) 
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2.2 Methods 
2.2.1 Cell culture methods 
2.2.1.1 Maintenance of cells 
Cells were grown at 37°C and 5% CO2 in a humidified incubator. To passage the cells, they 
were washed once with PBS, detached by incubation with 1-2 ml Trypsin for up to 15 min 
and splitted in a ratio of 1:10-1:40. In case of hTERT-HME1, the cells were scraped carefully 
from the bottom of the cell culture flask and splitted in a ratio of 1:5. All cell lines were 
routinely tested for contamination with Mycoplasma. To maintain cells over a longer period 
of time, they were frozen in DMSO +90% FCS and stored at -150°C.  
2.2.1.2 Generation of stable knockdown cell lines 
Cell lines with stable knockdown of EMMPRIN or Evi expression were generated through 
shRNA-mediated gene silencing. For production of lentiviral particles, HEK293T cells were 
co-transfected through calcium phosphate precipitation with the packaging plasmids pVSG-G 
and pCMVΔR8.91 as well as the shRNA construct of interest (see 2.1.5). The viral particles 
which are released from the cells into the supernatant were concentrated using a lentiviral 
enrichment reagent (MoBiTec) according to the manufacturer’s instructions and were used for 
subsequent transduction of SK-BR-3 or Wnt5a-L cells, respectively. Lentiviral vectors can 
infect a broad range of cells, including dividing and even non-dividing cells, and integrate 
into the genome of their target cells, which allows stable expression of the gene of interest. 
Selection of transfected cells was achieved by adding 2 μg/mL (for SK-BR-3) or 15 µg/ml 
(for Wnt5a-L cells) puromycin (Sigma Aldrich) to the culture medium. Since shEMMPRIN 
cells were transfected with a pTRIPZ vector that comprises a “Tet-On” system, gene 
knockdown had to be accomplished by addition of the tetracycline doxycycline (1 µg/ml, 
Clontech) for 72 h.  
2.2.1.3 Transient transfection with xWnt5a 
In order to investigate Wnt5a expression in SK-BR-3 shEvi and corresponding non-sense 
control cells, they were transiently transfected with a plasmid encoding a Xenopus Xwnt5a-
eGFP fusion protein. The transfection of the cell lines was performed by Dr. Eva Rietkötter 
(University Medical Center Göttingen). Briefly, 2 ∙ 10
6
 cells were seeded in T75 cell culture 
flasks and allowed to adhere overnight. Transient transfection was performed with the 
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Nanofectin Kit (PAA) according to the manufacturer’s instructions. This method is based on 
nanoparticles which contain DNA-binding positively charged polymers and mediate transfer 
of the DNA into the target cells. Each cell line was transfected with 16 µg plasmid in a 
DNA/Nanofectin ratio of 3. Twenty-four hours after transfection cells were trypsinized and 
used for protein (see 2.2.3.1) or RNA (see 2.2.5.2) isolation.  
2.2.1.4 Isolation of human monocytes from Buffy Coats 
Human monocytes were isolated from Buffy Coats with a double density gradient 
centrifugation protocol as described in (Menck et al, 2014a). A Buffy Coat is the interphase 
between plasma and erythrocytes which remains after density gradient centrifugation of blood 
samples and contains most of the platelets and leukocytes. Briefly, 40 ml of each Buffy Coat 
were layered carefully on top of a Ficoll gradient (15 ml Biocoll separating solution, 
Biochrom) and centrifuged at 400 g for 20 min (without brake). Due to their higher density, 
granulocytes and remaining erythrocytes pellet on the bottom of the gradient, while 
mononuclear cells as well as platelets are contained in the whitish interphase between plasma 
and Ficoll. The interphase was collected and washed twice with PBS +1 mM EDTA at 300 g 
for 10 min (without brake) to deplete remaining platelets. All leukocyte pellets from one 
Buffy Coat were pooled in 20 ml RPMI-1640 medium without phenol red (PAA) and layered 
carefully on top of 25 ml of a 46% iso-osmotic Percoll gradient. The gradient was centrifuged 
at 550 g for 30 min (without brake). The colloidal silica particles coated with 
polyvinylpyrrolidone which are contained in the Percoll solution lead to the separation of 
lymphocytes and monocytes (Feige, U et al, 1982, J Immunol Methods) which results in the 
sedimentation of the lymphocytes at the bottom of the tube while the monocytes are localized 
in the whitish interphase. The interphase was collected, resuspended in 20 ml PBS +1 mM 
EDTA and centrifuged again at 400 g for 10 min. The monocyte pellet was resuspended in 
20 ml RPMI-1640 +10% FCS and the cell count was determined with a Neubauer Cell 
Counting Chamber (LO Laboroptik).  
 
46% iso-osmotic Percoll gradient (for two Buffy Coats): 
 23,13 ml PercollTM solution (GE Healthcare) 
 1,87 ml 10x PBS (w/o Ca and Mg, Invitrogen) 
Transfer 23 ml of this solution to a new tube and add 27 ml RPMI+10%FCS with Phenol Red 
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2.2.1.5 Differentiation of human monocytes to macrophages 
The isolated monocytes were subsequently differentiated to macrophages (Mϕ) in the 
presence of low concentrations of Macrophage colony-stimulating factor (M-CSF/CSF1, 
ImmunoTools) in fluorinated ethylene propylene (FEP) Teflon-coated cell culture bags 
(CellGenix) which allows the detachment of the cells after the differentiation period.  
1,0-1,5 ∙ 10
8
 monocytes from one Buffy Coat were seeded in large, 3,0-5,0 ∙ 10
7
 monocytes in 
small FEP Teflon-coated cell culture bags. For each bag, culture medium containing 2% 
human AB-serum (see 2.1.1.3), 1% penicillin/streptomycin and 2,5 ng/ml M-CSF (total 
volume: 180 ml for large bags, 30 ml for small bags) was prepared and mixed with the 
respective number of isolated monocytes. The cells were differentiated for 6-7 days at 37°C 
and 5% CO2. To harvest the cells, the bags were incubated for 1 h on ice and subsequently 
pulled with minimal pressure 10 times over the edge of a desk or board. The cell suspension 
was removed from the bag and centrifuged at 400 g for 10 min to pellet the Mϕ. Cells were 
counted in a Neubauer Cell Counting Chamber and seeded according to the experimental set-
up. After adherence of the cells, Mϕ were washed twice before they were used for further 
experiments.  
2.2.1.6 Generation of activated macrophages by stimulation with tumor cell 
supernatant 
Human Mϕ show a specific activated phenotype when they get in contact with tumor cells. To 
simulate this activation without having to perform expensive and time-consuming co-culture 
experiments, Mϕ were seeded in 6-well-plates at a concentration of 2 ∙ 10
6
 cells per well. The 
wells had been previously coated with 80 µl ECM gel (R&D systems) diluted 1:16 in RPMI-
1640. After adherence of the cells, they were washed twice with PBS and then stimulated with 
2 ml tumor cell supernatant per well for 24 h.  
The tumor cell supernatant, which should still contain all of the MV and Exo present, was 
generated by culturing MCF-7 cells in T175 cell culture flasks (confluence of >70%) for 48 h 
in RPMI-1640 +10% particle-free FCS. The supernatant was collected and centrifuged for 
5 min at 750 g to remove cells and debris.  
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2.2.1.7 Assessment of cell vitality and proliferation 
2.2.1.7.1 MTT assay 
To measure cell viability upon treatment with different inhibitors, the MTT assay was used 
(Mosmann, 1983). The method is based on the conversion of the water-soluble, yellow 
tetrazolium salt 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromid (MTT, Sigma) 
to an insoluble, purple formazan. This reduction is mediated by NAD(P)H-dependent 
enzymes in the endoplasmic reticulum (Berridge et al, 1996) and is thus impaired in apoptotic 
or necrotic cells with an altered cell metabolism.  
For the MTT assay, 7,5 ∙ 10
4
 MCF-7, 4 ∙ 10
4
 SK-BR-3, 1 ∙ 10
4
 (Wnt5a-) L cells or 1,5 ∙ 10
5
 
human Mɸ per well were seeded in duplicate in a 24-well-plate and incubated with the 
respective inhibitors at the indicated concentrations and time periods. Subsequently, the cells 
were incubated with 500 µl culture medium +10% MTT (stock solution: 5 mg/ml) for 4 h at 
37°C and 5% CO2. The medium was aspired and cells lysed in 500 µl 5% formic acid +63% 
isopropanol +32% DMSO. The extinction at 540 nm was measured in triplicate in a 
photometer and related to the extinction of the untreated control.  
2.2.1.7.2 xCELLigence 
Analysis with the xCELLigence system (RTCA DP Analyzer, Roche), an electronic 
impedance-based cell sensing measurement system, was used as an additional method to 
measure changes in cell viability and proliferation. For the experiments, 1 ∙ 10
4
 MCF-7 cells 
were seeded per well in E16 plates (Roche) and stimulated with different concentrations of 
filipin III (Sigma) or dansylcadaverine (Santa Cruz) for 72 h. Since the area on the bottom of 
the wells is covered with a gold microelectrode, changes in electrical impedance can be 
measured when the cells attach and spread on the electrode surface. Thus, cell growth and 
spreading result in increased impedance, while detachment or rounding up of cells cause a 
reduction. The measured impedance is displayed as so-called cell index.  
2.2.1.8 Cell invasion assay in a modified Boyden chamber 
Cell invasion was quantified in a modified Boyden chamber assay (see Fig. 5) as described 
previously (Hagemann et al, 2004). Briefly, the lower wells of the chamber were filled with 
RPMI-1640 +10% (or 1% for co-culture experiments) particle-free FCS and sealed with a 
polycarbonate membrane (pore diameter: 10µm, Pieper Filter) which was coated with ECM 
gel (R&D systems) diluted 1:4 in RPMI-1640. This setting is thought to resemble the in vivo 
situation in the tissue where the tumor is forming.  
Materials and Methods  29 
 
Fig. 5: Schematic representation of the modified Boyden chamber assay. 
The cells are seeded in the upper wells of the chamber and stimulated with EV or other factors. After 96 h the 
number of invasive cells which had successfully degraded the ECM gel and invaded through the membrane into 
the lower wells was counted and related to the unstimulated control.  
1 ∙ 10
5
 cells were seeded in the upper wells and stimulated in triplicate with MV, Exo or other 
factors as indicated. The chamber was incubated for 96 h at 37°C, 5% CO2 and subsequently 
the number of invasive cells in the lower wells was determined with a Neubauer Counting 
Chamber and related to the unstimulated control. Because of the toxicity of the inhibitor, 
experiments with dynasore were already stopped after 48 h of stimulation.  
For quantification of tumor cell invasion in co-culture with human Mϕ, 2 ∙ 10
5
 Mϕ were 
seeded in co-culture inserts (Millipore). 1 h after seeding of the tumor cells in the upper wells, 
Mϕ inserts were added to the respective wells.  
2.2.2 Extracellular vesicle techniques 
2.2.2.1 Isolation of microvesicles (MV) and exosomes (Exo) 
2.2.2.1.1 Cell culture supernatants 
To isolate EV from adherent cells, the latter were cultured in seven T175 cell culture flasks up 
to 60-80% confluence, then washed twice with PBS and incubated for 48 h in culture medium 
supplemented with 10% particle-free FCS. Human Mϕ were seeded in 10 cm cell culture Petri 
dishes (Sarstedt) in a concentration of 3,5 ∙ 10
6
 cells per dish and incubated for 24 h in RPMI 
+1% particle-free FCS. The particle-free FCS was generated by pelleting endogenous EV by 
ultracentrifugation over night at 100.000 g and 4°C.  
Cell culture supernatants were collected and centrifuged at 750 g for 5 min, followed by 
1.500 g for 15 min to pellet cells and debris. MV were pelleted by ultracentrifugation in a 
Sw 32 Ti rotor at 14.000 g and 4°C for 35 min. The pellet was washed once in PBS and then 
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resuspended in PBS or RIPA lysis buffer. For the isolation of Exo, the supernatant of the 
14.000 g centrifugation step was filtered (0,22 µm filter, Sarstedt) and ultracentrifuged at 
100.000 g and 4°C for 2 h. The Exo pellet was washed once in PBS in a TLA-120.2 rotor and 
then resuspended in PBS or RIPA lysis buffer. MV and Exo counts were routinely determined 
as described in 2.2.3.2.  
 
Fig. 6: Schematic representation of the EV isolation protocol 
EV were isolated from cell culture supernatants by a series of differential (ultra)centrifugation steps as indicated. 
The particle-free supernatant (sn) after precipitation of Exo was employed as negative control for the 
experiments.  
2.2.2.1.2 Platelet concentrates 
P-MV were isolated according to the protocol in 2.2.2.1.1 from outdated platelet concentrates 
(outdated <2 days) which were provided by the Department of Transfusion Medicine, 
University Medical Center Göttingen.  
2.2.2.1.3 Peripheral blood from cancer patients and controls 
For the isolation of total MV and Exo from the peripheral blood of cancer patients, blood 
samples were collected from cancer patients with metastatic disease who did not receive 
chemotherapy at the time of sample acquisition. This setting should guarantee the maximal 
count of tumor-derived EV in the blood, while preventing the presence of apoptotic bodies or 
activated EV from dying cells which might be present during administration of chemotherapy. 
As negative control, blood was also collected from matched tumor-free patients or healthy 
individuals. Samples were collected through a 19 gauge butterfly needle and dispended into 
tubes containing either EDTA (1,6 mg / ml blood, Sarstedt) or lithium-heparin (16 I.E. / ml 
blood, Sarstedt). Serum was obtained by centrifugation at 1.200 g for 15 min and separation 
from the blood cells further supported through the application of a serum filter (Seraplas
®
, 
Sarstedt). The serum was centrifuged at 1.500 g for 15 min to pellet debris and then stored at -
20°C or directly subjected to EV isolation as described in 2.2.2.1.1. The isolation of tumor-
derived EV from cancer patients by magnetic-activated cell sorting (MACS) is further 
described in 2.2.4.3.  
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2.2.2.2 Sucrose gradient ultracentrifugation 
For sucrose gradient preparations, T-MVS and T-ExoS were isolated according to chapter 
2.2.2.1.1 and pellets were resuspended in 500 µl 0,25 M sucrose. The vesicles were then 
applied onto a sucrose step gradient which was prepared by layering decreasing sucrose 
density solutions (2 ml each) upon one another as listed in Tab. 9. The gradient was 
centrifuged in a Sw 32.1 Ti rotor for 16 h at 100.000g and 4°C.  
Tab. 9: Sucrose step gradient 
2,5 M sucrose [µl] HEPES buffer [µl] molarity [M] density [g ml
-1
] 
    
500 4500 0,25 1,03 
1500 3500 0,75 1,06 
2000 3000 1,00 1,09 
2500 2500 1,25 1,16 
3000 2000 1,50 1,19 
3500 1500 1,75 1,22 
4000 1000 2,00 1,25 
4500 500 2,25 1,28 
    
 
Eight fractions with 2 ml each were collected and proteins were precipitated by adding 18 ml 
ice-cold acetone and incubating overnight at -20°C. Samples were centrifuged for 30 min at 
10.000 g and 4°C. The supernatant was aspirated and protein pellets washed in 4 ml ddH2O + 
16 ml acetone (-20°C) until the remaining sucrose had been washed out. Pellets were dried for 
1 h at room temperature and the protein was resuspended in 80 µl RIPA lysis buffer for 
Western Blot analysis.  
 
HEPES buffer (20 mM): 
 4,766 g HEPES 
 Ad 1 l ddH2O and adjust pH at 7,4 
 
2,5 M sucrose solution: 
 42,75 g sucrose 
 Ad 50 ml 20mM HEPES buffer 
To solve the sucrose completely, the solution was carefully heated and stirred for at least 1 h 
at room temperature.  
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2.2.2.3 Labeling of MV through PKH26 staining 
To visualize uptake of MV into recipient cells, MV were labeled with PKH26 (Sigma). 
PKH26 is a red-fluorescent dye which intercalates non-specifically into lipid membranes and 
can be used for live cell tracking. Up to 100 µg MV were incubated with 250 µl working 
solution for 5 min under constant mixing by pipetting up and down. To stop the staining, 
250 µl particle-free FCS were added and incubated for 1 min. The suspension was diluted 
with 500 µl RPMI-1640 and MV were pelleted at 14.000 g and 4°C for 35 min. The MV 
pellet was washed once in PBS and then resuspended in PBS for further experiments.  
 
PKH26 working solution: 
 250 µl Diluent C 
 1 µl PKH26 
2.2.2.4 Coupling of rhWnt5a to EV 
In order to investigate if rhWnt5a can also associate unspecifically with EV, MV or Exo 
(100 µg each) from the Wnt5a-negative cell line MCF-7 were incubated with 100 ng/ml 
rhWnt5a for 12 h at 37°C. The reaction was carried out in 640 µl particle-free MCF-7 
supernatant in case that additional soluble factors in the tumor cell supernatant are required 
for Wnt5a binding to the vesicles. Subsequently, MV or Exo were isolated from the 
supernatant according to the protocol in 2.2.2.1.1, washed once in PBS and resuspended in 
RIPA lysis buffer for Western Blotting. As negative control, MV and Exo were incubated in 
particle-free MCF-7 supernatant without addition of rhWnt5a and treated as described above. 
To assess whether and how much of the added rhWnt5a remained unbound in the supernatant 
after 12 h of incubation, the supernatant after precipitation of MV or Exo was additionally 
loaded on Western Blot gels.  
2.2.3 Protein biochemistry 
2.2.3.1 Protein isolation 
To isolate protein from MV and Exo preparations, pellets were resuspended in RIPA lysis 
buffer and subjected to protein quantification as described in 2.2.3.2.  
To generate lysates from whole cells, cells were seeded in 6-well plates in a concentration of 
5 ∙ 10
5
 cells (MCF-7, SK-BR-3, Mϕ) or 2 ∙ 10
5
 cells ((Wnt5a-) L cells) per well, allowed to 
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adhere and then incubated with or without previous stimulation. After the indicated time 
points cells were washed once with PBS and then detached from the well with a cell scraper 
on ice in 100 µl RIPA lysis buffer. Lysates were centrifuged for 10 min at 20.000 g and 4°C 
to pellet cell debris and DNA. Supernatants were collected and stored at -20°C.  
 
RIPA lysis buffer: 
 50 mM Tris, pH 7,2 
 150 mM NaCl 
 0,1% SDS 
 0,55 Na-deoxycholat 
 1% Triton X-100 
For protein lysates from whole cells, protease inhibitors (Sigma) as well as phosphatase 
inhibitors (Roche) were added to the lysis buffer.  
2.2.3.2 Protein quantification by Lowry assay 
The protein concentration in whole cell lysates as well as the amount of isolated MV and Exo 
were quantified in a Lowry assay (DC protein assay, Bio-Rad) in relation to a BSA standard 
curve. Samples were diluted in 10 µl ddH2O (1:5 for MV and Exo, 1:10 for cell lysates) and 
the assay was carried out according to the manufacturer’s instructions. The Lowry assay is 
based on the formation of complexes between copper (II) ions and peptide bonds of the test 
sample in alkaline medium. They are subsequently reduced to monovalent cations and can 
react with the Folin-Ciocalteu reagent which results in a blue color that can be measured in a 
photometer at 750 nm (Lowry et al, 1951; Peterson, 1979).  
2.2.3.3 Protein deglycosylation by PNGaseF treatment 
For the analysis of the glycosylation status of EMMPRIN, 30 µg T-MVM were incubated 
under non-denaturing conditions with 1000 U Peptide N-Glycosidase F (PNGaseF, New 
England Biolabs) for 1 hour at 37°C and directly subjected to microinvasion assays or lysed 
in RIPA buffer for Western blotting. PNGaseF removes N-linked oligosaccharides from 
glycoproteins by cleaving between asparagine and N-acetylglucosamines (Maley et al, 1989). 
As deglycosylation control, T-MVM were incubated with 20 U PNGaseF under denaturing 
conditions according to the manufacturer’s instructions.  
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2.2.3.4 SDS-PAGE 
In order to analyze the protein expression in whole cell lysates or EV by Western Blotting 
(see 2.2.3.5), proteins were first separated according to their molecular weight by 
discontinuous SDS polyacrylamide gel electrophoresis (SDS-PAGE) (Laemmli, 1970) 
consisting of two separate gels cast at different pH values. The resolving gel (10%) was 
prepared and after its polymerization the stacking gel (5%) was layered on top. Protein 
samples (EV: 20 µg, cell lysates: 50 µg) were mixed with 4x loading buffer (Roth) and heated 
for 5 min at 95°C. On the one hand, the buffer contains ß-mercaptoethanol which reduces the 
protein disulfide bonds and on the other hand, it comprises SDS that quantitatively binds to 
proteins thereby applying a negative charge in proportion to their mass. Thus, the mobility of 
the proteins during the electrophoresis is solely influenced by their molecular weight. 
Electrophoresis for Wnt5a Western Blots was carried out under non-denaturing conditions 
with β-mercaptoethanol-free loading buffer (bioPLUS). The prepared samples were loaded 
onto the gel and focused in the stacking gel for 30 min at 90 V. Subsequently, proteins were 
resolved for around 90 min at 140 V. For determination of the protein size a protein standard 
(Bio-Rad) was applied.  
 
Stacking gel (5%): 
 1,5 M Tris +2% SDS (pH 6,8)  630 µl 
 Acrylamide/Bisacrylamide (30%) 830 µl 
 APS (10% w/v)    50 µl 
 TEMED     5 µl 
 H2O bidest.    3,45 ml 
 
Resolving gel (10%): 
 1,5 M Tris +2% SDS (pH 8,8)  5 ml 
 Acrylamide/Bisacrylamide (30%) 6,7 ml 
 APS (10% w/v)    200 µl 
 TEMED     20 µl 
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Electrophoresis buffer (1x): 
 25 mM Tris    3 g 
 192 mM Glycin    14,4 g 
 0,1% (w/v) SDS    1 g 
 H2O bidest.    Ad 1 l 
2.2.3.5 Western Blot 
After electrophoresis, proteins were blotted onto a nitrocellulose membrane (GE Healthcare) 
where they then can be detected by specific antibodies. The resolving gel was put on top of 
the nitrocellulose membrane (Hybond-C Extra, GE Healthcare) which had been equilibrated 
in transfer buffer. The blot sandwich was covered by three sheets of Whatman Paper (GB33, 
Heinemann Labortechnik) on each side. Blotting was performed using a semi-dry transfer 
system at 10 V for 75 min. Afterwards the membrane was routinely stained with 0,5% 
Ponceau S (Merck) as loading control and to confirm transfer efficiency. For protein 
detection, the membrane was blocked for 2 h in 5% milk powder (Bio-Rad) in TBST at room 
temperature to saturate unspecific binding sites and subsequently incubated with the specific 
primary antibodies (see 2.1.4) in 5% milk powder in TBST overnight at 4°C. After three wash 
steps with TBST for 5 min each, the membrane was incubated with secondary antibodies 
conjugated to horseradish peroxidase (HRP) (see 2.1.4) in 5% milk powder in TBST for 1 h at 
room temperature and rinsed again three times in TBST for 5 min each.  
 
TBST (1x): 
 20 mM Tris    2,4 g 
 137 mM NaCl    8 g 
 H2O bidest.     ad 1 l and adjust to pH 7,6 
 0,1% (v/v) Tween-20   1 ml 
 
Transfer buffer (1x): 
 25 mM Tris    3 g 
 192 mM glycine    14,4 g 
 20% (v/v) methanol   200 ml 
 H2O bidest.     ad 1 l and adjust to pH 8,3 
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Signals were detected using the ECLPrime detection reagent (GE Healthcare) in the LAS-
4000 imager (Fujifilm). HRP is an enzyme that catalyzes the oxidation of luminol, thereby 
producing a chemoluminescence signal which can be detected in a biomolecular imager.  
2.2.3.6 2D-DIGE 
Using a two-dimensional difference gel electrophoresis (2D-DIGE) approach (Unlu et al, 
1997) up to three different protein samples can be compared in one gel. Each sample is 
labeled with a different fluorescent dye so that after electrophoresis the gel can be scanned 
three times with the excitation wavelength of the respective dye and gel scans obtained 
separately for each sample. Overlay of the three images then allows identification and 
comparative analysis of up- or downregulated proteins. For identification of the proteins, the 
protein spots of interest are excised from the gel, digested with trypsin and subjected to mass 
spectrometry.  
T-MVM before and after N-deglycosylation with PNGaseF using non-denaturing conditions 
were labeled with the Refraction-2D
TM
 Labeling kit (DyeAGNOSTICS). The kit contains the 
fluorescent G-dye 200 and G-dye 300 which covalently bind to lysine residues in protein 
samples. 50 µg of each sample were transferred to a new reaction tube and 2D-DIGE lysis 
buffer was added to a final volume of 10 µl. The samples were vortexed, spun down and 1 µl 
of the respective G-dye working solution (1 nmol G-Dye in 2,5 µl G-Dye solvent, c= 
400 pmol/µl) was added. After incubation for 30 min on ice, the reaction was stopped by 
addition of 1 µl G-dye labeling stop solution and incubating samples for 10 min on ice. To 
avoid dye bias, technical replicates with a dye swap were included.  
 
2D-DIGE lysis buffer: 
 30 mM Tris   0,18 g 
 7 M Urea    21 g 
 2 M Thiourea   7,6 g 
 4% (w/v) CHAPS   2 g 
 H2O bidest.   Ad 50 ml and adjust to pH 8,5 
 
Subsequently, labeled MV samples were mixed and subjected to 2D electrophoresis which 
was performed by Kathrin Darm (University Medicine Greifswald). Proteins were first 
separated according to their isoelectric point by isoelectric focusing. Therefore, samples are 
loaded on an IPG strip which consists of an immobilized pH gradient. An electric potential is 
Materials and Methods  37 
applied to the strip and since the charge of a protein is determined by the pH of the local 
surroundings, proteins will migrate along the gradient until they arrive at the pH value which 
corresponds to their isoelectric point. After the first dimension, the strips were applied to a 
conventional SDS-PAGE (see 2.2.3.4) which further separates the proteins according to their 
molecular weight. Gels were scanned with the Typhoon 9400TM laser scanner (GE 
Healthcare) at 554 nm (G-Dye 200) or 648 nm (G-Dye 300) and an overlay was created using 
the Delta2D software (DECODON GmbH). Spots were numbered and subjected to mass 
spectrometry as described in 2.2.3.7. Mass spectrometry data were analyzed by Dr. Christian 
Scharf (University Medicine Greifswald).  
2.2.3.7 Analysis of the protein glycosylation status by 1D electrophoresis and mass 
spectrometry 
Differences in the glycosylation pattern of the EMMPRIN glyoforms were investigated by 
mass spectrometry in cooperation with Kathrin Darm and Dr. Christian Scharf (University 
Medical Center Greifswald). T-MVM before and after deglycosylation with PNGaseF under 
non-denaturing conditions (described in 2.2.3.3) were subjected to 1D SDS-PAGE. After 
electrophoresis all bands corresponding to the different EMMPRIN glycoforms (HG-, IG-, 
LG-EMMPRIN and core protein) were manually excised from the gel and sent to Greifswald 
for LC-MS/MS analysis. Gel bands were digested with trypsin (ratio 1:25, Promega) 
overnight at 37°C which was stopped by addition of 1% acetic acid. This digestion step is 
essential for the degradation of proteins which would otherwise be too large for analysis. 
Trypsin, a serine-protease, is very stable and has a well-defined specificity cleaving proteins 
at the carboxyl side of lysine and arginine residues.  
Desalting of the peptides was performed with C-18 ZipTip (Millipore) according to the 
manufacturer’s instructions. Tryptic peptides were separated by reverse phase liquid 
chromatography on a Proxeon Easy nano-LC system. Based on the polarity of the peptides, 
they bind to a hydrophobic matrix in an aqueous, polar buffer (0.1% acetic acid, 2% 
acetonitrile in water) and are then eluted by using a linear gradient of a non-polar, organic 
solvent (0,1% acetic acid in 100% acetonitrile). Mass spectrometry of the eluted peptides was 
performed on an Orbitrap Velos mass spectrometer (PicoTip Emitter, New Objective) and 
analyzed by Dr. Christian Scharf as described in detail in (Menck et al, 2014b).  
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2.2.3.8 Detection of metalloproteinase activity by zymography 
Activity of the two gelatinases MMP-2 and -9 can be determined in cell culture supernatants 
or cell lysates by gelatin zymography. Cell lysates (35 µg), supernatants (12 µl) or MV 
(35 µg) were mixed with equal amounts of non-reducing 2x loading buffer without ß-
mercaptoethanol (Invitrogen) and loaded onto SDS-PAGE gels (8%) which had been 
supplemented with 1 mg/ml gelatin. Supernatants (5 µl each) from MCF-7 cells stably 
transfected to overexpress either MMP-2 or -9 were mixed and used as standards. 
Electrophoresis was performed as described in 2.2.3.4 to separate proteins according to their 
molecular weight. Subsequently, gels were washed for 30 min in 2,5% (v/v) Triton-X 100 to 
remove residual SDS from the electrophoresis and incubated for 30 min in renaturation buffer 
at room temperature. The buffer was exchanged and gels incubated overnight at 37°C to 
restore MMP activity. During this time, the gel is locally degraded due to the gelatinase 
activity of MMP-2 and -9. This degradation can be visualized by staining of the gels with 
Coomassie Blue. For the staining, gels were incubated for 4 h in stain/destain solution (1:10). 
To reduce background staining, gels were washed in destain solution until the gelatinase 
bands were clearly visible and fixed for 15 min in fixative solution before gels were dried.  
 
Renaturation buffer: 
 50 mM Tris    6,06 g 
 200 mM NaCl    11,7 g 
 5 mM CaCl2    0,56 g 
 H2O bidest.     ad 1 l and adjust to pH 7,5 
 0,02% (v/v) Brij-35   0,67 ml 
 
Stain solution: 
 0,5% (w/v) Coomassie Brilliant Blue 5 g 
 30% (v/v) methanol   300 ml 
 10% (v/v) acetic acid   100 ml 
 H2O bidest.    ad 1 l 
 
Destain solution: 
 30% (v/v) methanol   300 ml 
 10% (v/v) acetic acid   100 ml 
 H2O bidest.    ad 1 l 
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Fixative solution: 
 30% (v/v) methanol   300 ml 
 5% (v/v) glycerol    50 ml 
 H2O bidest.    ad 1 l 
2.2.4 Immunological methods 
2.2.4.1 Flow cytometry 
2.2.4.1.1 Characterization of MV by flow cytometry 
For characterization of MV by flow cytometry, MV (6 µg) were transferred to round-bottom 
FACS tubes (BD) and incubated in 14 µl PBS +1% particle-free FCS for 15-30 min at room 
temperature to saturate unspecific binding sites. The fluorochrom-labeled antibodies were 
added at the indicated concentrations (see Tab. 4) and samples stained for 20 min at room 
temperature in the dark. For unlabeled primary antibodies the staining was performed at 26°C 
for 40 min, MV washed twice in PBS and signals detected by incubation with FITC-labeled 
anti-mouse or anti-rabbit secondary antibodies (#406403, BioLegend; #sc-2010, santa cruz) 
for 20 min at room temperature in the dark. Irrelevant IgG1 or IgG2b antibodies were used as 
respective isotype-matched negative controls. MV were resuspended in 250 µl PBS and 
fluorescence was measured with a FACSCanto II flow cytometer (BD Biosciences) using the 
FACSDiva software version 6.1.3 (BD Biosciences). Forward scatter (FSC) versus side 
scatter (SSC) dot plots were used to gate the MV population which was then characterized 
further. Histogram overlays were created with GIMP for Windows version 2.8.  
2.2.4.1.2 Characterization of Exo by flow cytometry 
Since Exo are too small to be detected by a normal flow cytometer, they have to be coupled to 
larger latex beads (Ø 4 µm) prior to analysis. For the preparation of the latex beads stock 
solution 30 ∙ 10
6
 aldehyde/sulfate beads (23,08 µl, Invitrogen) are transferred to a reaction 
tube and centrifuged for 20 min at 3000 g. The pellet was washed twice in MES buffer and 
resuspended in 100 µl MES buffer (c=300.000 Beads/µl).  
10 µg Exo per sample were incubated with 1 µl of the beads stock solution in 300 µl MES 
buffer for 1 h at room temperature with gentle shaking. After addition of 300 µl MES buffer, 
samples were put in a tube rotator and gently agitated over night at 4°C. To stop the coupling 
reaction, 400 µl glycine (200 mM) were added followed by incubation at room temperature 
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for 30 min. Exo-Bead complexes were washed twice in PBS +0,5% particle-free FCS for 
10 min at 2.500 g and then subjected to staining and subsequent flow cytometric analyses as 
described in 2.2.4.1.1.  
 
MES buffer: 
 0,025 M MES 
 0,154 M NaCl, pH 6,0 
2.2.4.1.3 Characterization of cells by flow cytometry 
For immunophenotyping of human Mɸ, cells were seeded in 6-well plates at a concentration 
of 1 ∙ 10
6
 cells per well and allowed to adhere overnight. They were washed twice with PBS, 
carefully scraped from the surface of the well and transferred to FACS tubes. Cells were 
pelleted at 750 g and incubated in PBS +1% particle-free FCS for 15 min at room 
temperature. The staining procedure and flow cytometry were performed as described in 
2.2.4.1.1.  
2.2.4.1.4 Determination of MV counts by flow cytometry 
For the determination of MV counts in samples which had been resuspended in equal volumes 
of PBS, 6 µl of each sample were transferred to FACS tubes. After addition of 250 µl PBS 
and 10 µl Flow-Set Beads (Ø 3,3 µm, Beckman Coulter) the samples were measured in a 
FACSCanto II flow cytometer. Next to the routinely used MV gate, a second gate was defined 
around the population of Flow-Set Beads. In each sample 1000 events in the Beads gate were 
recorded and the numbers of MV which had been counted meanwhile were compared. Each 
measurement was performed in triplicate.  
2.2.4.1.5 Measurement of MV uptake by flow cytometry 
For uptake studies, cells were seeded in 6-well plates (human Mϕ: 1 ∙ 10
6
, MCF-7: 5 · 10
5
) 
and pre-incubated for 2 h with 1 µM ZA, 1,25 µM filipin III, 25 µM dansylcadaverine or the 
indicated concentrations of dynasore before 10 µg PKH26-labeled T-MVM were added. After 
24 h of stimulation, cells were washed once in PBS and carefully scraped from the wells in 
500 µl PBS. The red fluorescence of the population of intact cells was measured in a 
FACSCanto II flow cytometer.  
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2.2.4.2 Calcein staining of MV and cells 
The calcein staining is based on the metabolization of calcein-AM to green fluorescent 
calcein. This reaction is catalyzed by esterases in the cytoplasm and only takes place in viable 
cells with an intact plasma membrane. Human Mϕ (1 ∙ 10
6
) or MV (25 µg) were incubated in 
1000 µl PBS + 2 µl calcein-AM (Fluo Cell double staining kit, MoBiTec) for 15 min at 37°C. 
Subsequently, they were washed once with PBS and directly subjected to confocal 
microscopy (2.2.6.2) or measured by flow cytometry (2.2.4.1.1). As negative control for flow 
cytometry assays, MV were incubated for 3 h in 2 ml acetone to destroy membrane integrity 
before calcein staining was performed.  
2.2.4.3 Separation of T-EV by MACS 
For separation of T-EV from human serum samples, the latter were prepared as described in 
2.1.1.3 or 2.2.2.1.3, respectively, and the supernatant after the centrifugation step at 1500 g 
stored for up to 2 weeks at -20°C. To 5 ml of each serum sample 5, 10 or 50 µl magnetically 
labeled anti-EpCAM MicroBeads (Miltenyi Biotec) were added and samples incubated for 2 h 
at 4°C under gentle movement for antibody binding. Subsequently, they were applied to LD 
or LS columns onto a MACS Vario separator (Miltenyi Biotec) which had been equilibrated 
with 2 x 1 ml MACS buffer. Due to the strong magnetic field in the separator, the labeled EV 
are captured in the column, while all EpCAM-negative EV are eluted. The flow-through was 
collected for EV isolation and used as negative control. The EpCAM-positive sorted EV 
bound to the column were eluted in 5 ml MACS buffer after removal of the column from the 
separator and also employed for EV isolation as described in 2.2.2.1.1.  
 
MACS buffer: 
 2 mM EDTA 
 0,5% particle-free FCS 
 Ad 100 ml PBS, adjust to pH 7,2 
2.2.4.4 Measurement of cytokine concentrations by ELISA 
Concentrations of IL-1ß, IL-10 and IL-12 (p70) in supernatants of human Mɸ were measured 
with Legend Max
TM
 ELISA kits (#437007, #430607, #431707, all three from BioLegend) 
with pre-coated plates. Briefly, human Mϕ were seeded in 6-well plates at a concentration of 
5 ∙ 10
5
 cells per well, washed twice with PBS and stimulated for 24 h with LPS (100 ng/ml), 
T-MVM or P-MV (both 25 µg/ml) in 2 ml RPMI +1% particle-free FCS. Supernatants were 
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collected and centrifuged at 2.000 g for 5 min to remove residual cells and debris. The ELISA 
tests were carried out according to the manufacturer’s instructions. Samples (100 µl) were 
measured in triplicate and concentrations calculated in relation to an IL-1ß, IL-10 or IL-12 
standard curve.  
2.2.5 Gene expression analysis 
2.2.5.1 Isolation of total RNA from human tissue samples 
The isolation of total RNA from human brain metastases samples was carried out with the 
TRIzol (Invitrogen) reagent. First, small tissue samples were homogenized in 1 ml TRIzol, 
before 200 µl chloroform were added, mixed and incubated for 5 min at room temperature. 
Centrifugation at 20.000 g for 15 min at 4°C yields three phases with the RNA being present 
in the colorless upper aqueous phase. The upper phase was transferred to a new tube and 
500 µl isopropanol were added. For the precipitation of the RNA, the sample was incubated 
for 10 min at room temperature followed by centrifugation at 13.000 g and 4°C for 30 min. 
The pellet was washed in 1 ml 70% ethanol at 20.000 g and 4°C for 5 min and afterwards air 
dried for 5-10 min. To remove contaminating DNA, the pellet was resuspended in 50 µl DNA 
digestion mix and incubated for 20 min at 37°C. To purify the remaining RNA, 150 µl 
nuclease-free water and 200 µl phenol/chloroform/isoamyl alcohol were added. The sample 
was vortexed for 30 sec and subsequently centrifuged for 2 min at 20.000 g and 4°C. The 
upper aqueous phase which contains the RNA was transferred to a new tube. 20 µl sodium 
acetate (3 M, pH 4,8) and 200 µl isopropanol were added and the sample centrifuged for 
30 min at 20.000 g and 4°C to precipitate the RNA. The pellet was washed twice in 1 ml 70% 
ethanol for 5 min each at 20.000 g and 4°C and was air dried afterwards. The RNA was 
resuspended in 15 µl nuclease-free water and the concentration and purity determined at the 
NanoDrop ND-1000 spectrophotometer (Peqlab).  
 
DNA digestion mix: 
 1 µl DNase I (10 U/µl, Roche) 
 0,5 µl RNase OUT (40 U/µl, Invitrogen) 
 5 µl DNase I incubation buffer (10x, Roche) 
 Ad 50µl nuclease-free water 
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2.2.5.2 Isolation of mRNA from eukaryotic cells and vesicles 
The isolation of mRNA from cultured cells and MV was carried out with the spin column-
based High Pure RNA isolation kit (Roche) according to the manufacturer’s instructions. 
Briefly, the cells were seeded in a concentration of 5 ∙ 10
5
 cells per well in 6-well plates and 
stimulated as indicated. Human Mϕ were seeded at a concentration of 1 ∙ 10
6
 cells on wells 
previously coated with 80 µl ECM (diluted 1:16 in serum-free RPMI-1640). Subsequently, 
cells were washed once with PBS and as well as MV pellets lysed in 400 µl of the lysis-
/binding buffer supplemented with 200 µl PBS. While RNases are inactivated, the buffer 
further contains Triton X-100 which mediates permeabilization of the cell membrane and 
guanidine hydrochloride which induces protein denaturation. The samples were vortexed for 
15 sec to help cell lysis and subsequently applied onto a spin column that consists of glass 
fiber fleece. Columns were centrifuged at 8000 g for 15 sec which leads to the binding of the 
nucleic acids to the column, while proteins, salts and cellular debris are eluted. Contaminating 
DNA was digested directly on the column by incubation with DNase I for 15 min. The 
remaining RNA was washed three times, before 50 µl nuclease-free water were added to the 
column for elution of the isolated RNA. Concentration and purity were measured with the 
NanoDrop ND-1000.  
2.2.5.3 Reverse transcription 
For the analysis of gene expression changes by qRT-PCR, the isolated RNA was transcribed 
into complementary DNA (cDNA) using the iScript cDNA synthesis kit (Bio-Rad). The 
reaction is carried out by the reverse transcriptase, an RNA-dependent DNA polymerase. The 
enzyme binds to the random hexamer oligonucleotides and oligo(dT) primers which are 
contained in the kit. The latter are complementary to the poly-A tail of eukaryotic mRNAs 
allowing reverse transcription of all mRNAs in the sample. The reaction setup was prepared 
as follows: 
 
5x iScript reaction mix    4 µl 
iScript reverse transcriptase    1 µl 
RNA template (1 µg)     x µl 
Nuclease-free water     y µl 
Total volume    20 µl 
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The prepared reaction mix was incubated in a thermal cycler (Biometra) for 5 min at 25°C 
followed by 30 min at 42°C and 5 min at 85°C. Each sample was diluted in a ratio of 1:5 with 
nuclease-free water and stored at -20°C.  
2.2.5.4 Quantitative real-time PCR (qRT-PCR) 
Changes in gene expression were analyzed by quantitative real-time PCR (qRT-PCR) using 
SYBR green detection. The basic principle of this method is a conventional PCR reaction. 
After activation of the hot-start polymerase, the gene of interest is amplified during 40 cycles 
of DNA denaturation, followed by annealing of gene-specific primers and extension of the 
product. Every cycle is completed by measurement of the fluorescence of SYBR green which 
is an intercalating dye that emits a fluorescent signal when bound to double-stranded DNA. 
Since the copy number of the gene of interest is amplified with every cycle, the fluorescence 
increases proportionally and can be plotted versus the cycle number. The number of the cycle 
in which the fluorescence reaches the threshold level is called Ct value and was normalized on 
the expression of two house-keeping genes (=ΔCt value). For relative quantification, the ΔCt 
values were related to an unstimulated control (=ΔΔCt value) which can be used to calculate 
the fold change of the gene of interest according to following equation: 
                   
The primers used in this study were designed as described in 2.2.5.4.1 and are listed in Tab. 5. 
Human samples were normalized on HPRT1 and GNB2L1 expression, murine samples on 
GAPDH and TBP expression. For each gene 8 µl from the prepared PCR reaction mix were 
pipetted into a 384-well plate (Greiner Bio-One) in triplicates. To each well 2 µl cDNA 
(10ng) diluted in nuclease-free water were added. The plate was sealed, spun down (2 min, 
750 g) and RT-PCR was carried out according to the following protocol in the Taqman ABI 
PRISM 7900 HT detection system (Applied Biosystems).  
 
Standard qRT-PCR program: 
 Activation of taq-polymerase:  95°C  12 min 
 Denaturation:    95°C  15 sec  40 cycles 
 Annealing and elongation:  60°C  1 min 
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10× PCR buffer: 
 Tris-HCl pH 8,8    0,75 M 
 Ammoniumsulfate   0,2 M 
 Tween-20     0,1% (v/v) 
 
SYBR-Green master mix: 
All solutions were prepared in nuclease-free water, except the trehalose solution which was 
resuspended in 10 mM Tris-HCl pH 8,0.  
 10x PCR buffer    2,5 ml 
 25 mM MgCl2    3 ml 
 SYBR green (1:100)   31.3 µl 
 20 mM dNTP mix   250 µl 
 5 U/µl Taq polymerase   100 µl 
 10% Triton X-100   652 µl 
 1 M trehalose    7,5 ml 
 
PCR reaction mix: 
 SYBR green master mix   5,6 µl 
 fw-primer (10 µM)   0,3 µl 
 rv-primer (10 µM)   0,3 µl 
 nuclease-free water   1,8 µl 
The qRT-PCR was analyzed with SDS version 2.4 (Applied Biosystems) and fold changes or 
ΔCt values plotted with GraphPad Prism for Windows (version 5.04, GraphPad software).  
2.2.5.4.1 Establishment of primers for qRT-PCR reactions 
Primer pairs for qRT-PCR analyses were designed with PerlPrimer version 1.1.21 (Marshall, 
2004) and then tested for their efficiency. Since analysis of relative gene expression by the 
ΔΔCt-method assumes an amplification efficiency of 100%, comparable primer efficiencies 
are important. A primer efficiency of 100% means that during each PCR cycle the PCR 
product is exactly doubled. To test primer efficiency, a cell line or tissue with high expression 
of the gene of interest was chosen from the BioGPS database (Wu et al, 2009) and a serial 
dilution series of the cDNA with known concentrations was prepared. The measured Ct-
values were plotted versus the amount of input cDNA and the slope of the resulting graph 
Materials and Methods  46 
calculated with SDS version 2.4. A slope of -3,33 equals a primer efficiency of 100%. 
Primers with an efficiency of 90-110% were chosen for further analysis. Moreover, for each 
primer pair the melting curve was analyzed and the PCR product visualized on a 2% agarose 
gel to verify that a single gene product with the correct size was generated.  
2.2.5.4.2 Visualization of qRT-PCR products on agarose gels 
Due to their negative charge DNA fragments can easily be separated according to their size by 
agarose gel electrophoresis. This was used to visualize gene-specific products which have 
been amplified during qRT-PCR. Briefly, 2% agarose (HEEO Ultra, Roth) were added to 
100 ml TAE buffer (1x) and boiled up in a microwave until the agarose was dissolved. The 
solution was allowed to cool down for 3-5 min and 0,1% (v/v) SERVA DNA Stain G (Serva) 
were added. This dye intercalates into nucleic acids which leads to the emission of green 
fluorescence. The agarose solution was poured into a horizontal gel tray and incubated until 
polymerization was finished after 30 min.  
The triplicates of each gene or sample of interest were pooled after successful qRT-PCR 
reaction and transferred to new reaction tubes. 10 µl of each sample were mixed with 2 µl 6x 
loading buffer (Fermentas) and loaded onto the agarose gel. To confirm the correct size of the 
amplified gene products, a molecular weight ladder (Fermentas) was additionally applied to 
the gel. Electrophoresis was performed in a horizontal electrophoresis chamber (Biotec-
Fischer) at 100 V for 45 min and gene-specific products subsequently visualized on an UV 
Transilluminator (Biometra).  
 
10x TAE buffer: 
 0,4 M Tris  
 0,2 M acetic acid 
 0,01 M EDTA 
 ad 1 l H2O bidest and adjust pH to 8,5 
2.2.6 Microscopy 
2.2.6.1 Fluorescence microscopy 
MV uptake into MCF-7 or SK-BR-3 cells was evaluated by fluorescence microscopy. 
Therefore, MV were labeled with the red fluorescent dye PKH26 as described in 2.2.2.3. 
5 ∙ 10
5
 tumor cells were seeded in 6-well plates followed by stimulation with 10 µg PKH26
+
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MV for 24 h. Uptake was visualized using the Axiovert 200M fluorescence microscope 
(Zeiss). For quantitative analyses particular care was taken to record all images with the same 
exposure time.  
2.2.6.2 Confocal microscopy 
Uptake of T-MVM into Mϕ was analyzed by confocal microscopy to ensure that the vesicles 
were indeed present inside the cells and did not only stick to the cellular surface. Human Mϕ 
were seeded in 6-well plates (5 ∙ 10
5
 per well), washed twice with PBS and stimulated with 
10 µg PKH26
+
 T-MV for 24 h. Afterwards, cells were washed twice with PBS and the 
cytoplasm of the Mϕ was counterstained with calcein-AM (2.2.4.2). Pictures were taken at the 
LSM 510 Meta confocal microscope (Zeiss).  
2.2.6.3 Electron microscopy 
The electron microscopy of MV was performed by Dr. Dirk Wenzel (Max Planck Institute for 
Biophysical Chemistry, Göttingen) and Exo were analyzed by Dr. Julia Gross (German 
Cancer Research Center, Heidelberg). Vesicle pellets were fixed in 2% paraformaldehyde and 
applied to carbon-coated grids (400 mesh, Plano GmbH). After postfixation in 1% 
glutaraldehyde, the grid was washed in dH2O. Negative contrasting was achieved by 
incubating the grid for 30 s in 1% uranyl acetate and EV visualized with the CM 120 Bio 
Twin transmission electron microscope (Philips) and iTEM software (Olympus). For 
immunogold staining of Wnt5a, MV pellets were stained with rat anti-Wnt5a primary 
antibody (#MAB645, R&D systems) followed by detection with an immunogold-labeled 
secondary antibody (#810.077, Aurion).  
2.2.7 Statistical analysis 
All experiments were performed at least in biological triplicates. Data are displayed as 
means±SD and statistical significance was calculated with a two-sided student’s t-test, unless 
indicated otherwise. P-values <0,05 were considered significant. Data were plotted with 
GraphPad Prism for Windows (version 5.04, GraphPad software). Significance for patient 
data was calculated by Dr. Annalen Bleckmann (University Medical Center Göttingen, Dept. 
Hematology/Oncology).  
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3 Results 
The aim of this thesis was to investigate the influence of tumor-derived extracellular vesicles 
(T-EV) on the local tumor microenvironment, especially regarding their impact on the 
invasiveness of breast cancer cells.  
Therefore, the first part of the thesis focusses on the role of T-EV for the intercellular 
communication between neighboring tumor cells. In this context, we tried to elucidate the 
molecular mechanisms which are responsible for the phenotypic differences between different 
microvesicle (MV) populations and to identify markers which are characteristic for pro-
invasive MV. The major part of this subproject is to be published in (Menck et al, 2014b).  
In the second part of the thesis we further investigated whether EV are also involved in the 
pro-invasive interactions between tumor cells and macrophages (Mϕ). In this context, we 
analyzed the influence of tumor-derived EV for the induction and transport of the tumor-
promoting factor Wnt5a. Special attention was paid to the protein Evi/WLS and its 
significance for the expression of Wnt5a on MV. Moreover, we investigated the effect of the 
bisphosphonate zoledronic acid (ZA) on MV-mediated tumor-Mϕ crosstalk. Most of the 
results have been published in (Menck et al, 2013) and (Rietkotter et al, 2013).  
In a translational approach we then tried to establish a reproducible method to isolate EV from 
peripheral blood which is described in the last part of the thesis. T-EV were screened in vitro 
for the expression of suitable tumor markers which were then conferred to EV isolated from 
metastatic cancer patients and used to identify T-MV in the blood of these patients.  
3.1 EV as mediators of tumor-tumor interactions 
The fact that cells release extracellular vesicles into the extracellular space is already known 
for a long time. However, they were always considered as cellular debris and are only recently 
increasingly accepted as novel means of intercellular communication. We hypothesized that 
T-EV play an important role in tumor-tumor crosstalk and aimed to investigate their mode of 
action. Since MV are far less investigated than Exo, we further tried to define MV-associated 
tumor markers which allow their discrimination from Exo.  
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3.1.1 Tumor cells release two distinct populations of extracellular vesicles 
In order to investigate if our EV isolation protocol indeed allows the preparation of two 
distinct vesicle populations, MV and Exo were isolated from cell culture supernatants of 
MCF-7 (T-MVM and T-ExoM) and SK-BR-3 (T-MVS and T-ExoS) breast cancer cells as well 
as from outdated (< 1 day) platelet concentrates (P-MV) and the benign mammary epithelial 
cell line hTERT-HME1 (hTERT-MV). Since there is increasing evidence that the vesicular 
cargo is modulated by the state of the cell of origin (Mause & Weber, 2010), all vesicles were 
obtained under basal conditions without any previous stimulation of the cells which could 
alter the EV protein expression pattern. Moreover, particular care was taken to use only viable 
cells to prevent the release of apoptotic bodies from the tumor cells.  
 
Fig. 7: MV and Exo are different populations of extracellular vesicles 
A+B, TEM images of T-MV (A) and T-Exo (B) preparations showing two different types of extracellular 
vesicles (scale bars: 200 nm). C, Expression of the MVB protein Tsg101 was analyzed on MV and Exo from 
SK-BR-3 cells in comparison to whole cell lysates (C) by Western Blotting. D-F, MV and Exo were analyzed by 
flow cytometry: Forward scatter (FSC) versus side scatter (SSC) plots were used to gate the respective MV or 
Exo population (D) which was then used for further characterization. As size control for MV gating, calibration 
beads (3,3 µm, indicated in red) were used. MV and Exo were characterized for the expression of the known Exo 
marker CD63 (E) and membrane integrity of MV was determined by staining with calcein-AM (F). Specific 
signals are indicated in green, corresponding isotype controls in grey. Modified from (Menck et al, 2013).  
Results  50 
Transmission electron microscopy (TEM) revealed two distinct populations of extracellular 
vesicles: 1) MV consisting of a population of very heterogeneous, large vesicles with a 
diameter > 100 nm which neither contained cell organelles nor fragmented DNA (Fig. 7A) 
thereby excluding the presence of apoptotic bodies; 2) typically cup-shaped Exo with a 
diameter of < 100 nm (Fig. 7B).  
Moreover, the preparations were analyzed for the expression of known Exo marker proteins 
(Fig. 7C-E). Tsg101, typically associated with multivesicular bodies (MVB), as well as the 
intracellular tetraspanin CD63 were found exclusively on Exo preparations, while they were 
not present on MV. This confirms that MV and Exo not only differ in their morphology, but 
also in their protein content. To investigate if membrane integrity of the vesicles was 
maintained during the isolation process, we stained T-MVM as well as P-MV with calcein-
AM which is converted by cytoplasmic esterases to green fluorescent calcein. Indeed, both 
MV populations were positive for calcein, confirming the presence of intact membrane 
vesicles (Fig. 7F).  
3.1.2 T-MV enhance human breast cancer invasion 
While T-Exo have already been desribed to increase cancer cell invasion (Graves et al, 2004; 
Higginbotham et al, 2011), little is known about the effect of T-MV on tumor progression. To 
address this question, we stimulated MCF-7 and SK-BR-3 breast cancer cells with autologous 
and heterologous T-MV (10 µg/ml) as well as with the corresponding vesicle-free 
supernatants which neither contain MV nor Exo. Stimulation with MV isolated from benign, 
immortalized hTERT-HME1 mammary epithelial cells (hTERT-MV) was employed as 
negative control. Interestingly, T-MV were able to enhance tumor invasion by up to 400%, 
whereas neither hTERT-MV nor the vesicle-free supernatants influenced tumor invasion (Fig. 
8A+B) indicating that the effect is a special feature of T-MV populations. T-ExoM also 
significantly increased MCF-7 invasion, although the effect was clearly less pronounced 
compared to MV (Fig. 8A). For this reason, we decided to focus further investigations 
regaring tumor-tumor crosstalk on T-MV.  
To exclude that the observed effect was due to an influence of T-MV on cancer cell 
proliferation, we seeded MCF-7 cells on ECM-coated 24-well plates and stimulated them 
with T-MVM (10 µg/ml) for 96 h. However, the proliferation rate of the cells remained 
unchanged (Fig. 8C). Dilution experiments revealed that already 0,1 µg/ml T-MVM are 
sufficient to exert a pro-invasive influence on MCF-7 cells (Fig. 8D) in microinvasion assays. 
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Taken together, the finding that T-MV stimulate tumor invasion in a dose-dependent manner, 
while hTERT-MV have no such effect, confirms that MV-induced tumor invasion is indeed a 
specific and not an unphysiological, artificial effect.  
 
Fig. 8: T-MV enhance tumor invasion in an autologous and heterologous way 
A+B, Microinvasion assays of MCF-7 (A) and SK-BR-3 (B) cells stimulated with T-MV (10 µg/ml), T-Exo 
(10 µg/ml) or the corresponding vesicle-free supernatants (T-sn, diluted 1:3 in culture medium). Benign hTERT-
MV (10 µg/ml) were used as negative control, stimulation with rhWnt5a (100 ng/ml) was employed as positive 
control (means±SD, n=3, *p<0,001). C, T-MV have no influence on MCF-7 proliferation as determined by cell 
counting experiments (means±SD, n=3). D, T-MV were able to enhance MCF-7 cell invasion in a dose-
dependent manner (microinvasion assays, means±SD, n=3, *p<0,05, **p<0,001). E, Microinvasion assay of 
hTERT-HME1 cells stimulated with autologous hTERT-MV or heterologous T-MV (both 10 µg/ml). MCF-7 
cells ± rhWnt5a (100 ng/ml) are displayed as positive control (means±SD, n=3, *p<0,0001). Modified from 
(Menck et al, 2014b).  
Since EV have often been described to transfer malignant characteristics to surrounding 
benign cells, we examined the influence of T-MV on benign hTERT-HME1 cells in 
microinvasion assays. As shown in Fig. 8E, neither stimulation with autologous hTERT-MV 
nor heterologous malignant T-MVM was able to induce an invasive phenotype in the cells 
suggesting that the recipient cell has to be predisposed for an invasive phenotype.  
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3.1.3 Uptake is essential, but not specific for pro-invasive MV 
We then hypothesized that the phenotypic difference between pro-invasive and non-pro-
invasive MV populations is caused by a differential uptake of the vesicles into their target 
cells. To address this question, we incubated MCF-7 breast cancer cells with PKH26-labeled 
MV and assessed MV uptake by fluorescence microscopy (Fig. 9A). Nonetheless, after 24 h 
all MV populations had been taken up by the cancer cells, arguing against a differential 
uptake as discriminating criterion between pro-invasive and non-pro-invasive MV.  
In order to investigate if uptake is nonetheless essential for the pro-invasive function of T-
MV, we tried to inhibit MV uptake through incubation with endocytosis inhibitors which 
target different endocytotic pathways. On the one hand, we chose filipin III which interferes 
with caveolae-mediated uptake, on the other hand, we employed dansylcadaverine which 
blocks clathrin-mediated endocytosis. To titrate the highest tolerable dose of both inhibitors 
which can be used for treatment without affecting cellular viability, we performed MTT 
assays (Fig. 9B) as well as proliferation assays with the xCELLigence system (Fig. 9C). 
Based on known IC50 concentrations in the literature as well as the data from our viability 
analyses we chose to assess the inhibitory effect of 10 µM filipin III as well as 25 µM 
dansylcadaverine on T-MV uptake into MCF-7 cells. However, MV uptake was influenced by 
neither of the two inhibitors (Fig. 9D) suggesting that MV uptake occurs independent of 
classical endocytotic routes via clathrin- or caveolin-mediated endocytosis.  
Next, we targeted dynamin which is a large membrane protein involved in diverse endocytotic 
pathways. It is required for the scission, and thereby uptake, of invaginated endocytotic 
vesicles into the cell (Doherty & McMahon, 2009; McNiven et al, 2000). Interestingly, 
dynasore which is a potent inhibitor of the GTPase activity of dynamin was able to reduce T-
MV uptake into MCF-7 cells by around 50% in concentrations which did not interfere with 
cellular viability (Fig. 9E+F). Moreover, pre-incubation of cancer cells with dynasore 
significantly impaired the pro-invasive effect of T-MV on MCF-7 cells in microinvasion 
assays (Fig. 9G). These results indicate that MV uptake occurs in a dynamin-dependent 
mechanism and is an important pre-requisite for MV function.  
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Fig. 9: MV uptake does not differ between MV populations, but is important for their pro-
invasive function and relies on a dynamin-dependent mechanism 
A, MCF-7 cells were stimulated with PKH26-labeled MV (5 µg/ml) for 24 h and uptake was evaluated by 
fluorescence microscopy (magnification: 10x, inserts: bright fields). B+C, MTT assay (B) and xCELLigence 
measurements (C) of MCF-7 cells treated for 96 h or 72 h, respectively, with filipin III (Fil) or dansylcadaverine 
(Cad). OS = Overall survival D, Flow cytometry: Treatment of MCF-7 cells with Fil (10 µM) or Cad (25 µM) 
for 24 h has no effect on MV uptake (means±SD, n=3). E, MTT assay of MCF-7 cells incubated for 48 h with 
increasing concentrations of the dynamin-inhibitor dynasore (Dyn) (means±SD, n=3, *p<0,01, **p<0,001). 
F+G, Treatment with Dyn significantly decreases MV uptake into MCF-7 cells (F) (means±SD, n=3, *p<0,01, 
**p<0,001) resulting in a reduction of the pro-invasive effect of T-MV on MCF-7 cell invasion in microinvasion 
assays (G) (means±SD, n=3, *p<0,001). H, Heating of T-MV (5 min, 95°C) significantly reduces the pro-
invasive potential of T-MV on MCF-7 invasiveness (means±SD, n=4, *p<0,001). Modified from (Menck et al, 
2014b).  
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Next, we asked whether the pro-invasive effect of T-MV might be caused by proteins which 
are differentially expressed on malignant and benign MV. Therefore, we heated T-MV for 
5 min at 95°C which leads to protein denaturation due to the disruption of hydrogen bonds 
and non-polar hydrophobic interactions. Heated T-MV induced significantly less tumor 
invasion compared to non-heated T-MV (Fig. 9H) which points to the fact that parts of the 
pro-invasive effect of malignant MV are indeed mediated by proteins.  
3.1.4 EMMPRIN – a novel marker for MV 
In order to identify which proteins are differentially expressed on pro-invasive and non-pro-
invasive MV, we investigated EMMPRIN as a possible candidate protein. Previous 
experiments from our group had shown that knockdown of EMMPRIN in tumor cells 
antagonizes the pro-invasive tumor-Mϕ crosstalk in co-culture experiments (Hagemann et al, 
2005). Western Blot analyses revealed an enrichment of EMMPRIN on T-MV, whereas it was 
absent on T-Exo (Fig. 10A+B). Since EMMPRIN can be glycosylated at different sites, it can 
be found in two different glycoforms: Either in its highly glycosylated form (HG EMMPRIN, 
45-65 kDa) or in a less glycosylated form (LG EMMPRIN, 32 kDa). Both forms were found 
on T-MV, although LG-EMMPRIN was only weakly expressed compared to HG-EMMPRIN.  
In order to evaluate EMMPRIN as a novel marker for MV, we screened EV from both breast 
cancer cell lines, MCF-7 and SK-BR-3, for the expression of known MV and Exo markers 
(Fig. 10C). The established Exo marker Tsg101 was indeed predominantly present on Exo, as 
was the transcription factor Runx1. In contrast, α-tubulin was mainly found at high levels in 
MV. Surprisingly, Flotillin-2 which is often used as marker for Exo was expressed on MV as 
well as Exo and is therefore in our hands no suitable marker for the discrimination of both. 
We additionally investigated these established markers for discrimination of MV and Exo in 
sucrose gradient preparations. Exo usually float in density fractions ranging from 1,13-
1,19 g/ml
-1
 (Thery et al, 2006) and sucrose gradient ultracentrifugation is often recommended 
as the standard method to separate Exo from MV (Gyorgy et al, 2011b).  
T-MVS and T-ExoS were layered separately on sucrose step gradients. The distribution of the 
markers was analyzed by Western Blotting (Fig. 10D). Interestingly, both vesicle populations 
floated in comparable density fractions ranging from 1,13-1,22 g/ml
-1
. Compared to the other 
markers, EMMPRIN was the only protein which was almost exclusively found on MV, while 
the others were present to some extent on both EV populations. Furthermore, the results 
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suggest that sucrose gradient floatation alone is no suitable method for the accurate separation 
of MV and Exo in the same solution.  
 
Fig. 10: EMMPRIN expression discriminates MV and Exo 
A+B, Western Blot analysis of EMMPRIN (EMP) expression on MV (A) and Exo (B) from MCF-7 and SK-BR-
3 cells showing an enrichment on T-MV, while it is absent on T-Exo. Due to differential glycosylation 
EMMPRIN can occur in a highly glycosylated (HG EMP) or low glycosylated (LG EMP) form. C = Whole cell 
lysates; C, Comparative analysis of known MV and Exo markers (Western Blot). D, T-MVS and T-ExoS were 
loaded separately on sucrose step gradients and the distribution of the vesicles in the eight different density 
fractions was analyzed based on the established MV and Exo markers. Modified from (Menck et al, 2014b).  
3.1.5 EMMPRIN is involved in the pro-invasive function of T-MV 
After having established EMMPRIN as a sensitive and specific marker which is expressed at 
high levels on T-MV, we asked if it is critical for the pro-invasive phenotype of T-MV. 
Therefore, we performed a stable knockdown of EMMPRIN via shRNA (see 2.2.1.2) in SK-
BR-3 cells because their MV showed the highest endogenous EMMPRIN expression (Fig. 
10A).  
After knockdown, EMMPRIN was only weakly detectable in the cells and their released MV 
(Fig. 11A). Consistently, this resulted in a significantly impaired pro-invasive effect of T-
MVS from EMMPRIN-knockdown (shEMP) cells compared to T-MVS from cells transfected 
with an unspecific non-sense control shRNA (ns ctl) (Fig. 11B+C). These results point 
towards EMMPRIN as one of the factors which mediate the pro-invasive phenotype of T-MV. 
Since we had shown that ingestion of T-MV is important for their pro-invasive effect, we 
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analyzed whether EMMPRIN knockdown interferes with this process. However, there was no 
difference in the uptake of T-MVS from shEMP or ns ctl cells into MCF-7 or SK-BR-3 breast 
cancer cells (Fig. 11D+E).  
 
Fig. 11: Knockdown of EMMPRIN in SK-BR-3 cells reduces the pro-invasive effect of T-MV 
A, Western Blot: Comparison of the EMMPRIN expression on cells and corresponding MV from SK-BR-3 cells 
stably transfected with a non-sense shRNA (ns ctl) or an EMMPRIN-specific shRNA (shEMP). B+C, The pro-
invasive effect of T-MVS (1 µg/ml) from SK-BR-3 shEMP cells on MCF-7 (B) and SK-BR-3 (C) cell invasion 
was significantly reduced compared to MV from SK-BR-3 ns ctl cells (microinvasion assays, means±SD, n=3, 
*p<0,01). D+E, There was no significant difference in the uptake of PKH26-labeled T-MVS from shEMP or ns 
ctl cells into MCF-7 (D) or SK-BR-3 (E) cells as visualized by fluorescence microscopy (magnification: 10x, 
inserts: bright fields). Modified from (Menck et al, 2014b).  
3.1.6 The glycosylation status of EMMPRIN is important for its function 
Since the experiments identified EMMPRIN as one of the pro-invasive factors on T-MV, we 
then asked whether differential expression on malignant and benign MV would explain their 
different function (Fig. 12A). Surprisingly, the benign hTERT-HME1 displayed the strongest 
EMMPRIN expression in Western Blot analyses indicating that EMMPRIN expression per se 
does not discriminate malignant and benign MV. However, while all pro-invasive T-MV 
seemed to express a very highly glycosylated form of EMMPRIN (HG-EMMPRIN, 
>50 kDa), benign P-MV and hTERT-MV both expressed a less glycosylated form which has 
been undescribed so far and which we termed intermediately glycosylated EMMPRIN (IG-
EMMPRIN, 45-50 kDa).  
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Fig. 12: The pro-invasive effect of T-MV is mediated by HG-, and not IG-EMMPRIN 
A, Western Blot: Expression of EMMPRIN was analyzed in various cells (=C) and their corresponding MV. 
While all pro-invasive MV carry a very highly glycosylated form of EMMPRIN (HG-EMP, >50 kDa), all benign 
MV express an only intermediately glycosylated form (IG-EMP, 45-50 kDa). B, Deglycosylation of T-MVM 
under non-denaturing conditions with PNGaseF (1 h, 37°C, visible as unspecific band in lane 1+3) results in a 
loss of HG-EMP and reveals the less glycosylated IG- and LG-EMP. As positive control T-MVM were 
deglycosylated under denaturing conditions which leads to full deglycosylation to the core protein. C, 
Microinvasion assay: T-MVM (10 µg/ml) deglycosylated under non-denaturing conditions induce significantly 
less MCF-7 cell invasion compared to control T-MVM (1 h, 37°C, w/o PNGaseF), while PNGaseF itself 
stimulates tumor invasion (means±SD, n=3, *p<0,001). Taken from (Menck et al, 2014b).  
To confirm that HG- and IG-EMP are indeed two different glycoforms, we deglycosylated T-
MVM with Peptide-N-Glyosidase F (PNGaseF) which cleaves between asparagine residues 
and N-acetylglucosamines and thereby specifically releases N-linked oligosaccharides (Maley 
et al, 1989). Deglycosylation under non-denaturing conditions for 1 h at 37°C led to only 
partial deglycosylation with a loss of HG-EMMPRIN which was converted to less 
glycosylated IG- and LG-EMMPRIN (Fig. 12B). Complete deglycosylation to the core 
protein (27 kDa) was only observed when T-MVM were denatured (10 min, 100°C) prior to 
incubation with PNGaseF in corresponding G7 reaction buffer. To test whether T-MV 
carrying IG- and LG-EMMPRIN instead of HG-EMMPRIN are still able to induce tumor 
invasion, we stimulated MCF-7 cells in microinvasion assays with T-MVM which had been 
deglycosylated under non-denaturing conditions (Fig. 12C). Interestingly, these T-MV had a 
significantly less pronounced effect on tumor invasion compared to control T-MV. This 
clearly suggests that especially HG-EMMPRIN is involved in the pro-invasive MV function. 
To exclude that the diminished tumor cell invasiveness is caused due to a direct effect of 
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residual PNGaseF activity on the tumor cells, we additionally stimulated MCF-7 cells with 
the enzyme alone. On the contrary, this increased tumor invasion (Fig. 12C) which shows that 
there are indeed additional effects due to deglycosylation of other proteins on the tumor cells, 
however, they rather counteract the observed effect of deglycosylated T-MV.  
 
Fig. 13: 2D-DIGE of deglycosylated T-MV 
This image represents an overlay of two separately scanned images from a 2D-DIGE gel of untreated versus 
deglycosylated (non-denaturing conditions) T-MVM (30 µg each). Protein spots were numbered, manually 
excised and subjected to mass spectrometry. Green = proteins with stronger expression on untreated T-MVM; 
Red = proteins with stronger expression on T-MVM after deglycosylation with PNGaseF; Yellow = proteins 
equally expressed in both samples.  
Since PNGaseF deglycosylates all N-glycosylated proteins on T-MV, it is possible that other 
proteins contribute to the observed reduction in MV-mediated tumor invasion. In order to 
investigate whether and which other glycoproteins on T-MVM might be affected by removal 
of N-linked oligosaccharides, we performed 2D-DIGE from untreated versus PNGaseF-
treated T-MVM in cooperation with Kathrin Darm and Dr. Christian Scharf (University 
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Medicine Greifswald). In first experiments a good separation of the MV proteins was 
achieved and 388 protein spots were identified, excised and subjected to mass spectrometry 
for protein identification (Fig. 13). Glycoproteins which are affected by PNGaseF treatment 
are visible as green or red spots on the gel, depending on the fact in which sample (untreated 
or PNGaseF-treated) they show a stronger expression. Yellow spots represent an equal 
expression of the protein under both conditions. All spots which could be identified by mass 
spectrometry exclusively in either condition (marked in red/green) are listed in chapter 7.1. 
Unfortunately, not all picked spots, including EMMPRIN, could be positively matched to a 
corresponding protein, probably due to the low abundance of these proteins which was not 
sufficient for mass spectrometry identification.  
3.1.7 Identification of a novel EMMPRIN glycoform 
To further confirm our hypothesis that HG- and IG-EMMPRIN are indeed characterized by a 
differential glycosylation pattern on T-MV, we deglycosylated T-MVM under non-denaturing 
conditions with PNGaseF and subjected them to SDS-PAGE for separation of the different 
EMMPRIN glycoforms. All EMMPRIN-containing bands identified by immunoblotting (see 
Fig. 12B) were manually excised from the gel and sent to Greifswald for LC-MS/MS 
analyses. Mass spectrometry and data analysis were performed by Dr. Christian Scharf and 
are described in detail in (Menck et al, 2014b).  
All peptides identified by mass spectrometry were aligned with the four known EMMPRIN-
isoforms to assess sequence coverage (Fig. 14A). As expected, neither the signal peptide (1-
21) nor peptides from the transmembrane domain (324-344) were found in any sample. 
Moreover, peptides specific for the isoforms EMMPRIN-1 or EMMPRIN-4 were also 
missing. Spectral counting of the N-terminal fragments of EMMPRIN-2 and -3 presented a 
ratio of 10:1 which confirms that EMMPRIN-2 is the most abundant isoform on T-MVM. To 
address the question if EMMPRIN-2 is also involved in tumor progression in vivo, we 
performed an mRNA screening on brain metastases from eight breast cancer patients and 
compared them to our in vitro breast (cancer) cell lines. Indeed, EMMPRIN-2 was expressed 
in the tumor tissues and samples as well as in the benign cell line hTERT-HME1 (Fig. 14B) 
which further supports the hypothesis that not EMMPRIN expression per se, but 
posttranslational modifications are essential for its function.  
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Fig. 14: EMMPRIN-2 is the predominant isoform on T-MVM 
A, Sequence coverage of the identified peptides (yellow) in LC-MS/MS analyses for the four known EMMPRIN 
isoforms (1-4). B, The expression of EMMPRIN-2 was assessed by qRT-PCR from total RNA samples of the 
two breast cancer cell lines MCF-7 and SK-BR-3, benign hTERT-HME1 mammary epithelial cells as well as 
eight brain metastases from breast cancer patients (BC brain mets). Modified from (Menck et al, 2014b).  
Mass spectrometry was further used to analyze the glycosylation status of the three predicted 
N-glycosylation sites of EMMPRIN which are displayed in Fig. 15A. Because of their large 
size, glycosylated peptides cannot be detected by mass spectrometry. In contrast, when N-
linked glucosaccharides are removed from their asparagine (=N) residues by PNGaseF 
treatment, this causes deamidation of the N-residues to aspartic acid (=D) and allows the 
detection of these fragments which are characterized by an increase in their peptide mass by 1 
mass unit. Therefore, absence of a peptide with a putative N-glycosylation site which 
reappears after deglycosylation of the samples with a deamidated N-residue, identifies N-
glycosylation sites.  
Based on this principle, we screened all three predicted N-glycosylation sites. Indeed, the two 
peptides which carry the glycosylation site N160 or N268, respectively, were absent in HG-
EMMPRIN, while they were detected with deamidated N-residues in IG-EMMPRIN and core 
protein samples (Fig. 15B-D, Fig. 47). Additionally, they were also found in the HG-
EMMPRIN spot after subsequent in-gel deglycosylation with PNGaseF. There was no 
consistent deamidation pattern detectable for the third predicted glycosylation site at N302. 
Taken together, these results show that HG-EMMPRIN on the pro-invasive T-MVM is N-
glycosylated at the residues N160 and N268, while they are not glycosylated in the IG-
EMMPRIN form which is expressed on non-pro-invasive MV.  
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Fig. 15: Mass spectrometry reveals differential glycosylation of HG- and IG-EMMPRIN 
A, Schematic representation of EMMPRIN-2 with the three known N-glycosylation sites. B, While the peptides 
with the two N-glycosylation sites N160 and N268 (yellow) are absent in HG-EMMPRIN, they are detectable in 
IG-EMMPRIN as well as core protein samples with deamidated N-residues (green). C+D, MS spectra for the 
two peptides carrying N160 or N268, respectively, which were not present in HG-EMMPRIN spots. E, In-gel 
deglycosylation of the HG-EMMPRIN spot with PNGaseF led to detection of both peptides with deamidated N-
residues which confirms glycosylation at N160 and N268 in HG-EMMPRIN. Modified from (Menck et al, 
2014b).  
3.1.8 EMMPRIN-carrying T-MV increase tumor invasion through activation of 
p38/MAPK 
Next, we were interested in the mechanism which mediates MV-induced tumor invasion. 
Since pro-invasive T-MV we found to express HG-EMMPRIN at high levels and the role of 
MV-bound EMMPRIN for induction of MMP is well established (Muralidharan-Chari et al, 
2010), we first investigated MMP levels in MCF-7 cells after stimulation with T-MVM. 
However, T-MVM did not augment the expression of selected MMP including MMP14, 
MMP15 or MMP9 (Fig. 16A). Moreover, also the expression of MMP-9 and MMP-2 
remained unchanged in zymography assays of the supernatant of MCF-7 cells after T-MV 
stimulation (Fig. 16B). Only P-MV which were employed as negative control seemed to 
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induce a slight induction of MMP-9 on the mRNA and protein level, however, this did not 
reach statistical significance. Although T-MV have been previously described as carriers for 
MMP (Dolo et al, 1998; Ginestra et al, 1997), neither T-MVM nor T-MVS were found to 
express MMP-2 (data not shown) or MMP-9 in zymography assays (Fig. 16C). In contrast, 
benign MV from unstimulated human Mϕ (Mϕ-MV) or P-MV were positive for MMP-9, 
suggesting that the presence of MMP is not essential for the conveyance of a pro-invasive 
phenotype of MV. We then looked for the activation of other known pro-invasive EMMPRIN 
target genes in MCF-7 cells after stimulation with EMMPRIN-bearing T-MVM. However, 
neither VEGFA, CSF1 nor TNFα expression was increased in the cells in qRT-PCR 
screenings (Fig. 16D). Moreover, EMMPRIN is known to induce its own transcription via a 
positive feedback loop mechanism. Nonetheless, we also could not observe such autologous 
stimulation of EMMPRIN expression itself (Fig. 16D).  
 
Fig. 16: T-MV have no effect on known EMMPRIN target genes in tumor cells 
A, The expression of selected MMP was measured by qRT-PCR from total RNA samples of MCF-7 cells 
stimulated for 24 h with T-MVM or P-MV (both 25 µg/ml) (means±SD, n=3). B, MCF-7 cells were stimulated 
for 24 h with increasing concentrations of T-MVM or P-MV and MMP-2 and -9 levels were assessed in tumor 
cell supernatants by zymography assays. C, Comparative analysis of MMP-9 expression in whole cell lysates 
(=C) and their corresponding MV (zymography). MCF: MCF-7, SK: SK-BR-3, P: platelets. D, No changes in 
mRNA levels of known EMMPRIN target genes were detected in MCF-7 cells after 24 h of stimulation with T-
MVM or P-MV (both 25 µg/ml) by qRT-PCR from total RNA samples (means±SD, n=3). Modified from (Menck 
et al, 2014b).  
For this reason, we decided to investigated signaling events upstream of target gene induction. 
One signaling pathway that has been described to participate in EMMPRIN-mediated 
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signaling is the p38 (MAPK14) pathway (Lim et al, 1998). Indeed, in time course analyses of 
p38 pathway activation in MCF-7 cells stimulated with T-MVM, we observed a 
phosphorylation, and thus activation, of p38 after 1 h of stimulation, while total p38 protein 
levels remained unchanged (Fig. 17A). To test if the activation of the p38 signaling cascade is 
indeed involved in MV-mediated tumor invasion, we pre-incubated MCF-7 cells for 2 h with 
the pyridinylimidazole compound SB-203580 which binds to the ATP-binding pocket of p38 
and thereby prevents its catalytic activity (Kumar et al, 1999). After treatment of the cells 
with SB-203580 in concentrations which did not interefere with cellular viability (Fig. 17B), 
T-MV were added and found to induce significantly less tumor invasion in microinvasion 
assays (Fig. 17C). This indicates that p38 signaling is in fact important for T-MV to confer 
their autologous pro-invasive effect on tumor cell invasion.  
 
Fig. 17: p38 signaling partially mediates the pro-invasive function of T-MV 
A, MCF-7 cells were stimulated with T-MVM (25 µg/ml) and expression of p38 and phosphorylated (P)-p38 was 
assessed by Western Blotting after different time points. B, MTT assay of MCF-7 cells treated for 96 h with SB-
203580 (SB, 0,5 µM). n.s. = not significant C, Microinvasion assay of MCF-7 cells pre-treated for 2 h with SB-
203580 before addition of 10 µg/ml T-MVM (means±SD, n=3, *p<0,001). Modified from (Menck et al, 2014b).  
Stimulation of MCF-7 cells with T-MVM further induced an increase in phosphorylated c-jun 
which suggests an additional activation of the JNK-pathway (Fig. 18A). However, in parallel, 
we observed a concordant augmentation of total c-jun protein levels (Fig. 18A). This raised 
the question if the observed increase might be caused due to enhanced JUN transcription and 
thus synthesis of the c-jun protein. Therefore, we performed qRT-PCR analyses of MCF-7 
cells which had been stimulated with T-MVM revealing that there was no increase, but, in 
contrast, a slight decrease in JUN mRNA levels (Fig. 18B). Since MV have often been 
demonstrated to function as vehicles for the transfer of proteins, we investigated whether this 
is also the case for the c-jun protein. Using Western Blots, we were indeed able to detect c-jun 
inside T-MVM (Fig. 18C) which suggests its transfer to the tumor cells via MV and might 
represent a possible explanation for the increased c-jun levels in MCF-7 after T-MV 
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stimulation. Nonetheless, inhibition of JNK signaling with a specific JNK inhibitor did not 
antagonize T-MV-induced tumor invasion (Fig. 18D) arguing against an involvement of JNK-
signaling in the conveyance of the autologous pro-invasive effect of T-MV. 
 
Fig. 18: JNK-signaling is not involved in the pro-invasive function of T-MV 
A, Western Blot: MCF-7 were stimulated with T-MVM (25 µg/ml) and the cells harvested after the indicated 
time points to examine the expression of phosphorylated (P-) c-jun and total c-jun. B, Expression of JUN was 
slightly reduced in MCF-7 cells after 24 h of stimulation with T-MVM (25 µg/ml) in qRT-PCR analyses from 
total RNA samples (means±SD, n=3, *p<0,01). C, The c-jun protein was detected inside T-MVM by Western 
Blotting. Whole cell lysates (=C) were used as positive control. D, However, inhibition of c-jun signaling with a 
JNK-inhibitor (JNK-I) was not able to antagonize MV-induced tumor invasion of MCF-7 cells (microinvasion 
assays, means±SD, n=3). Modified from (Menck et al, 2014b).  
3.2 EV as mediators of tumor-macrophage interactions 
The local microenvironment is increasingly recognized as important factor in the 
establishment of a favorable tumor niche. Especially tumor-infiltrating Mϕ are known for 
their protumoral effects (Allavena et al, 2008). Our group has already shown that co-culture 
of the breast cancer cell lines MCF-7 and SK-BR-3 with human Mϕ increases tumor cell 
invasion (Hagemann et al, 2004). The tumor-promoting effect is dependent on an induction of 
Wnt5a in the latter (Pukrop et al, 2006). However, so far it could not be elucidated how this 
pro-invasive tumor-stroma crosstalk is mediated. For this reason, we aimed to investigate if 
EV are the missing link and mediate intercellular communication.  
Results  65 
3.2.1 T-MV do not induce a typical M2 phenotype in human Mϕ 
We first analyzed which effects T-MV exert on human Mϕ. For these studies, monocytes 
were isolated from Buffy coats and further differentiated to Mϕ in the presence of low 
concentrations of macrophage colony-stimulating factor (M-CSF) which is described in detail 
in (Menck et al, 2014a). Since the differentiation method influences the phenotype of the 
obtained Mϕ, they were first characterized by flow cytometry (Fig. 19). Immunophenotyping 
confirmed that the cells were positive for typical markers for mature Mϕ, i.e. CD45, CD14, 
CD11c and CD11b as well as the mannose receptor CD206 corroborating that these cells 
represent a population of mature Mϕ.  
 
Fig. 19: Immunophenotype of isolated human Mϕ 
Monocytes were isolated from Buffy Coats and differentiated to Mϕ in the presence of low concentrations of M-
CSF. Mϕ were characterized for the expression of typical markers by flow cytometry (indicated in red). The 
corresponding isotype controls are shown in grey. Modified from (Menck et al, 2014a).  
Tumor-infiltrating Mϕ are often described to acquire an anti-inflammatory M2 phenotype due 
to tumor- and immune cell-derived cytokines present in the tumor stroma (Mantovani et al, 
2002). For this reason, we investigated if stimulation with T-MV contributes to the induction 
of a tumor-supporting phenotype in Mϕ. However, stimulation with T-MVM did not influence 
the expression or activation of selected pro-inflammatory M1 (i.e. IL-1ß, TNFα, IL-12) or 
anti-inflammatory M2 (i.e. IL-10) cytokines (Fig. 20A+B). Only P-MV which were used as 
negative control slightly induced IL-1ß mRNA expression which might point towards a shift 
to a pro-inflammatory Mϕ phenotype. However, there was no significant increase in secreted 
IL-1ß arguing against such effect. Moreover, also the expression of other protumoral factors 
including the vascular endothelial growth factor (VEGFA), which promotes angiogenesis, or 
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selected matrix metalloproteinases (MMP), which mediate extracellular matrix degradation, 
remained unchanged in Mϕ upon MV stimulation (Fig. 20A, C).  
 
Fig. 20: Analysis of the Mϕ phenotype after MV stimulation 
Human Mϕ were stimulated for 24 h with 25 µg/ml T-MVM or P-MV (negative control). LPS (100 ng/ml) was 
used as positive control. A+B, Expression of typical pro- or anti-inflammatory cytokines was analyzed by qRT-
PCR (A) or ELISA (B) (mean±SD, n=5,*p<0,05). C, Relative mRNA expression of selected MMP in Mϕ (qRT-
PCR, mean±SD, n=5,*p<0,05). Figure taken from (Menck et al, 2013).  
3.2.2 T-MV are responsible for the induction of Wnt5a in human Mϕ 
We next wanted to know whether T-MV might be responsible for the observed WNT5A 
induction in Mϕ under co-culture conditions. While the role of Wnt5a in cancer progression is 
controversially discussed, there is increasing evidence that its expression induces an 
immunosuppressive, tumor-supporting phenotype in human Mϕ (Bergenfelz et al, 2012; 
Pukrop et al, 2006).  
 
Fig. 21: T-EV induce Wnt5a in human Mϕ 
A+B, Human Mϕ were stimulated for 24 h with increasing concentrations of T-MVM , T-ExoM (A) or T-MVS (B) 
and qRT-PCR was carried out from total RNA samples. Benign MV from human platelets (P-MV) and the 
particle-free supernatant (T-snM) were used as negative controls (means±SEM, n≥5, *p<0,001, **p<0,01, 
***p<0,05). Modified from (Menck et al, 2013).  
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Indeed, stimulation with T-MV led to a concentration-dependent upregulation of WNT5A in 
human Mϕ (Fig. 21). The same effect was also observed for stimulation with T-Exo. 
However, neither benign P-MV nor the vesicle-free tumor cell supernatant (T-sn) induced 
WNT5A indicating that this is a specific feature of tumor cell-derived EV.  
Since MV have often been described as carriers of nucleic acids, we analyzed whether the 
increase in WNT5A mRNA was due to horizontal transfer. T-MV samples were used for 
mRNA isolation and were subjected to qRT-PCR. Agarose gel electrophoresis was used to 
visualize the amplified gene-specific product and confirmed the presence of WNT5A mRNA 
inside the vesicles (Fig. 22A). Nonetheless, inhibition of Mϕ gene transcription by the 
chemotherapeutic drug Actinomycin D, in concentrations which did not affect cell viability 
(Fig. 22B), antagonized the observed WNT5A induction by T-MV (Fig. 22C). This finding 
indicates that WNT5A is newly transcribed after MV stimulation.  
 
Fig. 22: Wnt5a is newly transcribed in Mϕ after T-MV stimulation 
A, Agarose gel: Wnt5a mRNA was visualized in T-MV after PCR amplification. MDA-MB231 (MDA) and 
MCF-7 are displayed as positive controls. NTC= No-Template-Control. B, ActD (32 µM) has no effect Mϕ 
viability as assessed by MTT assay (means±SD, n=3, n.s. = not significant). C, qRT-PCR: Pre-incubation of Mϕ 
with ActD significantly reduces Wnt5a induction by LPS (100 ng/ml, positive control) and T-MVM (25 µg/ml) 
after 24 h of stimulation (means±SD, n=3, *p<0,05). Modified from (Menck et al, 2013).  
In order to analyze whether uptake of T-MV is required for the observed WNT5A induction, 
Mϕ were incubated with T-MVM which had been previously labeled with the red membrane-
intercalating dye PKH26. After 24 h an uptake of T-MV into Mϕ was clearly visible by 
fluorescence microscopy (Fig. 23A). Additionally, we performed confocal microscopy to 
confirm that the vesicles are indeed incorporated into the cells and not only stick to the 
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cellular surface (Fig. 23B). The images showed that T-MV were found as vesicle-like 
structures in the cytoplasm of the cells, whereas the plasma membrane of the cells remained 
unstained. For analysis of MV uptake kinetics, we stimulated Mϕ with PKH26-labeled T-
MVM and measured the red fluorescence in the supernatant as well as in the cells after 
different time points. Already 1 h after stimulation a significant decrease of the fluorescence 
in the supernatant was observed, while in parallel there was a constant increase of cellular 
fluorescence (Fig. 23C) which further confirms a time-dependent uptake of T-MV into human 
Mϕ. The strongest fluorescence in the cells was observed after 24 h.  
 
Fig. 23: Human Mϕ incorporate T-MV, but their uptake is not essential for Wnt5a induction 
Stimulation of human Mϕ with PKH26-labeled T-MVM: A+B, Uptake was visualized after 24 h by fluorescence 
microscopy (A) (magnification: 10x, inserts: unstimulated control) or confocal microscopy (B) (magnification: 
40x, green: calcein). C, The distribution of the red fluorescence in supernatant and cells was measured by flow 
cytometry (means±SD, n=5, *p<0,01, **p<0,05). D, MV uptake into Mϕ can be significantly reduced by 
treatment with 12,5 µM dynasore (means±SD, n=3, *p<0,05). E, Cell viability is not influenced by dynasore 
(MTT-assay, 24h, mean±SD, n=3). F+G, Dynasore neither influences Mϕ-Wnt5a expression itself, nor does it 
inhibit T-MV-meditaed Wnt5a expression (qRT-PCR, mean±SD, n≥9, n.s. = not significant). Modified from 
(Menck et al, 2013).  
Next, we pre-incubated Mϕ with dynasore which was able to reduce MV uptake into Mϕ by 
around 50% without affecting cellular viability (Fig. 23D+E). In spite of inhibiting cellular 
MV uptake, WNT5A induction by T-MVM was not reduced, while also dynasore itself did not 
influence WNT5A mRNA levels (Fig. 23F+G).  
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3.2.3 Mϕ export the produced Wnt5a protein on own responding EV 
We further analyzed whether the observed induction of WNT5A expression was also 
translated to the protein level. Indeed, after 24 h of stimulation the Wnt5a protein was 
increasingly detectable inside the Mϕ (Fig. 24A). Next, we aimed to investigate whether and 
how the produced Wnt5a protein is exported from the Mϕ. Since Wnt proteins are very 
hydrophobic, their mobility in the extracellular space is limited. The question of how Wnt 
proteins travel through tissues is still under debate. First hints that Wnt proteins might be 
associated with membrane vesicles were presented in a study from Greco et al who showed a 
colocalization of the Drosophila Wnt1 homolog, Wingless, with exosomes-like vesicles, the 
so-called argosomes (Greco et al, 2001). In order to analyze whether the produced Wnt5a 
protein can be transported on MV and Exo in the human system, we investigated Wnt5a 
expression on EV which are secreted by Wnt5a-positive Mϕ.  
However, since a large amount of Mϕ is needed to isolate sufficient numbers of EV for 
further analysis which, in turn, would require a high quantity of T-MV for stimulation, we 
developed an alternative protocol for Mϕ activation: Mϕ were seeded in 6-well-plates on 
ECM gel (80 µl/well, diluted 1:16 in culture medium) and stimulated for 24 h with tumor cell 
supernatant which still contains all MV, Exo and soluble factors (for further details see 
2.2.1.6). This procedure led to a significant induction of WNT5A (Fig. 24B). Moreover, it 
prevented the inefficient and time-consuming isolation of pure vesicle populations by 
differential ultracentrifugation. Since after 24 h most of the T-MV in the tumor cell 
supernatant are ingested by Mϕ (Fig. 23C) and MCF-7 cells are negative for Wnt5a (Fig. 
27C), no contaminating Wnt5a signals are to be expected from T-MV.  
The generated Wnt5a-positive Mϕ were then used for EV isolation. Surprisingly, Wnt5a was 
detected on Mϕ-MV by electron microscopy in a Wnt5a-immunogold staining where it clearly 
localized to the membrane of the vesicles (Fig. 24D). To confirm this finding, we further 
analyzed Mϕ-EV by Western Blotting and indeed found Wnt5a on both vesicle populations, 
Mϕ-MV as well as Mϕ-Exo (Fig. 24C). We then investigated whether the Wnt5a-carrying 
Mϕ-EV had any influence on tumor invasion. As shown in Fig. 24E, MV and Exo from 
stimulated Mϕ significantly enhanced MCF-7 cell invasion, while neither the particle-free Mϕ 
supernatant nor benign P-MV had any influence on tumor invasion.  
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Fig. 24: Human Mϕ export the Wnt5a protein on their own EV 
A, Mϕ were stimulated with 25 µg/ml T-MVM and Wnt5a expression in the cells was analyzed after the indicated 
time points by Western Blotting. B, qRT-PCR: Stimulation of Mϕ with T-EV-containing (w/ EV) or particle-free 
(w/o EV) tumor cell supernatant (means±SEM, n≥3, *p<0,05). C, Wnt5a was detected on MV and Exo released 
by stimulated Mϕ (Western Blot). D, TEM of an immunogold staining against Wnt5a on MV from stimulated 
Mϕ. E, Microinvasion assay of MCF-7 cells: EV from stimulated Mϕ significantly enhance tumor invasion, 
while benign P-MV or the particle-free supernatants (sn) have no effect (mean±SD, n=3, *p<0,001). Modified 
from (Menck et al, 2013).  
So far Wnt5a was believed to be a secreted protein. A recent study from Gross et al 
demonstrated export of the canonical Wnt ligand Wnt3a on Exo (Gross et al, 2012), thereby 
supporting our results. However, presence of Wnt5a on MV was unexpected, since their 
biogenesis is completely different from Exo. Thus, we tried to further confirm this surprising 
finding. We first screened our cell lines for the expression of Wnt5a and indeed detected 
Wnt5a also on MV and Exo from SK-BR-3 breast cancer cells (Fig. 25A). In contrast, the 
Wnt-negative MCF-7 cells as well as unstimulated Mϕ and benign platelets showed no Wnt5a 
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expression. Subsequently, we layered the MV and Exo of the Wnt5a-positive cell line SK-
BR-3 separately on top of two sucrose gradients and analyzed the distribution of the vesicles 
based on the previously described markers (Fig. 25B). Wnt5a clearly co-localized with the 
MV marker EMMPRIN in sucrose gradients from T-MVS as well as with the exosome marker 
Tsg101 in gradients from T-ExoS confirming the presence of Wnt5a on both vesicle 
populations.  
 
Fig. 25: Wnt5a is expressed on MV and Exo 
A, Western Blot: Comparative analysis of the Wnt5a expression on MV (and Exo) from MCF-7 (MCF) and SK-
BR-3 (SK) breast cancer cells as well as on unstimulated Mϕ or platelets (P). B, T-MVS and T-ExoS were 
layered separately on sucrose gradients and the distribution of Wnt5a and known MV/Exo markers was analyzed 
by Western Blotting. Taken from (Menck et al, 2013).  
3.2.4 MV-induced Wnt5a expression is mediated through activation of 
p38/MAPK which can be antagonized by the Wnt-inhibitor DKK-1 
After having shown that T-MV are responsible for the Wnt5a expression in human Mϕ, we 
tried to elucidate which upstream mediators are activated in Mϕ after T-MV stimulation and 
mediate WNT5A induction. Therefore, we stimulated Mϕ with T-MVM and analyzed the 
activation of several signaling pathways after different time points. While levels of PKC, 
CamKII or c-jun remained unchanged (data not shown) indicating that the non-canonical 
Wnt/Ca
2+
 or PCP signaling pathway are not affected, we observed an activation of the p38 
(MAPK14) signaling pathway already 1 h after stimulation with T-MV (Fig. 26A). Pre-
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incubation of Mϕ with the p38-inhibitor SB-203580 (see 3.1.8) significantly decreased 
WNT5A induction mediated by T-MV without affecting Mϕ viability (Fig. 26B+C).  
Furthermore, it has already been shown that the pro-invasive effect of Mϕ on tumor invasion 
can be blocked by the Wnt-inhibitor DKK-1 (Pukrop et al, 2006). However, so far we could 
not explain how and on which of the cells involved, Mϕ or tumor cells, DKK-1 exerts this 
effect. Since our results suggest MV and Exo as main mediators of tumor-Mϕ crosstalk, we 
were now able to dissect the various aspects of intercellular communication, namely T-MV-
induced Wnt5a upregulation and Mϕ-MV induced tumor invasion, under co-culture 
conditions. To this end, we performed microinvasion assays in which we co-cultured MCF-7 
breast cancer cells either with whole Mϕ or with isolated Mϕ-MV from activated Mϕ and then 
analyzed the influence of DKK-1 on their pro-invasive effects (Fig. 26D). 
 
Fig. 26: MV-mediated Wnt5a induction in Mϕ is mediated by p38/MAPK signaling which can be 
antagonized by DKK1 
A, Mϕ were stimulated with T-MVM (25 µg/ml) and activation of the p38 signaling pathway at the indicated time 
points was analyzed by Western Blotting. B, Pre-incubation (2 h) of Mϕ with the p38 inhibitor SB-203580 (p38-
I, 0,5 µM) significantly reduces T-MV-mediated WNT5A induction. C, Mϕ viability during 24 h of treatment 
with 0,5 µM SB-203580 (p38-I) was assessed by MTT assay. D, Microinvasion assay of MCF-7 cells with or 
without pre-incubation with DKK-1 (200ng/ml) followed by co-culture of the cells with Mϕ or MV derived from 
activated Mϕ. E+F, Pre-incubation of Mϕ with DKK-1 (200 ng/ml) significantly reduces WNT5A induction by 
T-MV in qRT-PCR (E) or phosphorylation of p38 in Western Blots (F). Modified from (Menck et al, 2013).  
Interestingly, DKK-1 was able to antagonize the pro-invasive effect of the whole Mϕ, but did 
not influence the pro-invasive potential of Mϕ-MV. In parallel, DKK-1 did not decrease the 
pro-invasive autologous effect of T-MVM on tumor invasion (Fig. 26E). This led us to the 
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hypothesis that DKK-1 does not affect the tumor cells, but interferes with the induction of 
Wnt5a in Mϕ and thus their acquisition of a tumor-promoting phenotype. Indeed, pre-
incubation of Mϕ with DKK-1 significantly antagonized MV-mediated WNT5A induction 
(Fig. 26F). In line with this, DKK-1 further diminished p38 activation after T-MV stimulation 
confirming a link between both (Fig. 26G).  
3.2.5 MV-bound Wnt5a is taken up by the tumor cells 
Since T-MV stimulation induced the expression of the Wnt5a protein which was exported by 
activated Mϕ on their EV, we analyzed if vesicle-bound Wnt5a can then be transferred to and 
taken up by the tumor cells which would complete the pro-invasive communication loop 
between tumor cells and Mϕ. First of all, we investigated if Mϕ-MV can be ingested by breast 
cancer cells. For this reason MCF-7 cells were stimulated with PKH26-labeled Mϕ-MV 
followed by fluorescence microscopy. Indeed, after 24 h the red Mϕ-MV were detected inside 
the cancer cells (Fig. 27A).  
 
Fig. 27: Wnt5a-positive stroma-derived MV are ingested by breast cancer cells 
A, MCF-7 were stimulated for 24 h with PKH26-labeled MV from activated Mϕ. Uptake was visualized by 
fluorescence microscopy (magnification: 10x, inserts: unstimulated control). B, Western Blot: Wnt5a is present 
at high levels on MV from Wnt5a-overexpressing (Wnt5a) compared to wild type L cells (wt). C+D, Stimulation 
of Wnt5a-negative MCF-7 cells with rhWnt5a or L-MVWnt5a leads to the detection of the Wnt5a protein inside 
the cells (C, Western Blot) while there is no induction of WNT5A on the mRNA level in MCF-7 (D). Modified 
from (Menck et al, 2013).  
For further analysis of Wnt5a uptake, we decided to work with Wnt5a-overexpressing L cells 
(Wnt5a-L cells) as model cell line for Wnt5a-positive Mϕ since the generation of activated 
Mϕ still is a comparably expensive and time-consuming method. Wnt5a-L cells are a murine 
fibroblast cell line and can therefore be considered as an additional variant of tumor stroma 
cells. As these cells overexpress Wnt5a, it can also be found enriched on their released MV 
(L-MVWnt5a) (Fig. 27B). Stimulation of the Wnt5a-negative MCF-7 cells with Wnt5a-positive 
L-MVWnt5a led to the detection of the Wnt5a protein inside the tumor cells (Fig. 27C). High 
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doses of recombinant Wnt5a (rhWnt5a) were used as respective positive control and were also 
taken up by MCF-7. To exclude an induction of WNT5A which could also be responsible for 
the observed effect, we analyzed its expression in MCF-7 stimulated with L-MVWnt5a (Fig. 
27D). However, WNT5A mRNA levels remained unchanged, arguing for an uptake of MV-
bound Wnt5a.  
3.2.6 The role of Evi for Wnt5a expression on MV and Exo 
After having identified the release and transfer of Wnt5a from activated Mϕ to the tumor 
cells, we asked how Wnt5a is transported on EV. Transmission electron microscopy had 
revealed an association of Wnt5a with the membrane of the vesicles (see Fig. 24D). However, 
since Wnt proteins in general are palmitoylated by the acyltransferase porcupine in the 
endoplasmic reticulum (Tanaka et al, 2000; Willert et al, 2003), they are highly hydrophobic 
which would allow their unspecific association with membranes through hydrophobic 
interactions. Indeed, incubation of the Wnt-negative T-MVM and T-ExoM with high doses of 
rhWnt5a (see 2.2.2.4) led to unspecific binding of the protein to the vesicles (Fig. 28A). 
However, a significant part of the protein still remained in the EV-free supernatant after 
ultracentrifugation.  
Nonetheless, a specific association of canonical Wnt3a with the protein Evi has recently been 
described which is essential for Wnt secretion on Exo (Gross et al, 2012). Based on this 
finding we asked whether Evi is also required for Wnt expression on MV. Hence, we 
performed a stable knockdown of Evi in the Wnt5a-positive cell line SK-BR-3 as well as in 
Wnt5a-L cells (see 2.2.1.2). Expression of Evi/WLS was reduced by around 75% in Evi 
knockdown (shEvi) compared to non-sense control (ns ctl) cells on the mRNA level and was 
no longer detectable on the protein level (Fig. 28B+C). Although several commercially 
available antibodies against murine Evi had been tested, none gave reproducible results. For 
this reason, Evi expression and knock-down efficiency could only be confirmed on the protein 
level for human SK-BR-3, but not for murine Wnt5a-L cells. Evi expression was also lost on 
MV and Exo derived from SK-BR-3 shEvi cells (Fig. 28D).  
Evi knockdown resulted in a loss of Wnt5a expression on T-MVS/T-ExoS as well as L-
MVWnt5a/L-ExoWnt5a (Fig. 28E) while WNT5A expression in shEvi cells remained unchanged 
in SK-BR-3 and was only slightly diminished in Wnt5a-L cells (Fig. 28F). The results suggest 
that the export of Wnt5a on EV is impaired in shEvi cells which should lead to an 
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augmentation of the protein inside the cells as it was described for Wnt3a in Wnt3a-
overexpressing shEvi L cells (Gross et al, 2012).  
 
Fig. 28: Wnt5a is associated with EV in a nonspecific as well as specific, Evi-dependent way 
A, Wnt-negative T-MVM and T-ExoM were incubated with (+) or without (-) 100 ng/ml rhWnt5a which led to 
unspecific binding of the protein to the vesicles, while significant amounts of the protein still remained in the 
supernatant (Western Blot). B, Expression of Evi/WLS was analyzed in SK-BR-3 and Wnt5a-L Evi knockdown 
(shEvi) and non-sense control (ns ctl) cells by qRT-PCR (means±SD, n=3, *p<0,05). C+D, Evi knockdown was 
demonstrated on the protein level in SK-BR-3 cells (C) and their corresponding EV (D) by Western Blotting. E, 
Knockdown of Evi leads to the loss of Wnt5a on MV and Exo from SK-BR-3 and Wnt5a-L shEvi cells (Western 
Blot). F, qRT-PCR: WNT5A mRNA levels are unaffected in SK-BR-3 shEvi cells and only slightly reduced in 
Wnt5a-L shEvi cells (means±SD, n=3, *p<0,05). Modified from (Menck et al, 2013).  
Surprisingly, when we investigated Wnt5a expression in shEvi cell lines, the protein was 
significantly diminished and barely detectable inside the cells (Fig. 29A). Evi has often been 
suggested to exert a chaperone function required for correct folding of Wnt proteins (Ching & 
Nusse, 2006). Therefore, we asked if Evi knockdown might lead to increased Wnt5a 
degradation due to misfolding of the protein. To test this hypothesis we first treated SK-BR-3 
and Wnt5a-L shEvi cells with the proteasome inhibitor MG-132 and analyzed cellular 
viability. Already an incubation with 1 µM MG-132 for 6 h resulted in a beginning reduction 
of MTT conversion (Fig. 29B+C). Due to the high cytotoxicity of the inhibitor which blocks 
the proteolytic activity of the 26S proteasome complex (Han et al, 2009), longer incubation 
periods or higher doses were not possible without inducing apoptosis of the cells. Treatment 
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of the shEvi cells with the titrated amount of MG-132 for 6 h did not augment cellular Wnt5a 
levels (Fig. 29D) arguing against enhanced proteolytic degradation.  
 
Fig. 29: Implications of Evi knockdown for cellular Wnt5a expression 
A, Expression of the Wnt5a protein inside shEvi and non-sense control (ns ctl) cells was analyzed by Western 
Blotting. B+C, Cell vitality of SK-BR-3 (B) and Wnt5a-L (C) shEvi cells during 6 h of treatment with the 
proteasome inhibitor MG-132 (1 µM) was assessed by MTT assay (means±SD, n=3, *p<0,05, n.s. = not 
significant). D, Western Blot: Treatment of shEvi cells with MG-132 (1 µM) for 6 h did not increase cellular 
Wnt5a expression. E-G, SK-BR-3 shEvi and ns ctl cells were transiently transfected with an eGFP-tagged 
xWnt5a construct. Expression of the construct was visualized by qRT-PCR with primers directed against eGFP 
(E) or xWnt5a (F). Δct values >12 were considered as not detectable (n.d.). Expression of the transfected 
construct can additionally be confirmed by Western Blotting against GFP (G).  
Another possibility might be that the Wnt5a antibody is no longer able to detect the protein 
when it is misfolded due to knockdown of Evi. In order to investigate this in an indirect 
approach, we transiently transfected SK-BR-3 shEvi cells with a plasmid encoding eGFP-
tagged Xenopus Xwnt5a (see 2.2.1.3) and analyzed Wnt5a levels in the cells. Expression of 
the construct was confirmed by qRT-PCR with primers directed against eGFP (Fig. 29E) or 
Xwnt5a (Fig. 29F) which both could only be detected in the transfected and not in the non-
transfected cells. Furthermore, on the protein level expression of the construct inside the cells 
was visualized by Western Blots directed against GFP (Xwnt5a tagged with eGFP results in a 
band size of 42 + 27 = 69 kDa). This shows that Xwnt5a is in fact still present in shEvi cells 
and may even slightly accumulate in comparison to non-sense control cells (Fig. 29G).  
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Fig. 30: Knockdown of Evi impairs MV-mediated tumor invasion as well as the pro-invasive 
phenotype of the tumor cells per se 
A+B, Microinvasion assays of MCF-7 cells stimulated with 1 µg/ml T-MV/ExoS (A) or L-MV/ExoWnt5a (B) from 
shEvi or ns ctl cells (means±SD, n=3, *p<0,0001). C, Microinvasion assay of SK-BR-3 wt, shEvi or ns ctl cells 
(means±SD, n=3, *p<0,0001). D, In parallel to the microinvasion assay, SK-BR-3 cells were seeded on ECM-
coated 24-well plates and cell counts were determined after 96 h (means±SD, n=3, n.s. = not significant). 
Modified from (Menck et al, 2013).  
Since Wnt5a expression was lost on EV from shEvi cells, we asked whether this has any 
consequences for the pro-invasive function of the vesicles. To test this, we stimulated MCF-7 
breast cancer cells in microinvasion assays with 1 µg/ml T-MV/ExoS or L-MV/ExoWnt5a from 
shEvi cells. Wnt5a-negative EV from Evi knockdown cells induced significantly less tumor 
invasion (Fig. 30A+B) suggesting that it is indeed one of the factors which mediates the pro-
invasive phenotype of the vesicles in autologous as well as stroma cell-induced tumor 
invasion. Moreover, Evi knockdown additionally impaired the invasive potential of the SK-
BR-3 cells per se (Fig. 30C). To confirm that this effect was not due to differences in cell 
proliferation, we seeded the cells on ECM-coated 24-well plates and counted the number of 
cells after 96 h. However, there was no significant difference in the proliferation between Evi 
knockdown and non-sense control cells (Fig. 30D).  
Results  78 
3.2.7 Zoledronic acid inhibits T-MV uptake into human Mϕ 
Since EV have been identified as an important tool which tumor cells use to influence the 
surrounding stroma cells and drive tumor-associated Mϕ into a tumor-supporting phenotype, 
it might be clinically relevant to inhibit EV-mediated tumor-stroma crosstalk. Zoledronic acid 
(ZA) is a bisphosphonate and Mϕ inhibitor that is routinely used in the clinic against 
osteoporosis, where it antagonizes osteoclasts. Recently, it has also been demonstrated to 
increase the disease-free survival in breast cancer patients in combination with an adjuvant 
therapy (Gnant, 2009; Gnant, 2011). In mouse models it reduces metastatic tumor burden 
(Hiraga et al, 2004).  
 
Fig. 31: ZA influences MV-mediated tumor-Mϕ crosstalk 
A, Human Mϕ were pre-treated with 1 µM zoledronic acid (ZA) for 48h and then stimulated for 24 h with 5 µg 
PKH26-labeled T-MVM. MV uptake was assessed by flow cytometry by comparing the red mean fluorescence 
intensity (MFI) of the Mϕ (means±SD, n=8, *p<0,05). B, After pre-incubation of Mϕ with 1 µM ZA for 48h, the 
cells were stimulated with 25 µg/ml T-MVM for 24h and qRT-PCR was carried out from total RNA samples 
(means±SD, n=7). Modified from (Rietkotter et al, 2013).  
Results from our group suggested that 1 µM ZA effectively antagonized Mϕ-induced MCF-7 
invasion (Rietkotter et al, 2013). In search for a mechanism which might explain this 
phenomenon, we investigated whether ZA interferes with MV-mediated tumor-Mϕ crosstalk. 
As shown in Fig. 31, 1 µM ZA impaired T-MVM uptake into Mϕ, while there was no 
influence detectable on MV-mediated WNT5A induction. This is in line with our previous 
results showing that WNT5A induction is independent of MV uptake (3.2.2) and further 
suggests that there are additional pro-invasive factors induced in Mϕ by T-MVM stimulation 
which require an uptake of the vesicles into the cells.  
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3.3 EV in human peripheral blood samples 
The first two parts of this thesis have demonstrated the importance of T-EV, especially T-
MV, for the establishment of a favorable tumor microenvironment in vitro. They were shown 
to influence not only the tumor cells themselves in autologous as well as heterologous 
intercellular communication routes, but also to influence surrounding stroma cells and drive 
them in a tumor-supporting phenotype. Moreover, one of the pro-invasive factors, HG-
EMMPRIN, could be identified on T-MV and was established as a sensitive marker for 
malignant T-MV which discriminates them from T-Exo. We thus wanted to transfer our 
expertise to a more clinical setting and aimed to establish a reproducible isolation protocol for 
EV from peripheral blood of cancer patients. Based on additional T-MV-associated markers 
which we identified in screenings on T-MV from three different breast cancer cell lines in 
vitro, we evaluated the possible application of these markers to identify circulating T-MV in 
vivo which is an essential prerequisite for the specific isolation and further characterization of 
these vesicles.  
3.3.1 Identification of MV-associated tumor markers by in vitro screening of T-
MV 
In order to find proteins which are specifically expressed on T-EV and can be used to identify 
circulating T-EV in breast cancer patients, we screened three different breast cancer cell lines 
for the expression of potential tumor-specific proteins on their EV. These cell lines are 
thought to represent the three breast cancer subtypes which can be classified based on their 
receptor status as described in chapter 1.1: MCF-7 cells were used as model for hormone 
receptor-positive (ER+, PR+), SK-BR-3 cells for Her2/Neu-positive and MDA-MB231 for 
triple-negative (ER-, PR-, Her2-) breast cancers. T-MV and T-Exo were isolated from all 
three cell lines and characterized for the expression of EMMPRIN, EGFR, EpCAM, Her2 and 
MUC1 by flow cytometry (Fig. 32 and Fig. 33). These proteins were chosen because they all 
have been previously reported as prognostic markers in (breast) cancer (Duffy et al, 2000; Fox 
et al, 1994; Schmidt et al, 2008a; Zhong et al, 2008).  
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Fig. 32: Tumor marker on T-MV 
T-MV (5 µg) were stained for the indicated marker proteins and analyzed by flow cytometry. Representative 
histogram overlays are shown with the specific fluorescent signal in green and the corresponding isotype control 
in grey.  
 
Fig. 33: Tumor marker on T-Exo 
T-Exo (10 µg) were coupled to latex beads, stained for the indicated marker proteins and analyzed by flow 
cytometry. Representative histogram overlays are shown with the specific fluorescent signal in green and the 
corresponding isotype control in grey.  
Flow cytometry analysis revealed that EMMPRIN was the only protein which was expressed 
at high levels on all three MV populations, while EGFR, MUC1 and Her2 were positive on 
just one. EpCAM, a protein which is routinely used for the detection of circulating tumor 
cells, was detectable on T-MVM and T-MVS, but was lacking on MV from the triple negative 
MDA-MB231. Surprisingly, all investigated tumor markers were negative on T-Exo from 
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MCF-7 and SK-BR-3 cells so that further characterization of T-ExoMDA was not continued. 
Only EpCAM was expressed in very low levels on T-Exo from both cell lines.  
3.3.2 EpCAM-based MACS of T-EV from human serum samples 
Since we aimed to establish an isolation protocol for T-MV as well as T-Exo from peripheral 
blood of cancer patients, we selected EpCAM as marker for T-EV since it was the only 
protein that was expressed on both vesicle populations. To separate T-EV from other EV 
populations present in blood e.g. EV derived from platelets, leukocytes or red blood cells, we 
chose an EpCAM-based sorting approach via MACS (see 2.2.4.3) because this method was 
already described for the sorting of Exo from peripheral blood of ovarian cancer patients 
(Taylor & Gercel-Taylor, 2008). Moreover, EpCAM has been previously used to identify 
circulating tumor cells in metastatic breast cancer (Riethdorf et al, 2007).  
First, we tested the method in vitro by spiking 5 ml of human AB serum samples with a 
defined amount of T-MVS and titrated the amount of EpCAM-MicroBeads which allows 
sorting of these vesicles with the highest quality and quantity. Using MACS with different 
concentrations of EpCAM-MicroBeads, around 30% of the input T-MVS could be sorted on 
LD columns as determined by Lowry assay (Fig. 34A). There was no significant difference in 
MV yields between 50, 10 or 5 µl EpCAM-MicroBeads used for labeling of T-MVS. In order 
to assess if the MicroBeads also lead to non-specific selection of benign blood-derived MV, 
human AB serum was incubated with 10 µl EpCAM-MicroBeads alone. This resulted in 
selection of residual MV showing that to some extent unspecific binding occurs, however, 
MV counts were considerably higher in the presence of T-MVS. These results could be further 
confirmed by flow cytometric counting of MV yields as described in 2.2.4.1.4. Again, there 
was no significant difference in the addition of 5 or 10 µl EpCAM-MicroBeads for sorting 
and the number of sorted MV was clearly higher when T-MVS had been added to the serum 
samples compared to EpCAM-MicroBeads alone (Fig. 34B).  
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Fig. 34: MACS of T-MVS spiked into human AB serum samples 
Human AB serum samples were spiked with different concentrations of T-MVS and subsequently sorted by 
MACS. A+B, For quantification the amount of column-bound EpCAM+ MV was measured by Lowry assay (A) 
and MV counts were determined by flow cytometry (B). The indicated lines represent the means of the samples. 
C+D, Sorted MV were compared to standard samples with known concentrations by Western Blotting using the 
established T-MV markers (C) and the results of three independent experiments were averaged (D) (means±SD, 
n=3, n.d. = not detectable). E+F, The column-bound sorted MV (E) as well as the column flow-through (F) were 
characterized for expression of tumor and MV markers by flow cytometry. Histogram overlays show the specific 
fluorescent signal in green and the isotype control in grey. 
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The vesicles which had been positively selected on LD columns were characterized to 
confirm the specific binding of T-MVS. Western Blot analysis of established T-MV markers 
(see 3.1.4) demonstrated expression of Tubulin, EMMPRIN as well as Her2 on the sorted 
vesicles suggesting that they are indeed T-MVS (Fig. 34C). Moreover, the band densities of 
the samples from the sorted MV were further compared to a dilution series of T-MVS with 
known concentrations and thereby allowed quantification of the MV yields by Western 
Blotting which again confirmed that addition of 5 or 10 µl EpCAM-MicroBeads for labeling 
led to equal MV yields (Fig. 34D). In contrast, putative MV which had been sorted by 
EpCAM-MicroBeads in the absence of T-MVS, were negative for all markers and only a 
single band of 55 kDa was detected in these samples which corresponds to an unspecific 
background signal of the MicroBeads (Fig. 34C).  
Further characterization of the sorted MV by flow cytometry confirmed a high expression of 
EpCAM, EMMPRIN and Her2 on the column-bound vesicles while they were negative for 
the Exo marker CD63 (Fig. 34E). In contrast, none of the three tumor markers was found in 
the flow-through (Fig. 34F). Addition of 50 µl EpCAM-MicroBeads masked most epitopes on 
the sorted MV and did not allow subsequent characterization by flow cytometry (data not 
shown) which indicates that as low concentrations of the MicroBeads as possible should be 
used for MACS. Taken together, the results suggest that indeed the added T-MVS are selected 
on LD columns and can be eluted from them, although around 70% of T-MVS are lost during 
the sorting process, probably due to insufficient elution of the vesicles from the LD columns.  
 
Fig. 35: LD, rather than LS, columns lead to higher MV yields in MACS of T-MV 
Human AB serum samples were spiked with equal amounts of T-MVS, labeled with 5 µl EpCAM-MicroBeads 
and sorted on LS or LD columns by MACS. A, The yields of column-bound sorted MV were determined by 
Lowry assay. The lines represent the means of the samples. B, MV yields in both samples were further 
determined by comparing the band densities of three MV markers (EMMPRIN, Her2, Tubulin) in Western Blots 
analyses with a dilution series of T-MVS with known concentrations (as shown in Fig. 34C). The results for all 
three markers were averaged and are displayed as percentage of input T-MVS (means±SD, n=3, *p<0,05).  
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To test if the yields of sorted T-MVS can be increased by using LS columns, which are 
recommended for positive selection by MACS, instead of LD columns which were originally 
engineered for negative selection, we labeled T-MVS with 5 µl EpCAM-MicroBeads and 
sorted them from human AB serum with LS columns. Surprisingly, yields of positively-
selected MV were considerably lower in Lowry assays (Fig. 35A) as well as flow cytometric 
MV counting (Fig. 35B) when LS columns were used for selection. This might be explained 
by the fact that LS columns are specifically designed for positive selection of strongly labeled 
cells and since MV are much smaller and therefore display a weaker magnetic signal, they 
possibly pass through the columns.  
 
Fig. 36: MACS of T-ExoS spiked into human AB serum samples 
Human AB serum samples were spiked with T-ExoS, incubated with 5 or 10 µl EpCAM-MicroBeads and sorted 
on LD columns by MACS. A, The amount of input (w/o MACS) and column-bound Exo after MACS was 
determined by Lowry assay (n=2). The indicated lines represent the means of the samples. B, Western Blot 
analysis: Expression of Exo markers on input T-ExoS before (w/o) MACS and column-bound Exo after sorting 
of T-MVS with 5 or 10 µl EpCAM-MicroBeads (=B.). A dilution series of unsorted T-ExoS is shown on the left 
as positive control.  
After having established the type of column as well as the concentration of EpCAM-
MicroBeads which are most applicable for sorting of EpCAM-positive vesicles, we tested the 
method for its suitability to sort T-Exo. Again, human AB serum samples were spiked with T-
ExoS, labeled with 5 µl EpCAM-MicroBeads and sorted on LD columns. However, neither in 
Lowry assays nor in Western Blots we detected any signals in the sorted samples which had 
been eluted from the columns (Fig. 36). This indicates that EpCAM-based MACS is not 
suitable for the selection of T-Exo from human serum samples, probably due to the low 
expression of EpCAM on T-Exo (see Fig. 33).  
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Fig. 37: MACS for MV in serum samples from cancer patients 
A, Serum samples of five metastatic cancer patients were labeled with 5 or 10 µl EpCAM-MicroBeads and 
sorted for EpCAM-positive MV on LD columns by MACS. The amount of column-bound sorted MV was 
determined by Lowry assay. The indicated line represents the mean of the samples. B, Flow cytometry: Sorted 
MV from three of the patients were characterized for tumor and blood cell markers. n.d. = not detectable 
Nonetheless, since the established approach seemed to be appropriate for EpCAM-based 
MACS of T-MV, we investigated whether T-MV can also be sorted in vivo from serum 
samples of cancer patients. All patients were in an advanced disease stage with multiple 
metastases and were therefore expected to carry a high number of T-EV in their blood. 
Furthermore, we only included patients who did not receive chemotherapy at the time of 
sample acquisition to prevent the release of apoptotic bodies from dying tumor cells.  
Serum samples (5-10 ml) of five metastatic cancer patients including one patient with primary 
breast cancer and four patients with primary lung cancer were incubated with up to 10 µl of 
EpCAM-MicroBeads followed by MACS on LD columns. Column-bound vesicles were 
eluted, subjected to MV isolation and MV yields quantified by Lowry assays (Fig. 37A). In 
two of the samples from lung cancer patients high MV counts (408 µg and 205 µg) were 
measured, whereas the amount of sorted MV was comparably lower in the other three samples 
with only 14,6 µg, 9,3 µg or 3,8 µg, respectively. The three samples which contained 
sufficient protein for further analysis were additionally characterized by flow cytometry (Fig. 
37B). Although the sorted MV in all samples were positive for EMMPRIN, EpCAM could 
only be detected in one sample. Moreover, a considerable amount of the vesicles was positive 
for the platelet marker CD62P as well as the leukocyte marker CD45 and the endothelial cell 
marker CD62E which suggests that the MV sorted by EpCAM-MicroBeads are not derived 
from circulating tumor cells, but were false-positively sorted benign blood cell-derived MV.  
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3.3.3 Establishment of a protocol for the isolation of MV from peripheral blood 
Since we were not able to isolate pure T-MV from serum samples by EpCAM-based MACS, 
we asked if it is possible to detect T-MV in peripheral blood of cancer patients without any 
previous sorting steps. In order to investigate this question, we first aimed to define which 
MV populations are found in the blood of healthy individuals and then compare their 
distribution to samples from cancer patients.  
For the analysis of different MV populations in peripheral blood and to ensure that the 
previously established tumor marker proteins (see 3.3.1) are not expressed on MV from other 
cell types, we further started to identify markers which are specific for distinct benign MV 
populations. While CD62E has already been described as a marker for endothelial cell-
derived MV (Dignat-George & Boulanger, 2011) and CD235a as specifically expressed on 
red blood cell-derived MV (Setty et al, 2000), we characterized P-MV and Mϕ-MV to define 
markers for these two MV populations.  
 
Fig. 38: Characterization of P-MV 
P-MV (5 µg) were stained for different tumor and blood cell markers and analyzed by flow cytometry. 
Representative histogram overlays are shown with the specific fluorescent signal in green and the corresponding 
isotype control in grey. 
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As shown in Fig. 38 and Fig. 39, both MV populations were negative for expression of the red 
blood cell marker CD235a, the endothelial cell marker CD62E as well as the tumor markers 
EGFR and MUC1. In contrast, they expressed considerable amounts of EMMPRIN which 
indicates that EMMPRIN expression alone cannot be used for the flow cytometric 
identification of T-MV in peripheral blood. Furthermore, P-MV characteristically displayed 
high levels of the cell adhesion molecule CD62P and low expression of CD45, while CD11c, 
a marker for myeloid cells, was not present. On the contrary, Mϕ-MV carried low amounts of 
CD11c on their surface and showed a strong expression of CD45. The P-MV marker CD62P 
was not detectable on Mϕ-MV. In summary, the results show that CD45, CD62P and CD11c 
together with the established markers CD62E and CD235a can be used to define subsets of 
benign MV present in blood. Moreover, all of these markers were negative on malignant 
breast cancer-derived T-MV as confirmed by flow cytometry (Fig. 40).  
 
Fig. 39: Characterization of Mϕ-MV 
Mϕ-MV (5 µg) were stained for different tumor and blood cell markers and analyzed by flow cytometry. 
Representative histogram overlays are shown with the specific fluorescent signal in green and the corresponding 
isotype control in grey. 
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Fig. 40: Blood cell markers on T-MV 
T-MV (5 µg) were stained for the established blood cell marker proteins and analyzed by flow cytometry. 
Representative histogram overlays are shown with the specific fluorescent signal in green and the corresponding 
isotype control in grey.  
Regarding methodological issues, the choice of the anticoagulant which is used during 
collection of the blood samples can have significant effects on subsequently isolated EV. 
While some publications show a substantial loss of MV in EDTA-anticoagulated blood 
compared to sodium heparin-treated blood samples (Jayachandran et al, 2012), others 
discourage the use of heparin-based anticoagulants (Witwer et al, 2013) because heparin was 
shown to interact with MV (Maguire et al, 2012) and is able to activate platelets (Krauel et al, 
2012). For this reason, we analyzed which anticoagulant is most suitable for isolation of total 
EV from cancer patients.  
Peripheral blood was drawn from five cancer patients and either anticoagulated with EDTA or 
Lithium-heparin (Li-Hep). Serum or plasma samples were stored at -20°C for <14 days and 
then thawed for EV isolation (see 2.2.2.1.3) which resulted in visible agglutination in all 
samples derived from Lithium-heparin-anticoagulated blood. This could neither be prevented 
by EV isolation directly after blood withdrawal nor by addition of new heparin after each 
centrifugation step (personal observation). Correspondingly, comparison of EV counts 
elucidated that MV yields were significantly lower when lithium-heparin had been used as 
anticoagulant, while Exo, which also tended to aggregate after ultracentrifugation, were 
slightly increased. In line with this, the number of CD62P- and EMMPRIN-positive MV was 
decreased in lithium-heparin anticoagulated samples, although this trend did not reach 
statistical significance. Since both of these proteins had been found in high levels on P-MV 
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(see Fig. 38), these findings seem to support the results which demonstrated an activating 
effect of heparin on platelets, as well as their MV, thereby inducing coagulation. Interestingly, 
the percentage of CD11c-positive MV was elevated in samples with Lithium-heparin as 
anticoagulant (8,0%) compared to EDTA-coagulated samples (1,2%). However, the 
significance of this observation remains unclear.  
 
Fig. 41: Comparison of EDTA and heparin as anticoagulants for patient samples 
A-B, EV isolated from EDTA- or Lithium-Heparin (Li-Hep)-anticoagulated blood were quantified by Lowry 
assays (A) (*p<0,05) and MV further characterized for selected blood and tumor cell markers by flow cytometry 
(B) (means±SD, n=5, *p<0,05, n.d. = not detectable). C-D, EDTA-anticoagulated blood from six cancer patients 
was either directly or after storage at -20°C for <14 days used for EV isolation. EV yields were determined by 
Lowry assays (C) and MV analyzed regarding expression of selected markers (D) (flow cytometry, means±SD, 
n=6, *p<0,05). Lines display the mean of the samples.  
After having shown that EDTA is more suitable as anticoagulant for patient samples, we 
asked whether storage of serum samples at -20°C influences EV counts or distribution of MV-
associated markers. Therefore, EDTA-anticoagulated blood was drawn from six cancer 
patients and serum samples either directly subjected to EV isolation or frozen at -20°C for 
<14 days previous to ultracentrifugation. As shown in Fig. 41C+D, freezing of serum had no 
significant effects on MV or Exo counts or expression of any of the selected markers for 
tumor or blood cell-derived MV except a slight decrease in the number of CD62P-positive 
MV.  
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3.3.4 Isolation of EV from metastatic cancer patients 
Based on the established protocol for the isolation of total MV and Exo from peripheral blood 
samples, we aimed to investigate whether EV counts as well as the distribution of MV 
populations differs in cancer patients compared to tumor-free controls. EV were isolated from 
21 cancer patients with metastatic disease including patients with primary lung cancer (n=8), 
breast cancer (n=4), colorectal cancer (n=4), ovarian cancer (n=1), melanoma (n=3) and 
glioblastoma (n=1). Tumor-free volunteers (n=14) were used as negative controls. The 
median patient age at the time of sample acquisition was 64 [IQR 59 - 74] years and the 
median age of the controls 52,5 [IQR 43,25 – 68,5] years with a p-value of 0,03517 (Wilcox 
two-sided rank test) indicating that patients were slightly older compared to the controls.  
 
Fig. 42: Isolation and characterization of EV from peripheral blood of cancer patients 
A, Total EV were isolated from peripheral blood of tumor (n=21) and control (n=14) patients and EV yields 
determined by Lowry assay. Lines display the median of the samples. B, The isolated MV were further 
characterized for the established blood cell markers by flow cytometry (*p<0,05).  
Nonetheless, comparison of EV yields between control and patient samples showed no 
difference in the amount of MV present in blood (patients: median 30,98 [IQR 18,12-47,43], 
controls: median 31,36 [IQR 14,98-59,63]) with a p-value of 0,6778 (Wilcox one-sided rank 
test). In contrast, Exo counts seemed to be slightly increased in tumor patients (median 25,98 
[IQR 21,64-31,91]) compared to the controls (median 18,81 [IQR 9,57-31,85]), although with 
a p-value of 0,219 (Wilcox one-sided rank test) this did not reach statistical significance yet 
(Fig. 42A). Since none of the putative tumor markers was reliably expressed on T-Exo in in 
vitro screenings (Fig. 33), it was not possible to elucidate if this increase was due to an 
increased amount of T-Exo in blood. In case of MV, the established markers remained 
unchanged in both samples for platelet-derived (CD62P
+
, p=0,1632), erythrocyte-derived 
(CD235a
+
, p=0,4569) and myeloid cell-derived (CD11c
+
, p=0,7233) MV, whereas we 
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observed a slight increase in leukocyte-derived (CD45
+
) MV in tumor patients compared to 
the controls (p=0,01297, all Wilcox one-sided rank test) (Fig. 42B).  
Next, we investigated if it is possible to detect T-MV in peripheral blood based on the 
previously established MV-associated tumor markers (Fig. 43). EpCAM-positive MV were 
only detected at very low levels (median 1,6% of total MV) in 15 out of 19 tumor patients and 
5 out of 14 control patients. Although this represented a significant increase in patient 
samples (p=0,01262, Wilcox one-sided rank test), the low number of EpCAM-positive MV 
might explain the failure of EpCAM-based MACS for T-MV as described in 3.3.2. In 
contrast, neither MUC1 nor EGFR were expressed in any of the tested control samples (0/9), 
but positive in 5 out of 19 patients for MUC1 and 2 out of 18 patients for EGFR. However, 
this did not reach statistical significance.  
 
Fig. 43: Tumor markers on MV derived from metastatic cancer patients 
Whole MV were isolated from peripheral blood of metastatic cancer and control patients and analyzed by flow 
cytometry for the expression of the previously defined tumor markers EMMPRIN (A), EpCAM (B), EGFR (C) 
or MUC1 (D). Lines display the median±IQR. Significance was calculated with a one-sided Wilcox rank test.  
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Surprisingly, there was a high increase in the number of EMMPRIN-positive MV in tumor 
patients (median 31,6% of total MV) compared to tumor-free controls (median 11,2% of total 
MV) with a p-value of 8,633 ∙ 10
-5
 (Wilcox one-sided rank test). To exclude that this finding 
was due to the higher age of the patients compared to the control group and further clarify the 
nature of the EMMPRIN-positive MV, we isolated MV from peripheral blood of five 
metastatic breast cancer patients for whom we had earlier defined possible tumor markers on 
breast cancer-derived T-MV in vitro. The median age of the patients at the time of sample 
acquisition was 51 [interquartile range (IQR): 49,3 – 57,0] years and the median age of 5 
matched tumor-free controls 47 [IQR: 42,5 – 54,5] years with a p-value of 0,5196 (Wilcox 
two-sided rank test).  
 
Fig. 44: Detection of T-MV in peripheral blood of metastatic breast cancer patients 
A-B, Total MV from five metastatic breast cancer patients and matched controls were analyzed by flow 
cytometry (A) to determine the percentage of EMMPRIN-positive MV (%positive events - % isotype control) 
(B). The line indicates the mean of the samples. C, Corresponding histograms for the EMMPRIN expression on 
total MV from breast cancer patients and controls with the specific signal in green and the corresponding isotype 
control in grey. D, Co-localization of the tumor markers EMMPRIN and MUC1 on MV from two metastatic 
breast cancer patients compared to matched controls as shown in density plots (flow cytometry).  
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The number of EMMPRIN-positive MV in peripheral blood was measured by flow cytometry 
and was found again to be significantly higher in patient-derived MV samples (median 14,7 
[IQR 14,4-26,5] % of total MV) compared to controls (median 2,3 [IQR 2,3-6,2] % of total 
MV) with a p-value of 0,01366 (Wilcox one-sided rank test) as shown in Fig. 44A+B. Since 
our previous results had demonstrated that EMMPRIN can also be expressed on benign cells, 
e.g. platelets or myeloid cells (see Fig. 38 and Fig. 39), we investigated whether the 
EMMPRIN-positive MV additionally express other tumor markers which would argue for 
their origin from tumor cells. For this reason, we performed double stainings for EMMPRIN 
and MUC1 by flow cytometry. MUC1, also known as CA 15-3, is often found at high levels 
in the blood of hormone receptor-positive breast cancers (Park et al, 2012) and was already 
shown to be present on their released MV (Fig. 32). While two of the further investigated four 
breast cancer patients were negative for MUC1 on their MV and therefore could not be used 
for double stainings, the other two patients showed a co-expression of MUC1 with 
EMMPRIN on 34,2% or 18,7%, respectively, of all MV present in blood (B). Taken together, 
the results suggest that T-MV can indeed be found in high numbers in the blood of metastatic 
cancer patients and can be identified by co-localization of the established markers, including 
EMMPRIN and MUC1.  
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4 Discussion 
4.1 The role of EV in pro-invasive tumor-tumor crosstalk in breast cancer 
4.1.1 MV and Exo differ in their morphology and protein expression pattern 
So far most functional studies on EV have been conducted with mixed populations of MV and 
Exo. Accurate discrimination between MV and Exo has only recently gained attention. By 
using electron microscopy, flow cytometry and Western Blotting we showed that both vesicle 
populations are indeed morphologically and biochemically distinct and can be isolated 
separately by differential ultracentrifugation. However, an overlap in the range between 100-
200 nm cannot be excluded and might be responsible for the slight signals of the MVB 
protein Tsg101 in some MV samples. In correspondence with the known Exo markers 
summarized in 2002 by Clotilde Théry (Thery et al, 2002), T-Exo specifically expressed the 
tetraspanin CD63 as well as Tsg101. Moreover, RUNX1 was exclusively present on Exo, 
although only at very low levels, which confirms previous microarray-based mRNA 
screenings (Valadi et al, 2007). In contrast, the transmembrane protein EMMPRIN which is 
overexpressed in many cancers (Nabeshima et al, 2006) was found exclusively on T-MV and 
could be established as sensitive and specific marker for the discrimination of MV and Exo. 
This contradicts recent data from Redzic et al who detected EMMPRIN on Exo from MCF-7 
and MDA-MB231 cells (Redzic et al, 2013). However, the difference is probably caused by a 
leaky Exo isolation protocol which allowed the co-purification of MV. This can be concluded 
from the size reported for their Exo ranging from 50 to 250 nm (Redzic et al, 2013) thus 
pointing to the considerable presence of larger EMMPRIN-carrying MV in the sample. 
Several studies have demonstrated an enrichment of specific membrane proteins on MV. 
Correspondingly, we observe enrichment of EMMPRIN on MV in comparison to the parental 
cells. This fits to the hypothesis that MV are shed from lipid rafts which are specialized 
plasma membrane domains enriched in cholesterol and specific proteins (Lingwood & 
Simons, 2010). Cholesterol depletion of the plasma membrane results in decreased MV 
shedding (Del Conde et al, 2005; Pilzer et al, 2005). Although the mechanism of protein 
recruitment into lipid rafts is still a matter of debate (Lingwood & Simons, 2010), EMMPRIN 
was indeed recently found to be localized at lipid rafts in the plasma membrane of HAT-7 
dental epithelial cells (Schwab et al, 2007).  
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4.1.2 T-EV enhance breast cancer progression by stimulating tumor cell 
invasion in an autologous and heterologous way 
Until now, the role of T-EV in cancer progression has been attributed to their horizontal 
interaction with surrounding stroma cells or, in the case of T-MV, been seen as a consequence 
of their procoagulant or matrix-degrading activity (Muralidharan-Chari et al, 2010; VanWijk 
et al, 2003). In this study we demonstrated for the first time that T-EV also directly enhanced 
the invasive potential of the tumor cells themselves in an autologous and heterologous 
stimulation loop. The effect was specific for T-EV since neither the particle-free supernatant 
nor benign MV influenced tumor invasion. Although T-Exo from breast or colon cancer cell 
lines or ovarian cancer ascites had already been reported to have a pro-invasive potential 
(Graves et al, 2004; Higginbotham et al, 2011), this was unknown so far for T-MV. Since the 
effect was more pronounced for MV, we focused further studies of tumor-tumor interactions 
on MV.  
Several studies have demonstrated that EV are able to transfer malignant characteristics from 
highly invasive tumor cells to surrounding less malignant subclones (Al-Nedawi et al, 2008; 
Angelucci et al, 2000; Poste & Nicolson, 1980). However, benign human mammary epithelial 
cells remained non-invasive when stimulated with either autologous or heterologous MV 
indicating that the recipient cell has to be susceptible to transformation to a more invasive 
phenotype. Moreover, we found that T-MV uptake was an essential prerequisite for their pro-
invasive effect. Although the mechanism of MV uptake is largely unknown, it was initially 
hypothesized to occur via two ways (Cocucci et al, 2009): Either via direct fusion with the 
plasma membrane of the recipient cell as it was already observed for Exo (Montecalvo et al, 
2012; Parolini et al, 2009) or via endocytosis. Two of the classical endocytotic pathways 
involve clathrin- or caveolin-mediated endocytosis (Doherty & McMahon, 2009). Blocking 
one of these two pathways was already observed to inhibit uptake of T-Exo from SKOV3 
ovarian cancer cells into the same cells (Escrevente et al, 2011) or of T-Exo from U87 MG 
glioblastoma cells into HUVEC cells (Svensson et al, 2013). In our hands, inhibition of these 
pathways did not affect the uptake of autologous T-MVM into MCF-7 cells. In line with the 
study from Kawamoto et al (Kawamoto et al, 2012), inhibition of dynamin blocked MV 
uptake into breast cancer cells as well as into Mϕ in a dose-dependent manner. This argues for 
a nonclassical endocytotic pathway involving dynamin (Doherty & McMahon, 2009). 
Correspondingly, dynasore was able to reduce MV uptake. However, since it did so only 
partially, this suggests that additional dynamin-independent mechanisms are involved in this 
process. Taken together, these results indicate that different uptake mechanisms play a role in 
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different cell lines and between different EV populations. Comparative studies are needed to 
answer this question.  
4.1.3 Glycosylation at N160 and N268 is essential for the pro-invasive effect of 
MV-associated EMMPRIN on tumor invasion 
Heating of T-MV significantly reduced their effect on tumor invasion suggesting that a major 
part of their pro-invasive potential is mediated by tumor-supporting proteins which are 
enriched on T-MV compared to benign MV. However, even after heating T-MV still were 
able to increase tumor invasion to a certain extent indicating that a contribution of lipids to the 
pro-invasive phenotype of T-MV cannot be completely excluded.  
After having found EMMPRIN enriched on T-MV and considering its important role for pro-
invasive tumor-stroma crosstalk (Hagemann et al, 2005; Sidhu et al, 2004), we analyzed 
whether EMMPRIN is also involved in MV-mediated pro-invasive crosstalk between tumor 
cells. Indeed, shRNA-mediated knockdown of EMMPRIN decreased, but not completely 
abrogated, the pro-invasive effect of T-MV pointing to the fact that EMMPRIN is one of the 
proteins that mediate MV-induced tumor invasion. In line with this, the main isoform 
EMMPRIN-2 was expressed at very high levels in breast cancer cell lines in vitro as well as in 
human brain metastases from breast cancer patients in vivo. 
However, EMMPRIN expression per se is not sufficient to convey a pro-invasive MV 
phenotype, since the non-invasive hTERT-HME1 displayed the highest expression of the 
protein on the cells and their released MV. Posttranslational modifications, especially 
glycosylation, are known to influence the function of EMMPRIN. In this context, N-
glycosylation was demonstrated to be required for MMP-2 induction (Sun & Hemler, 2001). 
Moreover, a positive correlation between HG-EMMPRIN and MMP-1 expression was found 
in patients with chronic periodontitis (Wang et al, 2013). In line with this, all pro-invasive T-
MV expressed a highly-glycosylated form of EMMPRIN with a size of 50-65 kDa, whereas 
non-pro-invasive MV from platelets and hTERT-HME1 expressed a less glycosylated isoform 
of only 45-50 kDa which we termed IG-EMMPRIN.  
P-MV, which we had identified as non-pro-invasive, displayed only low levels of IG-
EMMPRIN. Other studies reported that MV isolated from platelets which had been activated 
with thrombin and/or collagen prior to MV isolation were able to enhance invasion of prostate 
and lung cancer cells (Dashevsky et al, 2009; Janowska-Wieczorek et al, 2005). Moreover, it 
was revealed that activation of platelets led to the release of EMMPRIN from intracellular α 
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granules which resulted in its increased expression on the cell surface (Schmidt et al, 2008b). 
Although the glycosylation status of the released EMMPRIN was not determined, it is 
tempting to speculate that its expression on MV from activated platelets is responsible for 
their reported pro-invasive effect.  
Deglycosylation of T-MVM with PNGaseF resulted in a loss of HG- in favor of IG-
EMMPRIN which was associated with a decrease in MV-induced tumor invasion. Addition of 
PNGaseF alone also affected invasiveness of the tumor cells. However, it did not inhibit, but, 
in contrast, enhance MCF-7 invasion and therefore rather counteracted the observed effect of 
deglycosylated T-MV. However, since PNGaseF treatment leads to deglycosylation of all 
glycoproteins present on T-MV, it cannot be ruled out that also other tumor-supporting 
proteins on T-MV are affected and contribute to the decreased pro-invasive potential. 
Unfortunately, 2D-DIGE experiments which were carried out to answer this question could 
not be completed successfully yet.  
Nonetheless, the observation that both HG- and IG-EMMPRIN differ in their function has 
already been made in atherosclerotic lesions where EMMPRIN with a size of 45 kDa was 
predominantly present in advanced stable plaques, whereas higher glycosylated EMMPRIN of 
58 kDa was found in unstable ruptured plaques with ongoing inflammation (Sluijter et al, 
2006). Based on our observations we aimed to discriminate IG- and HG-EMMPRIN on the 
underlying glycosylation pattern to confirm that they indeed represent two different 
glycoforms. By proteomics approaches we revealed that the two asparagine residues N160 
and N268 are glycosylated in HG-, but not in IG-EMMPRIN. Synthetic peptides which cover 
the glycosylation site at N160 in the first Ig loop were shown to reduce EMMPRIN-mediated 
MMP induction in fibroblasts (Koga et al, 2011; Sato et al, 2009). Moreover, the first Ig 
domain seems to be required for homo- and heterophilic interactions which are the basis for 
induction of MMP-2 (Sun & Hemler, 2001; Yoshida et al, 2000). In contrast, the second Ig 
loop which contains the second N-glycosylation site N268 is known to be important for 
interaction with caveolin-1 (Tang et al, 2004a) which is associated with lipid rafts 
(Yamaguchi et al, 2009) and could explain the enrichment of EMMPRIN in these specialized 
membrane domains (Schwab et al, 2007). Furthermore, caveolin-1 was shown to bind to LG-
EMMPRIN and thereby inhibit its glycosylation and conversion to HG-EMMPRIN which 
again resulted in reduced MMP induction (Tang et al, 2004a). Altogether, these studies 
suggest that both extracellular loops with the two N-glycosylation sites N160 and N268 seem 
to contribute to the pro-invasive function of HG-EMMPRIN on T-MV.  
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4.1.4 The pro-invasive function of EMMPRIN-carrying T-MV is independent of 
MMP 
Since the enrichment of HG-EMMPRIN on T-MV as well as its glycosylation at the second 
Ig loop suggested that MV-induced tumor invasion is mediated by induction of MMP in the 
tumor cells, we aimed to address this question by zymography and qRT-PCR. However, 
MMP levels remained unchanged in breast cancer cells upon stimulation with MV. Moreover, 
T-MV carried neither MMP-2 nor MMP-9, although MMP-9 was found to be present on 
benign P-MV and Mϕ-MV indicating that the presence of MMP is not the critical determinant 
that confers pro-invasive activity to MV. Although most protumoral effects of EMMPRIN 
have been associated with regulation of MMP (Muralidharan-Chari et al, 2010), also MMP-
independent functions have been demonstrated, such as regulation of angiogenesis (Bougatef 
et al, 2009) and maintenance of normal cell architecture in Drosophila melanogaster (Curtin 
et al, 2005). We therefore investigated other known EMMPRIN target genes including TNFα, 
CSF1, VEGF or EMMPRIN itself (Schmidt et al, 2008b; Seizer et al, 2010; Tang et al, 2005). 
However, they all remained unchanged in MCF-7 upon T-MV stimulation. Upstream of the 
induction of EMMPRIN target genes, we detected phosphorylation of p38/MAPK occurring 
in MCF-7 1 h after stimulation with T-MV. Phosphorylation of p38 could be blocked by the 
specific p38 inhibitor SB-203580 and resulted in a significant decrease in MV-mediated 
tumor invasion. This argues for an involvement of p38 in the signal transduction after MV 
binding and is in line with a study from Lim et al who demonstrated p38 activation in 16-Lu 
lung fibroblasts after stimulation with EMMPRIN (Lim et al, 1998).  
4.2 The role of EV in Wnt5a induction and transport in Mϕ-induced 
breast cancer invasion 
4.2.1 T-MV drive Mϕ in a tumor-supporting phenotype by inducing Wnt5a 
Previously, our group had demonstrated that tumor-associated Mϕ can enhance breast cancer 
invasion and progression (Hagemann et al, 2004; Pukrop et al, 2006). In the present study we 
demonstrated that EV, and not soluble factors, are responsible for this pro-invasive tumor-
stroma crosstalk. Interestingly, EV stimulation did not induce the expected phenotype switch 
in Mϕ characterized by a typical M2 profile of secreted cytokines. Instead, it led to 
upregulation of Mϕ-Wnt5a which was characteristic for EV from malignant cells, since it was 
not observed with benign P-MV. Wnt5a is a factor that is typically induced in myeloid cells 
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upon inflammatory responses (Blumenthal et al, 2006; Pereira et al, 2008). Although its 
induction was reported to occur via activation of the Wnt/Ca
2+
 pathway (Pereira et al, 2008; 
Valencia et al, 2011), we did not observe activation of CamKII, PKC or JNK signaling in Mϕ 
after MV stimulation. This indicates that none of the two known non-canonical Wnt pathways 
was involved in Wnt5a induction.  
Several studies demonstrated that Wnt5a influences dendritic cell differentiation. This results 
in a tolerogenic phenotype with an impaired ability to react properly to TLR stimulation or to 
promote Th1-directed immune responses (Bergenfelz et al, 2012; Valencia et al, 2011). 
Moreover, Wnt5a, but not Wnt3a, was found to induce expression of anti-inflammatory 
cytokines and block differentiation of monocytes to pro-inflammatory M1 Mϕ which 
significantly reduced their cytotoxic anti-tumor response (Bergenfelz et al, 2012). Based on 
these findings it has been suggested that Wnt5a is part of a negative feedback loop 
(Bergenfelz et al, 2012) that is thought to prevent an excessive immune reaction after TLR 
stimulation. Thus, it seems that a physiologic phenomenon is exploited by the tumor cells for 
reprogramming tumor-associated Mϕ to support tumor progression.  
T-MV-mediated WNT5A induction in Mϕ was shown to be independent of MV uptake which 
suggests that MV interact with a still unknown receptor on the Mϕ surface to induce p38 
signaling and WNT5A transcription. Similar observations have been made for interactions of 
platelet- or neutrophil–derived MV which bound to specific target cells including monocytes 
or platelets and induced specific signaling responses (Gasser et al, 2003; Losche et al, 2004; 
Pluskota et al, 2008). The fact that the Wnt-inhibitor DKK-1 was able to block p38 activation 
and subsequent WNT5A induction points to Wnt ligands as putative mediators of receptor 
activation. On the other hand, ZA which inhibits Mϕ-assisted tumor cell invasion (Rietkotter 
et al, 2013) was found to decrease MV uptake into Mϕ without affecting WNT5A expression. 
One explanation for ZA influencing MV uptake is its inhibitory effect on small G proteins 
which are involved in almost all endocytotic pathways, especially the ingestion of particles 
into phagocytes (Doherty & McMahon, 2009). Studies from Luckman et al revealed that 
nitrogen-containing bisphosphonates including ZA can inhibit enzymes of the mevalonate 
pathway which results in impaired protein prenylation, an important posttranslational 
modification for the activity of small G proteins (Luckman et al, 1998a; Luckman et al, 
1998b). Since small G proteins also include proteins of the Arf family and Arf6 has been 
shown to regulate MV shedding (Muralidharan-Chari et al, 2009), it would be interesting to 
investigate whether ZA additionally impairs the release of MV from tumor cells or Mϕ. This 
could provide an additional explanation for its effect, however, it has not been tested yet.  
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Taken together, the results imply that T-MV influence human Mϕ in at least two ways: 1) by 
binding to a membrane-associated receptor which activates p38 signaling and leads to 
induction of WNT5A transcription, 2) by horizontal transfer of tumor-promoting proteins or 
nucleic acids which require to be taken up into the Mϕ in order to fulfill their function.  
4.2.2 Wnt5a is transported on MV and supports tumor progression 
The augmented WNT5A transcription was translated into increased expression of the Wnt5a 
protein in T-MV-stimulated Mϕ. Earlier in vivo studies had already identified Wnt5a-positive 
Mϕ in immunohistochemical tissue stainings of colon cancers (Smith et al, 1999) as well as 
breast cancers where they were predominantly localized at the invasive front of the tumor 
(Pukrop et al, 2006). Furthermore, Wnt5a has been detected at the leading edge of basal cell 
carcinomas in the tumor cells as well as in associated fibroblasts (Pourreyron et al, 2012). 
Therefore, one could hypothesize that stroma cells, especially Mϕ recruited to the tumor site, 
are primed by T-MV to express and release Wnt5a which then acts back on the tumor cells 
and enhances tumor invasion into the surrounding non-malignant tissue. This is in accordance 
with our finding that Wnt5a which was exported on Mϕ-EV in response to T-MV stimulation 
was transported back to the tumor cells where it increased the invasiveness of the tumor cells.  
Until recently, Wnt proteins have been regarded to act predominantly as secreted proteins. 
However, we found that MV and Exo, although they are two biological distinct populations of 
extracellular vesicles, both carried Wnt5a produced by stimulated Mϕ. Association of the 
Wnt5a protein with MV, which was unknown so far, could additionally be confirmed for MV 
of the Wnt5a-positive breast cancer cell line SK-BR-3 as well as for murine Wnt5a-
overexpressing L cells. By electron microscopy, we revealed that Wnt5a was not delivered 
inside the vesicles, but was associated with the membrane of Mϕ-MV. This can be partly 
explained by an unspecific binding of Wnt proteins to biological membranes due to their lipid 
moieties. In this context, studies from Morrel et al demonstrated a stabilization and 
potentiation of the activity of canonical Wnt3a when bound to liposomes (Morrell et al, 
2008). Moreover, association of Wnt proteins with EV is thought to be important for their 
long-range signaling capacity as well as in the formation of gradients which are essential for 
the activity of Wnt proteins (Solis et al, 2013). For instance, in in vitro migration assays, a 
constant Wnt5a concentration was shown to inhibit cell migration, whereas a Wnt5a gradient 
induced exactly the contrary (Pourreyron et al, 2012). This might, to some extent, explain the 
varying results concerning the role of Wnt5a in tumor progression. Nonetheless, Wnt 
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gradients seem to reflect the in vivo situation more accurately since Wnt5a gradients could 
already be visualized in non-melanoma skin cancers (Pourreyron et al, 2012). 
Although there was some unspecific association of Wnt5a with EV in our study, we showed 
that it was predominantly bound via specific association to the seven-pass transmembrane 
protein Evi. This was surprising since an Evi-dependent export had only been demonstrated 
so far for Exo and the canonical ligand Wnt3a (Gross et al, 2012). It was unknown for MV 
and non-canonical Wnt ligands like Wnt5a. Knockdown of Evi led to an almost complete loss 
of Wnt5a on MV as well as Exo. In accordance with the results from Gross et al we expected 
that this should lead to an accumulation of Wnt5a inside the cells (Gross et al, 2012). 
However, after Evi knockdown we could no longer detect the protein inside the cells. 
Inhibition of protein degradation with the proteasome inhibitor MG-132 at the highest 
tolerable dose did not augment Wnt5a expression, indicating that an increased degradation is 
not the explanation for the observed effect. Therefore, we hypothesized that the putative loss 
of Wnt5a was probably due to conformational changes of the protein which no longer allowed 
its detection with the used antibodies. This observation supports the often proposed, but until 
now unproven, theory that Evi is not only important for the export of Wnt proteins, but also 
has an important chaperone function. To further corroborate this assumption, we assessed 
Wnt5a distribution by transfecting SK-BR-3 shEvi cells with an eGFP-tagged Xwnt5a fusion 
protein. Thus, Wnt5a could be visualized by antibodies directed against GFP. Using this 
approach, Wnt5a was not only detectable in shEvi cells, but its levels even seemed to be 
slightly compared to non-sense controls. This may indeed point to an accumulation of the 
protein inside the cells due to the impaired export on EV.  
Wnt5a-positive EV released from stroma cells, including Mϕ and Wnt5a-L cells, were shown 
to highly increase the invasive potential of human breast cancer cells. Again, the particle-free 
supernatant had no effect, although it still contained all soluble mediators which our group 
had previously identified as essential for tumor invasion (Hagemann et al, 2004). 
Interestingly, loss of Wnt5a on EV due to the knockdown of Evi was found to significantly 
decrease the invasive potential of EV derived from Wnt5a-L cells. The same effect was 
observed for the MV-induced heterologous invasion of MCF-7 cells stimulated with T-MVS 
from SK-BR-3 shEvi cells. These results indicate that in MV-induced human breast cancer 
invasion Wnt5a acts as tumor-promoting factor in tumor-tumor as well as tumor-stroma 
interactions. However, loss of Wnt5a did not completely revert the pro-invasive phenotype of 
tumor- and stroma-derived vesicles which shows that additional pro-invasive factors like e.g. 
HG-EMMPRIN are present on the vesicles and contribute to their tumor-supporting function.  
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After uptake, MV-bound Wnt5a was detectable within the tumor cells. However, the 
pathways activated by the MV-delivered Wnt5a in the tumor cells are still unclear. Previous 
studies with MCF-7 cells reported an activation of JNK signaling in the tumor cells after 
stimulation with rhWnt5a, whereas PKC was not involved (Pukrop et al, 2006). In contrast, 
Wnt5a-induced migration and invasion of melanoma cells was mediated by the Wnt/Ca
2+
 
pathway with enhanced PKC phosphorylation (Weeraratna et al, 2002). This could be 
antagonized by blocking the Wnt5a receptor Frizzled 5 pointing to a receptor-ligand-mediated 
effect. Additionally, also the involvement of canonical Wnt signaling for the protumoral 
effect of Wnt5a is under discussion: On the one hand, Wnt5a was found to increase 
invasiveness of pancreatic cells by inducing epithelial-mesenchymal-transition (EMT) in the 
cells in a ß-catenin-dependent way (Bo et al, 2013). On the other hand, our own results 
showed that, although a functional ß-catenin pathway was required, canonical Wnt signaling 
was not activated in MCF-7 cells under co-culture conditions with Mϕ (Pukrop et al, 2006).  
Taken together, our observation that breast cancer cells can specifically reprogram Mϕ into a 
tumor-supporting phenotype with the help of T-EV seems to be in accordance with the 
proposed “Seed and Soil” hypothesis formulated by Stephen Paget: Breast cancer cells tend to 
metastasize to specific organs including liver, lungs, bone and brain. Each of these organs 
harbors a specific Mϕ population: Kupffer cells in the liver, alveolar macrophages in the 
lungs, osteoclasts in the bone as well as microglia in the brain. One possible explanation for 
the organ tropism in breast cancer therefore might be that these specialized Mϕ populations 
are prone to be influenced by the tumor cells. After reprogramming, they support the tumor 
cells in the establishment of a premetastatic niche via the release of Wnt5a-positive pro-
invasive EV, thereby promoting metastasis formation in the respective tissue.  
4.3 EV in peripheral blood of metastatic cancer patients 
4.3.1 Isolation of T-EV from human serum samples 
In the last years EV have been increasingly recognized as potential cancer biomarkers which 
deliver valuable information about the underlying tumor biology. EV can be obtained easily 
by non-invasive methods from body fluids such as blood or urine which is especially 
important for cancers where tissue samples are not easily accessible e.g. pancreatic cancer or 
glioblastoma (D'Souza-Schorey & Clancy, 2012). In order to establish a protocol for the 
specific isolation of T-EV from peripheral blood of cancer patients, we screened T-EV in 
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vitro for the expression of different tumor markers which allow the discrimination of T-EV 
from non-malignant EV. EpCAM was identified as the only protein which was present on T-
MV as well as T-Exo. In line with our in vitro data, EpCAM has also been identified by other 
authors in vivo on EV isolated from ascites and serum of ovarian cancer patients (Keller et al, 
2009). These findings argued for the possible use of EpCAM as marker for the detection of 
circulating T-EV. Based on the study from Taylor et al who described an EpCAM-based 
MACS approach to specifically sort T-Exo from serum samples (2,5 ml) of ovarian cancer 
patients (Taylor & Gercel-Taylor, 2008), we tried to adopt this method for the specific 
isolation of T-MV as well as T-Exo from serum samples of metastatic cancer patients.  
First, the method was tested in vitro by spiking human AB serum samples with T-MV or T-
Exo. Even though we optimized the concentration of anti-EpCAM MicroBeads as well as the 
type of separation column, this method allowed us to sort only 20% of the input T-MV in 
vitro. Furthermore, we were not able to sort T-Exo from AB serum, possibly due to the low 
expression of EpCAM on T-Exo. Nonetheless, we decided to test whether the established 
method would work in vivo, at least for MV. Since in the study from Taylor et al a positive 
correlation was found between the number of EpCAM-positive Exo and tumor stage (Taylor 
& Gercel-Taylor, 2008), we chose cancer patients with metastatic disease who should have 
the highest number of circulating T-EV in their blood. Although we were indeed able to 
isolate high amounts of EpCAM-positive MV from some patient samples, further 
characterization of the sorted vesicles revealed that most of the sorted vesicles were false-
positively selected MV from normal blood cells which in some cases even lacked EpCAM-
expression. This control procedure had not been performed in the other two studies (Keller et 
al, 2009; Taylor & Gercel-Taylor, 2008). Thus, in our hands, EpCAM-based MACS does not 
seem to specifically capture T-EV from human serum samples which might be explained by 
the low number of EpCAM-positive MV present even in advanced cancer patients. However, 
it cannot be excluded that MACS might work with MicroBeads coated with antibodies 
directed against other tumor proteins which are specific for T-EV and are expressed at higher 
levels on the surface of the vesicles.  
4.3.2 Detection of circulating T-MV 
Since it was not possible to specifically sort T-EV from human blood samples, we isolated the 
complete EV population from peripheral blood of metastatic cancer patients. Based on the 
previously identified markers for T-MV as well as non-malignant MV in our in vitro 
screenings, we analyzed which MV populations are present in blood and whether we can 
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identify circulating T-MV without any previous sorting step. Since so far we could not 
identify tumor-specific Exo markers, except EpCAM, we choose to not perform further 
characterization of patient-derived Exo populations.  
Complete MV and Exo could be successfully isolated from serum samples of EDTA-
anticoagulated blood from cancer and control patients. Plasma from lithium-heparin-
anticoagulated blood was less suited for EV isolation since it displayed delayed agglutination 
which corresponded with significantly reduced MV counts. In particular, the number of 
CD62P- and EMMPRIN-positive MV was reduced which we had identified as markers for P-
MV. These observations seem to confirm recent data which suggest that heparin interacts with 
certain MV and forms immune complexes with platelets (Krauel et al, 2012; Maguire et al, 
2012).  
Several studies report an increase in the total number of isolated EV from cancer patients 
(Baran et al, 2010; Ghosh et al, 2010), while others only find an increase in protein density, 
but not in the amount of EV (Peinado et al, 2012). Elevated EV counts are not only associated 
with cancer, but are also attributed to cardiovascular diseases including hypertension, diabetes 
or arteriosclerosis which mainly occur in elderly patients (VanWijk et al, 2003). Although the 
patients included in our preliminary study were slightly older compared to the control group, 
we did not detect a significant increase in the total number of isolated MV, whereas Exo were 
slightly, but not significantly, elevated. A larger group of patients with age-matched controls 
will be necessary to further strengthen this finding. Interestingly, while most blood-derived 
MV markers did not differ between patients and controls, we observed an increase in the 
number of leukocyte-derived CD45-positive MV in cancer patients which has already been 
described before in breast cancer patients with advanced disease (Toth et al, 2008b). 
However, it still has to be clarified whether this is caused by an influence on leukocyte cell 
counts or on MV release by leukocytes. While some studies of healthy individuals or breast 
cancer patients reported that more than 80% of MV in blood are derived from platelets 
(Flaumenhaft et al, 2009; Toth et al, 2008a), we observed expression of the platelet marker 
CD62P on only around 30-35% of the isolated MV (see Fig. 42). However, P-MV still 
represented the largest group of circulating blood-derived MV in the samples.  
Next to the analysis of benign MV populations in blood, we aimed to identify circulating T-
MV in cancer patients based on the established tumor markers EGFR, MUC1, EpCAM and 
EMMPRIN. We detected expression of the tumor marker EGFR on MV from 2 out of 18 
investigated cancer patients. Although EGFR overexpression is mostly attributed to colorectal 
Discussion  105 
cancer, it has also been associated with breast, lung or gastric cancer (Spano et al, 2005). 
Correspondingly, one patient with MV-bound EGFR suffered from primary breast cancer, the 
other from primary lung cancer. In breast cancer patients, EGFR overexpression is mostly 
associated with the triple-negative subtype (Burness et al, 2010) which corresponds to the 
data from our in vitro screening of T-MV, where EGFR was only found on T-MV from the 
MDA-MB231 triple-negative breast cancer cell line (see Fig. 32). Apart from breast cancer, 
first clinical investigations detected Exo-bound EGFRvIII in 7 out of 25 investigated 
glioblastoma patients by nested RT-PCR, whereas it was present in none of the 30 control 
patients (Skog et al, 2008).  
Besides EGFR, we identified MUC1 on MV from 5 (lung cancer: 3, breast cancer: 1, colon 
cancer: 1) out of 19 cancer patients. While in healthy individuals MUC1 is present on 
specialized secretory epithelia as well as in epithelia lining the respiratory and gastrointestinal 
tract (Kufe, 2009), it was not detectable on MV from peripheral blood of any of the 
investigated controls suggesting its specificity for T-MV. MUC1, corresponding to the serum 
marker CA 15-3, is specifically found at high levels in various epithelial cancers 
(Hollingsworth & Swanson, 2004; Szabo, 2003). Moreover, it is used as a prognostic 
parameter in breast cancer (Duffy et al, 2000) and was proposed to contribute to tumor 
invasion and metastasis (Hollingsworth & Swanson, 2004).  
In contrast to EGFR and MUC1, EpCAM was also found on MV of some of the control 
patients. However, the EpCAM-levels were significantly increased in MV derived from 
cancer patients, although the number of EpCAM-positive MV was still comparably low. The 
low number of EpCAM-positive MV in cancer patients might explain the failure of EpCAM-
based sorting of T-MV as discussed above. One disadvantage of EpCAM as a tumor marker is 
that it is only expressed on cancers of epithelial origin and cannot be utilized for malignancies 
of mesenchymal provenience, such as sarcomas. EMMPRIN, in contrast, is frequently 
overexpressed in many types of malignant tumors including lymphomas, sarcomas and 
carcinomas (Li et al, 2009; Nabeshima et al, 2004; Riethdorf et al, 2006). In line with this, we 
found EMMPRIN-positive MV in the blood of all investigated cancer patients (21/21). 
Although EMMPRIN was also detected on MV from control patients (12/13), the number of 
EMMPRIN-positive MV was highly increased in metastatic cancer patients. This finding 
retrospectively reinforces a study from Baran et al who detected EMMPRIN in a small series 
of plasma samples of gastric cancer patients. While no direct EMMPRIN staining was 
performed in that work, centrifugation of the samples at 50.000 g resulted in a loss of 
EMMPRIN expression suggesting that it was associated with MV (Baran et al, 2010).  
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Since EMMPRIN is also expressed on MV shed by benign blood cells like e.g. P-MV or Mϕ-
MV, we performed double stainings with the tumor marker MUC1 to confirm that the 
EMMPRIN-positive MV are indeed released by tumor cells. From the investigated breast 
cancer patients two were positive for MUC1 and both showed a co-localization of MUC1 and 
EMMPRIN on their MV which was not seen on MV from control patients. This confirms that 
parts of the EMMPRIN-positive MV are indeed T-MV and circulate at high levels in the 
blood of metastatic cancer patients suggesting that they could be used as potential biomarkers. 
However, it still remains to be investigated whether the level of EMMPRIN-positive MV 
correlates with prognosis or disease progression to evaluate its usability as potential 
biomarker. Moreover, considering their effect on tumor invasion in vitro, it is possible that 
EMMPRIN-positive MV are not only important for prognosis or diagnosis, but also 
contribute to tumor progression in vivo. In this context, further studies are needed to address 
this question.  
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5 Summary and conclusions 
This study investigated the role of EV derived from human breast cancer cells for tumor 
invasion, which represents a crucial step in cancer progression and metastasis formation. EV 
are continuously released from every cell in the body, although increased shedding can be 
observed during cellular activation. However, functional studies investigating their biological 
impact are limited due to a lack of suitable markers to discriminate between MV and Exo. 
Using a differential ultracentrifugation approach, we were able to separately isolate and 
analyze MV and Exo. Surprisingly, even though both populations differ in their biogenesis 
and protein expression pattern, they were found to exert similar biological effects: 1) MV and 
Exo increase breast cancer cell invasion in an autologous feedback loop; 2) MV and Exo are 
able to reprogram Mϕ into a tumor-supporting phenotype by inducing Wnt5a.  
Although some studies have already demonstrated the pro-invasive potential of T-Exo, the 
influence of T-MV on tumor invasion has not been investigated yet. In this study, we showed 
that T-MV, comparable to T-Exo, influence malignant invasion i) by acting back on the tumor 
cells themselves and ii) by mediating the pro-invasive communication between tumor cells 
and Mϕ. The first route is exemplified in Fig. 45: T-MV strongly increased the invasive 
potential of surrounding tumor cells in an autologous and heterologous loop. This effect was 
not observed when tumor cells were stimulated with the corresponding particle-free 
supernatant or with benign MV. We showed that uptake of MV into their recipient cell in a 
dynamin-dependent way as well as expression of tumor-supporting proteins on T-MV are 
prerequisites for MV function. EMMPRIN is one of these proteins and was identified as a 
sensitive and specific marker for MV.  
 
Fig. 45: Schematic presentation of EV-mediated tumor-tumor crosstalk in human breast cancer 
Breast cancer cells release T-EV which are enriched in pro-invasive factors (e.g. HG-EMMPRIN or Wnt5a). 
These T-EV act back on the surrounding tumor cells where they can either horizontally transfer their messages 
after dynamin-dependent incorporation or they interact with cell surface-associated receptors. T-MV stimulation 
activates p38/MAPK signaling which is partly involved in the subsequent increase in tumor invasion.  
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All pro-invasive T-MV carried a highly glycosylated form of EMMPRIN which was found to 
be N-glycosylated at N160 and N268. Knockdown of EMMPRIN or deglycosylation partly 
reduced the invasive potential of T-MV confirming that HG-EMMPRIN is one of the pro-
invasive factors on T-MV. The MV-induced tumor invasion was not mediated by MMP 
induction, but by activation of the EMMPRIN downstream target p38/MAPK.  
The second route is shown in Fig. 46: T-EV from human breast cancer cells, apart from 
influencing the surrounding tumor cells, were found to reprogram Mϕ by inducing expression 
of the non-canonical Wnt ligand Wnt5a. Wnt5a expression is associated with a tolerogenic 
phenotype in Mϕ (Bergenfelz et al, 2012) and was identified earlier as indispensable for the 
pro-invasive tumor-Mϕ crosstalk by our group (Pukrop et al, 2006). In case of T-MV, 
induction of Wnt5a is independent of MV uptake and is mediated by p38/MAPK signaling 
which can be antagonized by the Wnt-inhibitor DKK-1. These results suggest a receptor-
ligand-mediated interaction at the Mϕ surface. After T-EV stimulation, Mϕ shuttle the 
produced Wnt5a protein out of the cells on their own EV, a process which depends on the 
expression of the seven-pass transmembrane protein Evi. Wnt5a is delivered to the tumor 
cells where it is incorporated and supports tumor progression. EV-bound Wnt5a is not only 
involved in pro-invasive tumor-Mϕ crosstalk, but was also shown to be released on T-EV 
from Wnt5a-positive breast cancer cell lines (e.g. SK-BR-3) and to contribute to their pro-
invasive effect on neighboring tumor cells (Fig. 45). Thus, it seems highly likely that both 
routes, the tumor-tumor as well as the tumor-Mϕ loop are interconnected and act 
synergistically in vivo.  
 
Fig. 46: Schematic presentation of EV-mediated tumor-Mϕ crosstalk in human breast cancer 
On the one hand, T-EV released by human breast cancer cells influence human Mϕ by horizontally transferring 
tumor-supporting proteins or nucleic acids which need to be incorporated to fulfill their function. MV uptake can 
be impaired by the bisphosphonate ZA. On the other hand, T-EV interact with an unknown cell surface-bound 
receptor to induce expression of Wnt5a which is mediated by p38 signaling and can be antagonized by DKK-1. 
Stimulated Mϕ then export the produced Wnt5a protein in an Evi-dependent way on their own EV and shuttle it 
to the tumor cells where it is incorporated and increases tumor invasion. Modified from (Menck et al, 2013).  
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In order to further characterize the situation in vivo, we established a protocol for the isolation 
of the complete EV populations from peripheral blood of cancer patients and controls. While 





 T-MV at high numbers in the blood of metastatic breast 
cancer patients suggesting their potential use as novel biomarkers in cancer.  
Taken together, in this study we demonstrate that human breast cancer cells release T-EV into 
the local tumor microenvironment as well as the bloodstream. These T-EV represent novel 
means of intercellular communication which the tumor cells use to influence the adjacent 
stroma and tumor cells to create a favorable and permissive tumor niche and drive progression 
to metastasis.  
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7 Appendix 
7.1 List of identified N-linked glycoproteins in 2D-DIGE gels 
Tab. 10: Proteins exclusively present on untreated T-MVM  
Spot Nr. Protein Protein full name 
70 Anxa5 Annexin A5 
86 Actb ß-actin 
130 Arpc2 Actin-related protein 2/3 complex subunit 2 
135 Csk21 Casein kinase II subunit alpha 
143 K1c9 Keratin, type I cytoskeletal 9 
143 K2c1 Keratin, type II cytoskeletal 1 
149 Acts α-Actin, skeletal muscle 
162 Mfgm milk fat globule-EGF factor 8 protein 
164 Serph Serpin H1 
169 Fa5 Coagulation factor V 
210 Trap1 Heat shock protein 75 kDa, mitochondrial 
262 Djb11 DnaJ homolog subfamily B member 11 
263 Arp2 Actin-related protein 2 
306 Atpb ATP synthase subunit beta, mitochondrial 
309 Pdia1 Protein disulfide-isomerase 
370 Hyou1 hypoxia up-regulated 1 
 
Tab. 11: Proteins exclusively present on deglycosylated T-MVM 
Spot Nr. Protein Protein full name 
26 Hba Hemoglobin subunit alpha 
66 Actb Beta-actin 
268 Scmc1 Calcium-binding mitochondrial carrier protein SCaMC-1 
342 Mvp Major vault protein 
373 Itav Integrin alpha-V 
381 Basp1 Brain acid soluble protein 1 
382 Rcn2 Reticulocalbin-2 
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7.2 LC-MS/MS analysis 
 
Fig. 47: MS/MS spectra 
These images display the MS/MS spectra which were generated on the Orbitrap Velos mass spectrometer for the 
two identified peptides with deamidated N-residues which were detected in the IG-EMMPRIN spot. The 
corresponding parent ion masses are shown in Fig. 15C+D. 
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